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AB = Acidic box 
ACH = Achondroplasia 
BMP = Bone Morphogenetic Protein 
CAN = Crouzon with Acanthosis Nigricans 
syndrome 
CATSHL = CAmpodactyly, Tall Stature, and 
Hearing Loss syndrome 
CNP = C­type Natriuretic Peptide 
COL = Collagen 
EGF = Epidermal growth factor 
ERK = Extracellular signal­Regulated Kinase 
FGF = Fibroblast Growth Factor 
FGFR = Fibroblast Growth Factor Receptor 
HBS = Heparin Binding Site 
HCH = Hypochondroplasia 
HS = Heparan sulfate 
IGF = Insuline Growth Factor  
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PTHrP = Paratyroid Hormone­Related Peptide 
RANK = Receptor activator of nuclear factor κB 
RANKL = Receptor activator of nuclear factor 
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Developmental Delay and Acanthosis 
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SNAIL = Zinc finger protein SNAI1 
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TD = Thanatophoric Dysplasia 
TGFβ = Transforming Growth Factor β 
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TKI= Tyrosine Kinase Inhibitor 
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Introduction 
 
1. FGFs and FGFRs 
 
1.1 Fibroblast Growth Factors (FGFs) 
 
The fibroblast growth factor (FGF) family consists of a large group of 
structurally and evolutionarily related polypeptides. In human and mouse, 22 FGF 
genes exist (FGF1-FGF23) it being understood that the human and mouse FGF 
families do not include FGF15 and FGF19 respectively, as they are orthologs (1). 
The first two FGFs discovered, FGF1 and FGF2, were named acidic and basic 
FGF (aFGF and bFGF) based on their activity to stimulate fibroblast proliferation and 
their isoelectric point (2, 3). It was later found that the name “fibroblast growth factor” 
was not the best name to describe the diverse functions of the family members and 
their receptors since many FGFs do not even have receptors expressed in fibroblasts 
and elicit no activity in fibroblasts (4). However the name “fibroblast growth factor” 
followed by a number (FGF1, 2, 3, 4…) has been preserved. 
FGFs are usually classified in 3 different sets (Figure 1). 15 out of 22 FGFs 
(FGF1-10, 16-18, 20, 22) are paracrine factors belonging to the canonical FGFs 
group. These growth factors are able to stimulate Fibroblast Growth Factor 
Receptors (FGFRs) assisted by heparin or heparan sulfate. 3 polypeptides 
(endocrine FGFs: FGF15/19, 21, 23) are hormone-like factors that need the presence 
of co-factors belonging to the Klotho family of proteins to perform their action. The 4 
lasts FGFs (intracellular FGFs: FGF11-14) are intracellular proteins lacking the 
capacity to bind FGF receptors at the cell surface. Those FGFs (also known as 
iFGFs) interact with the cytosolic carboxy terminal tail of voltage gated sodium (Nav) 
channels. 
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Figure 1. FGFs and their subfamilies. Phylogenetic analysis suggests that 22 Fgf genes can be 
arranged into seven subfamilies containing two to four members each. FGFs can also be regrouped in 
three classes based on their biological action: Canonical FGFs, Endocrine FGFs and Intracellular 
FGFs (1). 
 
FGFs control a variety of physiological responses during embryonic 
development and in adult organisms. During development FGFs play key roles in 
patterning and morphogenesis by controlling cell proliferation, survival, migration and 
differentiation. In adult organisms, they are involved in tissue repair, response to 
injury, as well as energy, bile acid, mineral ion and metabolic homeostasis. The 
identification of the roles of most FGFs was made possible by the use of knock-out 
mouse models for one or more of these factors (Table 1). 
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Table 1. Phenotypes of germline and conditional loss-of-function Fgf mutations in mice. (Ornitz 
& Itoh 2015). 
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1.2 Fibroblast Growth Factor Receptors (FGFRs) 
 
The FGFR family is composed by 5 proteins: FGFR1, 2, 3, 4 and L1. The 
FGFR1, 2, 3, 4 are single chain transmembrane tyrosine kinases that consist of a 
ligand binding extracellular domain, a single transmembrane domain (TM), and an 
intracellular tyrosine kinase domain that is separated into two parts by an insertion 
domain. FGFRL1 (also recently called FGFR5) is an exception to this scheme since it 
has a short intracellular tail with no tyrosine kinase domain (Figure 2). The FGFR 
extracellular domain contains two or three immunoglobulin (Ig)-like loops (D1, D2, 
D3). D1 loop and the D1-D2 link, also known as acidic box (AB) due to the presence 
of acidic residues, are involved in receptor autoinhibition (5) and they’re not 
necessary for FGF binding (6). FGFR portion responsible for the ligand binding is 
composed by D2 and D3, with the first loop presenting the heparin binding site 
(HBS). While FGFR4 and L1 present only one splice isoform, the other three FGFRs 
have been found to naturally encode different variants. In fact in FGFR1–FGFR3, two 
alternative exons (IIIb and IIIc) code for the second half of D3 and are spliced to the 
common exon IIIa (encoding the ﬁrst half of D3) (Figure 2). These alternative splicing 
events occur in a tissue speciﬁc fashion, resulting in mesenchymal “c” and epithelial 
“b” isoforms and this variation deﬁnes ligand-binding afﬁnity and speciﬁcity of 
FGFR1-3. 
   
8
 Figure 2. FGFRs structures and isoforms. (N: N-terminus; D1-3: immunoglobulin (Ig)-like loops; AB: 
Acidic Box; HBS: Heparin Binding Site; TM: Transmembrane domain; TK1-2: Tyrosine kinase domain; 
C: C-terminus; a,b,c: exons participating to splicing events) (1, 6). 
 
FGFRs role has been evaluated through the use of null or conditional loss-of- 
function transgenic mice (Table 2). Fgfr1-/- mice do not survive early embryonic 
phases while, using conditional inactivation of Fgfr1 in osteo-chondrocyte progenitor 
cells and in differentiated osteoblasts, it has been shown that FGFR1 signalling is 
important in limb establishment and bone formation (7, 8). Mice lacking Fgfr2 survive 
until embryonic day 10–11. These embryos fail to form a functional placenta and do 
not form limb buds (9). The conditional inactivation of Fgfr2 showed osteoprogenitors 
proliferation defects and mice presented dwarfism (10). Fgfr3-null mice are viable 
and present a skeletal overgrowth and other defects. Mice lacking Fgfr4 are viable, 
and they present minor liver-related defects (11). Finally Fgfrl1-/- mice present 
diaphragm hypoplasia, heart and skeletal anomalies (12, 13). The involvement and 
role of FGFRs in skeletal development will be later discussed. 
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Table 2. Phenotypes of germline and conditional loss-of-function Fgfr mutations in mice. (1) 
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Ligand binding specificity of the 18 secreted (canonical and endocrine) FGFs 
have been compared using various mitogenic assays and by directly measuring 
affinity for FGFRs (Zhang 2006). Each FGFR isoform react to specific FGFs (Table 
3). These FGFs bind FGFRs in dimers in concert with heparan sulfate proteoglycan 
(HS). Complex FGF-HS-FGFR dimers stimulate the tyrosine kinase activity through a 
process of trans-autophosphorylation that triggers the transduction signalling that will 
end in the activation of the targeted genes. In fact the activated receptor is able to 
bind and phosphorylate other proteins that will lead to the transduction of the 
signalling through different pathways. 
FGFR dimerization is needed to transduce biochemical signalling, but the 
widely believed role of FGFs in producing FGFR dimerization (14) is a current object 
of debate since a recent study shows the presence of FGFR dimers in FGFs absence 
(15). The same study indicates the presence of FGFR phosphorylation in 
unlinganded dimers, however the FGF binding still determines a more consistent 
phosphorylation of the FGFR dimers. 
 
Table 3. Receptor speciﬁcity of canonical and endocrine FGFs. (1) 
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2. FGFR-related diseases 
 
Mutations in FGFRs have been found responsible for several pathological 
syndromes. Here we will detail the FGFR-related diseases with a special focus on 
pathologies du to FGFR3 mutations. 
2.1 FGFR1 and FGFR2-related diseases 
 
Fgfr1 is located on 8p11.23 and spans 58 kb whereas Fgfr2 is located on 10q26.13 
spanning 120 kb. Both Fgfr1 and Fgfr2 transcripts are composed of 18 exons (17 
coding exons), their expression is limited to bone and cartilage (16). Most of the 
activating mutations in Fgfr1 or Fgfr2 have been detected in cranyosinostosis 
syndromes that are briefly describe in Table 4. Craniosynostosis occurs in 
approximately 1 in 2 100 to 1 in 2 500 live births (17, 18), and is characterized by the 
premature fusion of one or more cranial sutures resulting in malformation of the skull. 
Potential consequences of abnormal skull growth include increased intracranial 
pressure, problems with hearing and vision, impaired blood ﬂow in the cerebrum, and 
developmental delay (19). 
Table 4. FGFR1 and FGFR2 related craniosynostoses. 
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2.2 FGFR3-related diseases 
 
Fgfr3 is located on 4p16.3 and spans 16.5 kb. Its transcript is composed of 19 
exons which only 2 to 18 are coding exons. The gene expression has been 
demonstrated in brain (astrocytes and glial cells), growth plate cartilage, intestine,
pancreas, testis, cochlea and crystalline lens (20). Mutations in FGR3 are 
responsible for bone disorders (chondrodysplasias and craniosynostoses) and for 
various forms of cancer. Fgfr3 harbors almost exclusively dominant mutations leading 
to a gain of function in almost all cases. Only in the very rare case of Camptodactyly, 
tall stature, and hearing loss (CATSHL) syndrome it has been proposed a dominant 
negative mechanism. In any case Fgfr3 is not a haplo-insufficient gene: it means that 
removing one of the two copies of the gene doesn’t lead to mutant phenotype. In this 
chapter we explore the FGFR3-related pathologies highlighting their clinical features 
and the mutations underlying their etiology. 
 
2.2.1 Osteochondral disorders 
 
2.2.1.1 Chondrodysplasias 
 
Chondrodysplasias is a family of genetic diseases characterized by a 
disturbance in the development of the cartilage of the long bones, especially of the 
epiphysial plates, resulting in arrested growth and dwarfism. Here we present 
chondrodysplasias due to point mutations in FGFR3 gene. 
2.2.1.1.1 Achondroplasia (ACH) 
 
The term ‘achondroplasia’ was first used by Jules Parrot in 1878, and in 1900 
Pierre Marie described the main features in children and adults. As ACH 
(OMIM#100800) is the most common disorder associated and with its 
disproportionate short stature is probably one of the best-known and -defined 
chondrodysplasias (Figure 3). This condition is estimated to occur in between 1 in 10 
000 and 1 in 30 000 live births (21, 22). ACH patients present a rhizomelic dwarfism 
associated with macrocephaly, midface hypoplasia, prognatism (23), kyphoscoliosis 
(24), cervicomedullary compression, spinal stenosis and loss of synchondroses (25). 
ACH is an autosomal dominant disorder, frequently de novo and associated with 
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advanced paternal age due to an increased presence of FGFR3 mutations during 
spermatogenesis in men over 35 (26). The cause of this disease has been identified 
in a point gain-of-function heterozygous mutation in FGFR3 (27, 28). The most 
recurrent mutation (over 95% of cases (21)) is Gly380Arg localized in the TM domain 
of the receptor (Figure 9). In adulthood affected patients reach an average of 130 cm 
for males and 125 cm for females (29) due to an abnormal development that can be 
diagnosed in utero through medical ultrasound since the beginning of the third 
trimester (30, 31). ACH patients face higher rates of deaths compared to the 
unaffected population (basically due to sudden death, heart diseases end 
neurological diseases) (32) and present severe medical complications (spinal 
stenosis, tibial bowing, obstructive apnea). 
  
Figure 3. ACH phenotype. In the left picture a couple of twins, the right one is affected by ACH. In the 
Right picture X-rays of ACH patient. 
 
2.2.1.1.2 Hypochondroplasia (HCH) 
 
HCH (OMIM#146000) (1 / 30 000 live births) is a skeletal dysplasia, 
characterized by short stature, disproportionately short arms and legs; broad, short 
hands and feet; mild joint laxity; and macrocephaly (33). The skeletal features are 
very similar to those seen in ACH but tend to be milder. Medical complications 
common to ACH (spinal stenosis, tibial bowing and obstructive apnea) occur less 
frequently in HCH, but intellectual disability and epilepsy may be more prevalent. The 
diagnosis is difficult to make in children under the age of three years, as skeletal 
disproportion tends to be mild and many of the radiographic features are subtle 
during infancy. DNA-based testing is possible and about 70% of affected individuals 
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are heterozygous for a mutation in FGFR3. However, there is evidence that locus 
heterogeneity exists, implying that mutations in other as-yet unidentified genes may 
result in similar, if not identical, phenotypes. The adult height for men with this 
condition ranges from 138 centimeters to 165 centimeters while the height range for 
adult women is 128 centimeters to 151 centimeters. Missense, gain-of-function, 
mutations responsible for this disease are localized in different FGFR3 domains: 
extracellular, transmembrane and tyrosine kinase with N540K as the most recurrent 
mutation. 
 
Figure 4. Patients affected by HCH. These sufferers show a rhizomelic dwarfism less severe 
compared to ACH patients. 
 
2.2.1.1.3 Thanatophoric Dysplasia (TD) and Severe Achondroplasia with 
Developmental Delay and Acanthosis Nigricans (SADDAN) 
 
TD and SADDAN are the more severe diseases related to gain-of-function 
mutations in FGFR3. TD (1 / 20 000 to 1 / 50 000 live births) is a lethal skeletal 
dysplasia due to heterozygous mutations in FGFR3. This pathology was firstly 
described in 1967 (34). Two types of TD are clinically diagnosed based on ultrasound 
and radiographic ﬁndings. TD type 1 (OMIM#187600) patients have prominently 
curved femurs, while TD type 2 (OMIM#187601) patients typically have straight 
femurs, a severe form of craniosynostosis (often referred to as a cloverleaf skull) and 
a small chest (35). Several different gain-of-function mutations in FGFR3 cause TD 
type 1. Mutations R248C, S249C, S371C, and Y373C create novel cysteine residues 
in the extracellular and intramembranous domains, while other mutations causing TD 
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type 1, such as X807R, X807C, X807E, X807S, and X807W, obliterate the stop 
codon resulting in extension of the intracellular domain by an additional 141 amino 
acids. TD type 2 is caused by the FGFR3 mutation K650E. SADDAN Severe 
achondroplasia, developmental delay and acanthosis nigricans (OMIM#616482) was 
first discovered in 1999 (36) and it is caused by a K650M mutation in FGFR3. Most of 
the patients develops extensive areas of acanthosis nigricans in early childhood, 
suffers from severe neurological impairments, and survives without prolonged life-
support measures (37). However the differences between TD and SADDAN 
phenotypes are not always evident (38). The substitution of a methionine residue at 
position 650 differentiates SADDAN from type 2 thanatophoric dysplasia, which 
arises from a glutamic acid substitution at the same position. Interestingly mutations 
at the same residue K650N, K650Q (39) and K650T (40) are responsible for the less 
severe hypochondroplasia. The SADDAN amino acid change induces a FGFR3 
phosphorylation that is threefold greater than normal. 
 
Figure 5. From left to right examples of TD type 1, TD type 2 and SADDAN. TD type 1 patients 
present femurs with a “telephone receiver" appearance. TD type 2 affected individuals are recognized 
by straight femurs and presence of cloverleaf craniosynostosis. SADDAN patients suffer of a severe 
dwarfism and feature the skin lesion acanthosis nigricans. 
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2.2.1.2 Craniosynostoses 
 
As previously defined for FGFR1 and FGFR2 related craniosynostoses, these 
pathologies arise from the premature fusion of skull sutures. Also mutations in 
FGFR3 can lead to craniosynostosis: until now this gene contributes to 
craniosynostoses family with two syndromes. 
 
2.2.1.2.1 Muenke Syndrome (MS) 
 
MS (OMIM#602849) constitutes the most common syndromic form of 
craniosynostosis, with an incidence of 1 in 30 000 births. Of all patients with 
craniosynostosis, 8% have MS (17, 18). Both sporadic and familial cases have been 
reported. MS displays incomplete penetrance and a variable phenotype even within 
families (41). Characteristics include bi- or unicoronal synostosis, midfacial 
hypoplasia, macrocephaly, and downslanting palpebral ﬁssures. Some affected 
individuals have additional features that may include sensorineural hearing loss, 
developmental delay, brachydactyly, and coned epiphyses in the hands and feet. MS 
craniosynostosis is a result of a speciﬁc heterozygous gain-of-function mutation, 
P250R, found in the linker region between domains D2 and D3 of FGFR3 (42). 
Increasing paternal age is a contributing factor for de novo mutations (43). 
 
 
Figure 6. 4 month child affected by MS. The MR images in sagittal and axial views show the 
severity of the brachycephaly. 
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2.2.1.2.2 Crouzon with Acanthosis Nigricans syndrome (CAN) 
 
Patients with CAN (OMIM#612247) have multiple sagittal or coronal fusions 
causing brachycephaly, trigonocephaly, and rare reports of cloverleaf skull 
malformation. Attributes typically include hypertelorism, a small midface, beaked 
nose and protrusion of the eyes. CAN has an estimated prevalence of 1 / 1 000 000 
newborns and most cases are sporadic and associated with paternal aging, although 
familial cases consistent with autosomal dominant inheritance have been reported. 
Characteristic of this disease is the presence of hyperpigmentation of the skin 
(acanthosis nigricans), hyperkeratosis, and other skin ﬁndings. A speciﬁc FGFR3 
heterozygous gain-of-function mutation A391E, responsible for the syndrome, is 
located in TM (44, 45). 
 
Figure 7. Manifestation of CAN syndrome. Lateral close up and radiograph. 
 
2.2.1.3 Other FGFR3-disorders 
 
Camptodactyly, tall stature, and hearing loss (CATSHL) syndrome 
 
Dominantly inherited, camptodactyly, tall stature, scoliosis, and hearing loss 
syndrome (CATSHL; OMIM#610474) is caused by a FGFR3 heterozygous missense 
mutation, R621H, residing within the tyrosine kinase domain generating a loss-of-
function that promotes endochondral bone growth (46). For several reasons, it is 
unlikely that the loss of function caused by p.R621H results from haploinsufficiency. 
In fact, mice heterozygous for an Fgfr3 null allele are phenotypically normal and the 
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fibroblasts of individuals affected with CATSHL syndrome express both wild-type and 
mutant FGFR3 RNA in nearly equal proportions, and the expression levels of all five 
FGFRs in patients are similar to those of normal individuals. Furthermore, both 
mutant and wild-type FGFR3 localize to their normal position in the cell membrane 
(46). These observations suggest that p.R621H might, instead, cause loss of FGFR3 
function by a dominant negative mechanism. Recently, a novel homozygous mutation 
T546K has been described as also causing skeletal overgrowth (47). 
 
Figure 8. Patient affected by CATSHL syndrome. The disorder is characterized 
by tall stature and scoliosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. FGFR3 mutations in osteochondro-related disorders. Most common mutations for each 
disease are underlined. 
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2.2.2 Cancer  
 
As already shown, germline mutations in FGFR3 cause skeletal disorders. The 
same point mutations have been identified to cause cancer (48). In literature we can 
find various examples of FGFR3 constitutive activation in the cancer field. In fact 
somatic mutations in this gene can induce the cancer progenitors to fulfill their 
maturation, meaning that FGFR3 mutations are tumorigenic thus FGFR3 is an 
oncogene. FGFR3 have been reported to play a role in multiple myeloma (49) where 
a translocation t(4;14)(p16.3;q32) causes the overexpression of the gene. This 
translocation links FGFR3 to the immunoglobulin heavy chain ICH locus. These 
translocations are intergenic, with the breakpoints occurring ~70 kb upstream of 
FGFR3, and bring FGFR3 under the control of the highly active IGH promoter. It is 
important to note that the translocations involving FGFR3 in multiple myeloma also 
involve the adjacent multiple myeloma SET domain-containing (MMSET) gene, and 
the relative contributions of FGFR3 and MMSET to oncogenesis are subject to 
ongoing debate. The ultimate effect of the translocation is to overexpress FGFR3 out 
of context, which might result in aberrant ligand-dependent signalling or ligand-
independent signalling. In a small proportion of t(4;14) multiple myeloma, FGFR3 is 
also mutated (~5% translocated cases), presumably further reinforcing FGFR3 
signalling. 
FGFR3 is also implied in bladder cancer, the fourth most common tumor 
among males. More than 90% of bladder cancers are urothelial cell carcinoma and 
about 5% are squamous cell carcinoma. The gender ratio of male to female is 3 to 1 
and the best known environmental risk factor is smoking. Urothelial cell carcinoma 
patients are classified by pathologic stage. The stage classification differentiates 
between non-muscle invasive (NMI; Tis, Ta, and T1) and muscle-invasive (T2, T3, 
and T4) tumors according to the invasion depth. Ta tumors are restricted to the 
urothelium, T1 tumors present invasion of the lamina propria, T2 of the superficial 
muscle, T3 of the perivesical fat and T4 of surrounding organs. Tis is poorly 
understood and believed to be a precursor of muscle-invasive tumors. Most of the 
patients (70%) initially present NMI tumors and after treatment up to 70% of these 
patients will develop one or several local recurrences. About 25% of NMI patients 
progress to muscle-invasive tumors disease that can potentially lead to metastasis. 
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About 50% of all patients present an FGFR3 mutation and the most recurrent is 
S249C (50–52). 
Somatic mutations were found also in other cancers: prostate cancer (53) with 
2 missense mutations (S249C and A393E), spermatocytic cancer (54) with the 
K650E mutation and in cervix cancer as well (55, 56) with the only S249C missense 
mutation.  
 
2.2.3 Skin lesions  
 
FGFR3 mutations are also associated with particular skin lesions. In the case 
of SADDAN we have already discussed the appearance of the skin lesion acanthosis 
nigricans, a velvety hyperpigmentation of the skin. Somatic FGFR3 mutations were 
also identified in benign skin tumors. Analysis of human seborrheic keratoses 
revealed somatic FGFR3 mutations in 40% of the benign tumors. The prevalence of 
FGFR3 mutations was even higher (85 %) in adenoid seborrheic keratoses, a 
particular histological subtype of seborrheic keratosis (57). FGFR3 mutations in 
human skin can cause common non-organoid epidermal nevi (58). In that study 
normal skin adjacent to the epidermal nevus did not show the presence of FGFR3 
mutations. Finally other studies showed the presence of FGFR3 mutations in solar 
lentigo, in 5 out 30 patients, (59) and in lichenoid keratosis, in 6 out of 52 patients 
(60). 
 
2.2.4 Consequences of different mutations on receptor activity 
 
FGFR3 mutations implied in chondrodysplasias are localised in different 
receptor domains (Figure 9). FGFR3 gain-of-function mutations are characterized by 
an abnormal phosphorylation of the receptor. However the phosphorylation level 
varies depending on the FGFR3 harboured mutation. FGFR3 studies in vitro have 
highlighted higher phosphorylation levels for the mutation K650M (SADDAN) and 
K650E (TD type 2) (61), with the K650M mutation presenting the higher 
phosphorylation level (62). This elevated FGFR3 phosphorylation will be transduced 
to the downstream signalling pathway activating its function disproportionately. We 
can imagine that mutations in TK1 and TK2 determine protein conformational 
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modification that increase the transphosphorylation between the receptors that make 
up the dimer (39). Even if other mutations are not localised in TK1 and TK2 as 
G380R (ACH), Y373C (TD Type 1) or A391E (CAN) the higher phosphorylation level 
compared to FGFR3 wild-type could be explained. In fact these mutations localised in 
TM domain could lead to an over-stabilization of the dimer causing an increase of the 
transmitted signals (63, 64). Other studies have also suggested that these mutations 
disrupt c-Cbl-mediated ubiquitination that serves as a targeting signal for lysosomal 
degradation and termination of receptor signalling. This defect would distance 
actively signalling receptors from lysosomes prolonging their survival and signalling 
capacity (65).  
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3. Skeletogenesis 
 
Skeletogenesis it is a hard task that consists in elaborating an edifice of more 
than 200 pieces of bone and cartilage. Each skeletal piece is modeled at a distinct 
location in the body, is articulated with others, and reaches specific sizes, shapes, 
and tissue compositions according to both species instructions and role. Here we will 
explore the main stages of this process with a special focus on FGFR role in the 
phenomenon. 
 
3.1 Early embryo development 
 
The first step in skeletogenesis consists in generating osteochondral 
progenitor cells. The origin of these cells is linked with the early stages of embryo 
development, when the vertebrate embryo is composed of three germ layers: 
ectoderm, mesoderm, and endoderm (Figure 10). From the neural crest several 
throat and craniofacial skeletal elements arise; the lateral plate mesoderm gives rise 
to other craniofacial skeletal structures, the limb skeletal elements (appendicular 
skeleton), the sternum (part of the axial skeleton); finally the paraxial mesoderm 
gives rise to somites, which develop into sclerotomes (ribs and vertebrae). The 
vertebrae, developing around the notochord, will force the notochord cells to change 
phenotype, migrate to the intervertebral spaces, and develop the nuclei pulposi (NP) 
of Intervertebral Discs (IVDs) (Lefebvre and Bhattaram, 2010).  
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Figure 10. Origin of osteochondro-progenitor cells in the vertebrate embryo. Scheme of a cross-
section of mouse embryo after gastrulation at day 8 of development (equivalent to day 17 in humans). 
The three germ layers are shown: ectoderm, endoderm, and mesoderm (66) 
These neural crest and mesoderm cells will reach their skeletal sites through 
the expression of specific factors as the Homeobox (Hox) genes (67). Before 
reaching their skeletal sites, neural crest- and mesoderm-derived cells produce a 
matrix rich in collagen-1, fibronectin, and hyaluronan, and they proliferate or die in a 
tightly controlled spatial and temporal manner (68). They thereby establish 
mesenchymal structures that prefigure the future skeletal elements. These cells are 
called osteochondro-progenitors because most of them give rise to osteoblasts and 
chondrocytes. 
Development of the vertebrate skeleton occurs through the processes of 
endochondral and intramembranous bone formation. Endochondral-derived bones 
comprise the appendicular skeleton, facial bones, vertebrae, and medial clavicles, 
while intramembranous bones comprise the cranium and lateral clavicles. 
Endochondral ossification initiates with the condensation of mesenchyme, followed 
by the formation of a cartilaginous template that patterns the developing skeleton and
the segmentation of this template into cartilaginous joints. Intramembranous bone 
forms from a mesenchymal condensation that directly gives rise to bone. 
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3.2 Chondrogenesis 
 
Mesenchymal condensation is characterized by the aggregation of loose 
mesenchymal cells and the expression of extracellular matrix proteins and cell 
adhesion molecules (type I collagen (Col I), hyaluronan, N-cadherin, tenascin-C). The 
transcription factor Sry box containing 9 (Sox9), that acts in concert with Sox5 and 
Sox6, is necessary for the beginning of the chondrogenesis as well as the bone 
morphogenetic protein (BMP) receptors 1a and 1b (69). Proliferating cells within the 
mesenchymal condensation begin to express type II collagen (Col II) 
(chondroprogenitors) while cells on the borders of the structure express Col I 
(osteoprogenitors) (70). Proliferating chondrocytes form columns that are oriented 
along the longitudinal axis of the developing bone to define the future growth plate 
(Figure 11).  
At the center of the developing bone chondrocytes expressing specific 
markers (type X collagen (Col X), Indian Hedgehog (IHH), ParaThyroid Hormone 
(PTH) 1 Receptor (PTH1R)) differentiate into prehypertrophic chondrocytes 
increasing their volume and arresting their proliferation. The down-regulation of Sox9 
is necessary to allow this chondrocyte maturation, however a level of expression of 
this transcriptor factor is a requirement for the chondrocyte identity (71, 72). Runt- 
related protein 2 (Runx2) and Runx3 are required for chondrocyte differentiation, with 
Runx2 determining chondrocyte proliferation through Ihh expression (73). Several 
signalling pathways (IHH, PTH, FGF, BMP and Wnt) regulate the equilibrium 
between proliferating and hypertrophic chondrocytes (74). Wnt and PTH-related 
peptide (PTHrP) signals modulates the calcium/calmodulin-dependent protein kinase 
II (CAMK2) level, which induces chondrocyte hypertrophy increasing RUNX2 and β-
catenin activity (75). Hypertrophic chondrocytes, pushed by the proliferative 
chondrocytes along the axis, in their late phase secrete vesicles containing enzymes 
that degrade the cartilage matrix and mineralize their surroundings (76). Finally those 
chondrocytes commit apoptosis or differentiate into osteoblasts (77, 78). 
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3.3 Endochondral ossification 
 
The formation of a primary ossification center and bone collar that starts prenatally 
(79) is characterized by the differentiation of Col I-producing osteoblasts on the 
border of the hypertrophic chondrocyte zone and determines the origin of mineralized 
bone. Osteoprogenitor cells (belonging to the Osterix lineage) localized in the 
perichondrium and in the periosteum differentiate into osteoblasts responsible of the 
trabecuale formation. The osteoblasts derived from the late hypertrophic cells 
(belonging to the Col I lineage) will be responsible of the cortical bone (80). The 
expression of Vascular Endothelial Growth Factor (VEGF-A) in hypertrophic 
chondrocytes determines the beginning of the vascularization leading to the 
recruitment of endothelial cells, osteoprogenitor cells, and osteoclasts that will later 
participate in the bone remodeling process (81). The cartilaginous matrix left behind 
by the hypertrophic chondrocytes will work like a mold for the osteoblastic progenitors 
that they will fulfill with mineralized matrix giving rise to the primary ossification 
center. The primary ossification center will progressively elongate following the same 
longitudinal axis primarily determined by the columnar chondrocytes. The late 
hypertrophic chondrocytes, osteoblasts and osteoclasts will take the charge of 
dismantling the remains of the cartilage matrix through Matrix metalloproteinases 
(MMP) expression (82). With the postnatal formation of a secondary ossification 
center at the epiphysis we observe the classic growth plate with well-demarcated 
zones of cells presenting vascular elements in the primary bone (Figure 12). Finally 
osteoclasts bone remodeling abilities will be applied in the definition of the bone 
marrow cavity in the diaphysis that presents an intricate network of vessels compared 
to the growth plate. 
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 Figure 11. Endochondral ossification. Long bones are formed by endochondral ossification (83). 
 
 
Figure 12. Long bone and growth plate structure. Primary Ossification Center (POC), Growth Plate 
(GP) and Secondary Ossification Center (SOC).  
 
3.4 Intramembranous ossification 
 
In the structure that will give rise to the skull, at the beginning of intramembranous 
ossification (Figure 13) mesenchymal cells condensate and differentiate primarily into 
osteoprogenitor cells and secondly into osteoblasts, in total absence of cartilage and 
chondrocytes. These osteoblasts directly derived from osteoprogenitor give rise to 
ossification centers where they will produce mineralized (84). These ossification 
centers are responsible for the development of the skull bone, but their osteogenic 
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fronts will never merge determining the appearance of the sutures (85). An abnormal 
fusion of the sutures (synostosys) would impair the skull growth. Mesenchymal cells 
surround the suture and part of them differentiate into osteoprogenitors and then into 
osteoblasts lining the developing bone. When the bone is formed osteoblasts finally 
die by apoptosis or become embedded in the bone matrix as osteocytes, which then 
also eventually undergo apoptosis (86). The expression of Runx2 is responsible for 
the differentiation of mesenchymal stem cells into osteoblasts (opposed to Sox9 
responsible for the differentiation of the same cells into chondrocytes). Runx2 is a 
fundamental transcription factor that regulates several genes in osteoblasts, such as 
Col I, bone sialoprotein (BSP), osteopontin (OP), alkaline phosphatase (ALP), 
transforming growth factor (TGFβ), and osteocalcin (OC) (87, 88). Transcription 
factors, such as Msh homeobox 2 (MSX2) and Distal-less homeobox 5 (DLX5), play 
important roles in osteoblast differentiation during cranial bone formation in part by 
interacting with RUNX2 (89). Several factors (as TGFβs, BMPs, FGFs, and Wnt 
signalling) are responsible for the regulation of differentiation and survival of the cells 
participating to the bone formation process (85, 89). 
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 Figure 13. Intramembranous ossification. Craniofacial bones are formed directly from 
condensations of mesenchymal cells without the formation of a cartilage intermediate. (83). 
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3.5 FGFR signalling and early skeletal development 
 
FGFs and FGFRs will participate in all the skeletal development stages. We 
can observe the first FGFR expression even before the mesenchymal cells 
condensation. The origin of the appendicular skeletal is recognizable in the 
embryonic mesenchymal limb bud formation (Figure 14). Different mechanisms have 
been proposed to determine the limb bud development process (90) and in all of 
them FGFRs and FGFs play an essential role. In fact the distal limb bud 
mesenchyme expresses both FGFR1 and FGFR2 (91, 92). FGFR3 and FGFR4 are 
not expressed, so they do not take part to the process (92). At the bottom of the limb 
bud the apical ectodermal ridge (AER) produces FGFs called AER-FGFs. AER-FGFs 
(FGF4 and FGF8) bind FGFR1 and FGFR2 stimulating the limb growth (90) (Figure 
14). FGFR1 and FGFR2 are redundant in this tissue (93). Conditional inactivation 
mice have been used to determine the function of FGFR1 and FGFR2 in the 
mesenchymal limb bud. The conditional knockout in mesenchymal cells of both Fgfr1 
and Fgfr2 or the knockout of Fgfr1 lead to severe skeletal hypoplasia highlighting the 
major role of the receptors in mesenchymal tissue (8, 94). On the other hand the 
knockout Fgfr1 or Fgfr2 in distal limb bud mesenchyme resulted in milder skeletal 
phenotypes (95, 96), thus FGFR1 and FGFR2 are redundant in distal limb bud.  
At the beginning of endochondral ossification an increase of FGFR2 and Sox 9 
expression is observed in condensing mesenchymal cells compared to the 
surrounding cells of the mesenchyme (92, 97) (Figure 15). At the borders of the 
mesenchymal condensation both FGFR1 and FGFR2 expressing-cells are present 
and they will constitute the perichondrium and periosteum (97) (Figure 15). With the 
differentiation of mesenchymal cells into chondrocytes there is an expression of 
FGFR3, Sox9 and Col II while FGFR2 expression is decreased (98). The expression 
of these markers indicate the appearance of proliferative chondrocytes. In 
hypertrophic chondrocytes FGFR3 expression is decreased whereas FGFR1 
expression is increased (7, 99) (Figure 15). The mesenchymal condensation and the 
differentiation of its cells in chondrocytes is modulated by the FGFRs (94, 100). In 
fact in chondroprogenitor cells and in primary chondrocytes the FGF signalling is 
responsible for an increase of Sox9 expression and Extracellular Signal-Regulated 
Kinase 1/2 (ERK1/2) activation (101, 102). FGFR3 expression in proliferating 
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chondrocytes requires Sox9 expression, and Sox9 regulatory binding sites have 
been found in the Fgfr3 gene (103). FGFR3 is activated by FGF9 and FGF18 
expressed in mesenchyme stimulating chondrocyte proliferation (104, 105). In the 
forming perichondrium, bonecollar, and trabecular bone the expression of FGFR1 in 
mesenchymal progenitors and FGFR2 in differentiating osteoblasts are detected (7, 
106). Moreover FGFR1 and FGFR3 are co-expressed in mouse and human articular 
chondrocytes (107, 108). Difference in FGFRs expression has been observed 
between immature cultured osteoblasts and mature osteoblasts in vitro: the first
express relatively higher levels of FGFR1, the second of FGFR2 (109) 
FGFs (FGF2, FGF4, FGF9, FGF18) and FGFRs (FGFR1, FGFR2, and 
FGFR3) are also determinant for the early stages of intramembranous ossification 
(110, 111). FGFR2 is expressed in early mesenchymal condensations and then in 
sites of intramembranous ossification, where it interacts with FGF18 (97). At later 
stages during cranial bone development, FGF8 is expressed in mesenchymal cells 
and differentiating osteoblasts (110, 112). FGF9 is expressed throughout calvarial 
mesenchyme during mid to late stages of embryonic development (113). Mice lacking 
both FGF9 and FGF18 have severe defects in skull bone formation (114). FGFR1 
and FGFR2, which are expressed in preosteoblasts and osteoblasts (109), are likely 
receptors for FGF9 and FGF18 in developing membranous bone (115). 
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Figure 14. Proximodistal limb bud axis development. The limb skeletal elements (stylopod, 
zeugopod, autopod) are determined early in embryo development. The origin of limb development is in 
the limb bud, however different models of this mechanism have been formulated. In all of them the role 
of AER and AER-FGFs is essential. Here it is presented the progress zone (PZ) model: the 
mesenchyme that underlies the AER contains mesenchymal cells regulated by AER signals. As limb 
bud growth progresses distally, proximal cells are too far to be influenced by AER-FGFs. The first cells 
to lack their influence will give rise to stylopod, the second the zeugopod and finally the autopod.(90). 
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Figure 15. FGF and FGFR expression during endochondral and intramembranous ossifications. 
(A–D) From chondrogenesis to the primary ossification center. (E) Embryonic growth plate. (F) 
Postnatal growth plate after formation of the secondary ossification center. (G) Intramembranous 
ossification. Cells and tissues are color-coded for expression domains of FGFs and FGFRs. (BM) 
Bone marrow. (93). 
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3.6 FGFR signalling in growth plate 
 
Chondrocytes FGFRs expression is different within the growth plate (Figure 
15). Briefly, there are low levels of FGFR2 in the resting zone, high levels of FGFR3 
in the proliferating and prehypertrophic zone, and high levels of FGFR1 in 
hypertrophic chondrocytes (99, 116). We will now investigate the role of the FGFRs 
and their signaling pathways in this tissue. 
Conditional inactivation experiments in mice shed light on FGFR2 function in 
resting chondrocytes. The conditional knockout in limb bud mesenchyme (10) leads 
to a reduced growth in mice. This data could suggest a role in skeletal development, 
but at the analysis of the growth plate no anomalies were detected in proliferative 
chondrocytes. The phenotype is probably linked to an effect on osteoblasts rather 
than on chondrocytes, or on an indirect increase of osteoclastic activity (10). Thus 
FGFR2 has more a redundant function in resting or proliferating chondrocytes. 
In early embryonic stages of skeletal development, during the growth plate 
formation, FGFR3 stimulates the chondrocyte proliferative activity (62, 104). By cons, 
during postnatal skeletal growth, FGFR3 signalling inhibits chondrogenesis, leading 
the proliferating chondrocytes to their differentiation into prehypertrophic and 
hypertrophic chondrocytes (117, 118). This paradoxical activity of FGFR3 is the 
reason why chondrodysplastic disorders due to gain-of-function mutations in FGFR3 
(that we have already discussed in chapter 2) have a decreased proliferation and 
differentiation of proliferating chondrocytes during pre-pubertal skeletal growth (119, 
120). 
FGFR3 downstream signalling pathways in growth plate chondrocytes involve 
several factors: Signal Transducer and Activator of Transcription 1 (STAT1), ERK1/2, 
p38, Snail1 (Zinc finger protein SNAI1), AKT, protein phosphatase 2a (PP2a), p107 
and p130 (Figure 16) (121, 122). The chondrocyte proliferation arrest resulted from 
FGFR3 activation is effected through increased expression of the cell cycle inhibitor 
p21Waf1/Cip1 and activation of p107 and p130 (121, 123). Snail1 expression is 
induced by FGFR3 and is expressed at high levels in human thanatophoric dysplasia 
bone tissue. Ectopic activation of SNAIL1 in mice resulted in an ACH phenotype with 
decreased chondrocyte proliferation and shortened bones at late embryonic stages 
(124). Interestingly SNAIL1 acts activating both STAT1 and MAPK branches of the 
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FGFR3 signalling pathway, as the ectopic activation of the protein resulted in nuclear 
translocation of STAT1 and increased phosphorylation of ERK1/2 (124). The 
mechanism behind SNAIL1 regulation of STAT1 and MAPK pathways is still poorly 
understood. However it has been proposed, analyzing breast cancer cells, that 
SNAIL1 may regulate the nuclear localization of p-ERK (125). In the same cells it has 
also been shown that activated ERK2 directly phosphorylates SNAIL1, leading to its 
nuclear accumulation (126). In support of a requirement for SNAIL proteins in 
regulating chondrogenesis, conditional inactivation of both Snail1 and Snail2 resulted 
in increased p21Waf1/Cip1 and decreased chondrocyte proliferation (127). The bone 
growth anomalies lead by activating mutations in FGFR3 are due to decreased 
chondrocyte proliferation and differentiation. Experiments have led us to consider that 
these chondrocyte defects are diverse and regulated by different members of the 
FGFR3 signalling pathway. It has been proven that STAT1 regulates chondrocyte 
proliferation through in vivo experiments when proliferative defects in growth plate of 
mice with activating mutations in FGFR3 were rescued by the full inactivation of Stat1 
(128). However, in this model, inactivation of Stat1 still does not rescue the overall 
ACH phenotype considering that chondrocyte differentiation to hypertrophy was not 
corrected: in FGFR3-related disorders impaired chondrocyte hypertrophy, and not 
only the defective proliferation, is responsible for the decreased bone growth. The 
same studies proved also that the activation of MAPK signalling suppressed 
chondrocyte hypertrophy, resulting in skeletal dwarfism (128).The mechanism may 
involve the suppression of SOX9 down-regulation in prehypertrophic chondrocytes by 
activated FGFR3 signalling (102, 129). Additionally, activation of the PP2A–B55α 
holoenzyme by FGFR3, which dephosphorylates and activates p107, could 
contribute to decreased chondrocyte hypertrophy (121, 122). In support of the model, 
previously presented, according to which STAT1 activation arrests chondrocyte 
proliferation and MAPK signalling is responsible for chondrocyte differentiation, there 
are the studies performed on the C-type natriuretic peptide (CNP) signalling pathway 
and its interaction with the FGFR3 pathway (130). In fact CNP expression was found 
to attenuate the phenotype of ACH mice through inhibition of MAPK signalling, which 
restored matrix production and hypertrophic differentiation. The activity of CNP was 
independent of the STAT1 one and did not modify chondrocyte proliferation. 
However that the functions of the STAT1 and MAPK pathways are completely distinct 
is still unsure. In fact it has been shown that in cultured chondrocyte the suppression 
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of proliferation required MAPK signalling and was independent of STAT signalling 
(131, 132). In support of these studies, mice lacking ERK1 and conditionally lacking 
ERK2 in chondrocytes showed an increase in chondrocyte proliferation at late 
embryonic stages (133, 134). Still we have to consider some variables that could 
have produced these results: the variability in the experiments may be due to in vitro 
culture conditions or by the developmental stage being examined. In fact it is really 
common to observe differences between the embryonic and postnatal signallings. 
 
Figure 16. FGF/FGFR signalling pathways involved in proliferating chondrocytes. (93) 
 
Other mechanisms by which FGFR3 signalling may indirectly regulate growth 
plate development include the regulation of BMP, Wnt, IHH, and PTHrP/PTH1R 
expression and activity (Figure 17). Comparisons of activating mutations in Fgfr3 and 
mice lacking Fgfr3 show that FGFR3 signalling suppresses expression of Bmp4, 
BMPR1a (BMP-receptor type 1A), Ihh, and PTH1R in postnatal growth plate 
chondrocytes (120, 135, 136). Additionally, in a chondrocyte cell line, overexpression 
of FGFR3 suppresses expression of both PTHrP and its receptor, PTH1R (137), and, 
in chondrocyte cell lines and micromass cultures, FGF signalling activates Wnt/β-
catenin signalling through phosphorylation of LRP6 (Low-density lipoprotein receptor-
related protein 6) and functions to suppress hypertrophic differentiation (138, 139). 
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PTHrP may also regulate FGFR3 expression. Analyses of the Fgfr3 promoter 
identified a transcriptional regulatory element, CSRh, which was repressed by PTH 
through a cAMP and protein kinase A (PKA)-dependent mechanism (140). 
 
 
Figure 17. Alternative pathways regulated by FGFR3. 
FGFR1 is prominently expressed in prehypertrophic and hypertrophic 
chondrocytes and overlaps with FGFR3 in the latters (Figure 15). To understand the 
role of FGFR1 signalling experiments have been performed in mice through the 
targeted inactivation of FGFR1. At early stages of development, Fgfr1 conditional 
knockout mouse shows impaired chondrocyte hypertrophy (105) on the other hand 
the Fgfr1 conditional knock-out mouse for later stages presents an increased 
hypertrophic zone (7).  
FGF9 and FGF18, FGFR3 ligands, are expressed in the perichondrium and 
are fundamental for growth plate organization (105, 112) (Figure 15). Mice lacking 
Fgf9, present rhizomelic shortening of the limbs. At early embryonic stages 
chondrocyte proliferation and differentiation are impaired in Fgf9 null mice (105). 
Mice lacking Fgf18 also showed decreased chondrocyte proliferation, but in the more 
distal part of the limb (141). These defects are related with FGF9 and FGF18 
signalling to FGFR3 and the proliferative-inducing activity FGFR3 in embryonic 
chondrocytes (62, 105). In fact the inactivation of FGF9 and FGF18 at later stages 
leads to an expansion of the hypertrophic chondrocyte zone, thus confirming that in 
mature growth plate FGFR3 suppresses chondrocyte proliferation and differentiation 
(105, 110).  
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3.7 Bone modeling 
 
Bone remodeling is required to repair old the bone and to prevent the aging 
effects and its consequences. This process requires balance between bone formation 
and bone resorption and direct communication among different bone cells. Cells of 
the osteoblast lineage (osteoblasts, osteocytes) and bone-resorbing cells 
(osteoclasts), together with their precursor cells, are organized in specialized units 
called bone/basic multicellular units (BMU) (142). We have already detailed the origin 
of osteoblasts, responsible for bone matrix synthesis and its subsequent 
mineralization, and osteoblasts-derived osteocytes. On the other hand osteoclasts 
are large, multinucleated giant cells formed from the fusion of mononuclear 
progenitors of the monocyte/macrophage in a process termed osteoclastogenesis 
(143). These cells are the main characters of the remodeling cycle. This process can 
be analyzed in seven sequential phases: quiescence, activation, resorption, reversal, 
formation, mineralization, and termination (Figure 18). The bone remodeling process 
is controlled by various local and systemic factors (Figure 19). The main factors 
regulating this system are Calcitonin, PTH, vitamin D3 and estrogen. PTH stimulates 
the proliferation and differentiation of osteoprogenitors to mature osteoblasts via IGF-
1 (144), induces RUNX2 expression in osteoblasts (145), increases osteoblast 
numbers and extends their survival (146). Along with IGF-I, PTH induces Receptor 
Activator of Nuclear factor κB Ligand (RANKL) and Macrophage Colony-Stimulating 
Factor (MCSF) from mature osteoblasts to promote osteoclastogenesis (147). PTH 
elevates cAMP levels and inhibits Mef2-stimulated Sost promoter activity in 
osteocytes, leading to decreased expression of sclerostin and an elevated bone 
formation rate (148). Vitamin D3 stimulates osteoblastogenesis via differentiation of 
mesenchymal stem cells to osteoblasts (149). Calcitonin suppresses bone resorption 
by inhibiting the activity of osteoclasts (150). Estrogen inhibits bone resorption by 
directly inducing apoptosis of the bone-resorbing osteoclasts (151). Androgens can 
also indirectly inhibit osteoclast activity and bone resorption via effects on 
osteoblasts/osteocytes and the RANKL/RANK/OPG (OPG: Osteoprotegerin) system 
(152, 153). In addition to systemic hormonal regulation, it is known that growth 
factors such as Insuline Growth Factors (IGFs), TGF-β, FGFs, Epidermal growth 
factor (EGF), WNTs, and BMPs play significant roles in regulation of physiological 
bone remodeling (143). 
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Figure 18. Bone remodeling sequencial phases. The ﬁrst stage of bone remodeling involves 
detection of an initiating remodeling signal, which has usually been described as resorption by 
osteoclasts. In the resorption phase, osteoblasts respond to signals generated by osteocytes or direct 
endocrine activation signals, recruiting osteoclast precursors to the remodeling site. It is followed by 
the reversal phase that is characterized by disappearance of almost all osteoclasts. The formation 
phase is distinct by complete replacement of osteoclastic cells with osteoblastic cells. The termination 
signals of bone remodeling include the terminal differentiation of the osteoblast. The resting bone 
surface environment is maintained until the next wave of remodeling is initiated. (143).  
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Figure 19. Regulation of bone remodeling. (143). 
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4. Therapeutic strategies 
 
Skeletal anomalies due to aberrant FGFR signalling require several surgical 
treatments to extend and improve the life of affected patients. For ACH, life 
threatening features as cervicomedullary compression, hydrocephalus and lumbar 
spinal stenosis are solved by surgical interventions (154, 155). Moreover affected 
individuals attain adult heights that are well below the fifth percentile and undergo 
long, painful and costly limb lengthening surgical treatments (156).Other surgical 
interventions are required for other FGFR-related pathologies, notably for 
craniosynostoses where they are necessary to allow a correct brain development 
(157). 
All treatments routinely administrated today to the affected population are 
surgical. There have been several trials of human growth hormone treatment in 
children with ACH: although there has been some increase in growth rate reported, 
especially early in the trials, no clear long-term benefit has been established and 
most experts do not recommend such treatment for ACH (158). However nowadays 
several alternative approaches have been proposed to enhance skeletal growth 
suppressing or counteracting the FGFR signalling pathway. We will now explore 
pharmacological approaches that have been tested or proposed to treat FGFR-
related diseases, focusing on the FGFR3 signalling pathway and ACH treatments.  
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4.1 FGFR3 signalling targeting strategies 
 
 
 
Figure 20. Strategies for therapeutic intervention. (1) chemical inhibitors to reduce fibroblast 
growth factor receptor 3 (FGFR3) tyrosine kinase activity; (2) antibodies to block receptor activation; 
(3) exogenous C-type natiuretic peptide (CNP) to enhance CNP-mediated antagonism of downstream 
signals; (4) RNAi to reduce FGFR3 production; (5) Hsp90 inhibitors to induce degradation of activated 
receptor; (6) agents to disrupt direct nuclear signalling of FGFR3. (7) Inhibition of FGF ligands that 
activate FGFR3; (8) chemical inhibitors to reduce SNAIL activity; (9) chemical inhibitors reducing MEK 
activity (modified from (159)). 
 
4.1.1 FGFR3 tyrosine kinase inhibitors (TKIs) (1) 
 
The rationale for this strategy is that activation and signalling of FGFR3 
depend on its kinase activity; consequently, chemical inhibition of its kinase activity 
should block its inhibitory output and restore bone growth. Several FGFR3 inhibitors 
have been discovered. CHIR-258, a small molecule inhibitor of receptor tyrosine 
kinase, inhibits FGFR3. Therapeutic efficacy of CHIR-258 was demonstrated in a 
xenograft mouse model of FGFR3 multiple myeloma (160). Two others inhibitors of 
FGFR3, PD173074 and SU5402, inhibit the growth and induce apoptosis of multiple 
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myeloma cells (161). PD173074 in mice can effectively block angiogenesis induced 
by either FGF or VEGF with no apparent toxicity and block small cell lung cancer 
growth (162, 163). A large number of these FGFR tyrosine kinase inhibitors reached 
the clinical trial phase (164).
However only two FGFR3 selective inhibitors have been reported to have an 
effect on bone growth. Aviezer and colleagues described synthesis of an oxindole-
based TKI selective for FGFR3 (165). The compound stimulated cartilage growth in 
cultured limb bones from a knock-in Fgfr3G369C/+ mouse model of ACH (166). Another 
effective TKI is A31 (167) that leads to the FGFR3 phosphorylation inhibition in cells 
and restores growth in limb explants of Fgfr3Y367C/+ mouse embryo, an ACH mouse 
model (168). However, because the structure of the tyrosine kinases domain is highly 
conserved among tyrosine kinase receptor subfamilies, kinase inhibitors frequently 
cross-react with other tyrosine kinase receptors. Such cross-reactivity is not 
problematic in cancer therapy, because cancer cells frequently depend on multiple 
tyrosine kinase receptors, but it could be more of a problem in the treatment of 
children with ACH, which involves only the single receptor. Moreover no TKI has 
been reported to be able to ameliorate growth in vivo (93). Gudernova and 
colleagues even assert that the use of TKIs in vivo show no positive effect on skeletal 
growth, but rather a toxic effect testing the compound AZD4547 (169). However such 
statements should be taken with a grain of salt since specificity and properties of 
chemical compounds as the TKIs vary widely depending on their molecular structure. 
 
4.1.2 FGFR3 antibodies (2) 
 
This strategy involves the use of humanized monoclonal antibodies to the 
extracellular domain of FGFR3. The binding between the antibody and the receptor 
constitutes a hindrance to the FGF ligand binding so that the activation of the 
receptor is no more inducible. These inhibitory antibodies have been developed and 
successfully applied as potential cancer therapeutics (170, 171). On the other hand a 
positive effect of these antibodies in an animal model of ACH has never been 
reported (93). Lack of efficacy for this approach in ACH studies could be linked to the 
nature of the receptor activation. If the gain of function mutation in the receptor leads 
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to its activation in absence of ligands, as it has recently been reported (15), the 
obstructive role of the antibody towards the FGF ligand would loose of importance. 
 
4.1.3 CNP antagonism of FGFR3 signalling (3) 
 
The C-type Natriuretic Peptide (CNP) approach is rooted in the observation 
that mice lacking CNP presented a severe dwarfism that was rescued when the 
strain was crossed with mice overexpressing CNP under the promoter Col2A1 (172). 
Considering the phenotypic similarity of CNP knock-out mice to mouse models of 
ACH, there was the chance that CNP could overcome the bone growth deficit caused 
by overactive FGFR3 in ACH. To explore this possibility, mice overexpressing CNP in 
cartilage were crossed with mice Fgfr3ach displaying an ACH phenotype resulting 
from overexpression of FGFR3 bearing the G380R ACH mutation in cartilage (120, 
130). The same Col2A1 promoter was used to drive the expression of both mutant 
FGFR3 and CNP. The growth deficiency of the ACH mice was corrected by the local 
overexpression of CNP and a dose effect was demonstrated since bone growth was 
greater in mice homozygous compared with heterozygous for the CNP transgene 
insertion. The results suggested that the antagonism was primarily directed at MAPK-
mediated FGFR3 signals. 
These promising studies lead to the idea that administrating exogenous CNP 
could ameliorate, if not reverse, the dwarf phenotype. The first experiments exploring 
this strategy were performed through continuous exogenous CNP intravenous 
infusion and a significant rescue of the bone growth deficiency was observed after 3 
weeks of treatment for the Fgfr3ach mice (128). However the study highlighted the 
limits of using exogenous CNP: since CNP half-life in plasma is estimated to be less 
than 2 minutes (173, 174) the continuous intravenous infusion was necessary to 
reach the positive effects on bone growth. It was clear that a similar treatment was 
not suitable for a pediatric population. 
To overcome the obstacle the company BioMarin (Navato, California) 
designed and produced BMN 111, a 39-amino-acid pharmacological variant of CNP, 
with the same pharmacological properties and an increased half-life. BMN 111 
harbors 17-amino-acid sequence necessary for CNP pharmacological activity and is 
resistant to neutral endopeptidase that normally digests the native CNP (175).The 
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compound was able to increase the skeletal growth in Fgfr3ach and in Fgfr3Y367C/+ 
mice (175, 176) through daily subcutaneous injections. The switch from continuous 
intravenous infusion to daily subcutaneous injections represents an important 
milestone if we consider the consistent reduction of the possible adverse effects due 
to the mode of administration. NPR-B, CNP receptor, it is not exclusively expressed 
in chondrocytes, but also in other cells in particular in cardyomiocytes (177) so that 
heart-related side effects due to a consistent CNP-like stimulation couldn’t be 
excluded. For this reason BMN 111 has been tested in juvenile cynomolgus 
monkeys, to assess hemodynamic and pharmacological effects in larger animals. 
ECG parameters were unaffected at any dose of BMN 111, and there were no clinical 
signs of hypotension or distress at any time during the treatment. Moreover monkeys 
treated with the compound presented an improved growth rate, an increased growth 
plate cartilage area and an enlarged spinal canal at the vertebral lumbar level (175). 
All these encouraging preclinical data allowed BioMarin to initiate a phase 1 clinical 
trial in healthy volunteers (ClinicalTrials.gov NCT01590446). The treatment was well 
tolerated, and a safe dose for the pediatric population was identified (178). In 2014 a 
multinational clinical trial for pediatric patients with ACH has started 
(ClinicalTrials.gov NCT01603095). Objectives of this clinical trial is to verify the 
tolerability and efficacy of daily administration of BMN 111 to an ACH pediatric 
population. As of today BioMarin communicated through its press the first results 
after 1 year of administration of BMN 111 (also called vosoritide). Today, we have 
entered a new era, and to cure patients with skeletal disorders is not a dream but a 
way of making dreams become reality. After 12 months of daily dosing at 15 
µg/kg/day, patients experienced a 46% or 1.9 cm/year increase in mean annualized 
growth velocity from baseline without serious adverse events (179). Furthermore the 
company is planning to initiate a single Phase 3 clinical trial by the end of 2016. It is 
clear that the most promising therapy thus far for treatment of ACH is the use of BMN 
111 (vosoritide).  
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4.1.4 RNA interference (4) 
 
The idea sustaining this strategy is to silence the expression of FGFR3 using 
techniques that interfere with translation of its mRNA transcripts. To describe these 
approaches it is used the term of RNA interference (RNAi) indicating a natural 
process used by cells to protect themselves from foreign DNA and that can be used 
to silence endogenous genes (180). RNAi can be triggered by endogenous micro 
RNAs (miRNAs) that are then reduced into short double stranded RNA. These 
fragments are incorporated into RNA-induced silencing complexes able to recognize, 
bind and silence target mRNA transcripts. A near-perfect base pairing of the miRNA 
to the target mRNA determines the cleavage of that specific transcipt, while an 
imperfect pairing leads to translational repression and mRNA decay (181). It is known 
that miRNAs participate in the growth plate development (182) and that targeted 
deletion of miRNA-140 in mouse leads to a mild short stature phenotype (183). 
Interestingly it has been shown that the overexpression of miR-100 is able to inhibit 
the growth of osteosarcoma through the reduction of FGFR3 expression (184). A 
lower level of FGFR3 could improve the ACH growth plate organization, however 
there’s no proof that miR-100 could be endogenously expressed in this cartilage. 
The cellular machinery that generates the endogenous genes silencing can 
also be activated by artificial RNAs that mimic miRNAs function: the so-called small 
interfering-RNAs or siRNAs. Because targeting is sequence specific, any genes can 
theoretically be silenced by designing an appropriate siRNA. It could be possible to 
cure ACH trough siRNA silencing of the FGFR3 allele harbouring the ACH gain-of-
function mutation leaving the wild-type FGFR3 allele to function normally. This 
approach was successful in a FGFR-related preclinical study concerning a mouse 
model of Apert syndrome (185). Nowadays there’s only one research concerning the 
use of FGFR3 siRNAs in chondrocytes and it was limited to in vitro studies (186). 
Even if a highly efficient FGFR3 siRNA would be developed there would be always to 
deal with the concern of the drug delivery that is common among all RNAi therapies.  
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4.1.5 Hsp90 inhibition and FGFR3 cleavage (5) 
 
The control of chaperone complexes to promote the folding or unfolding of 
disease-causing proteins has been tested for its therapeutic potential in both in vitro 
and in vivo experimental models (187) and the chaperone heat shock protein 90 
(Hsp90) protein has been the focus of many of these experiments. Inhibition of 
Hsp90 leads to the degradation of its “client proteins”; this property has been used to 
destabilize oncogenes in cancer and to reduce the accumulation of aggregation-
prone proteins in neurodegenerative disease animal models. FGFR3 has been 
identified as a client of the chaperone Hsp90 meaning that its stability is dependent 
on the function of Hsp90 (188). For this reason Hsp90 inhibitors could be used to act 
on the FGFR3 folding and thus reducing its growth inhibitory signals in ACH. 
However since FGFR3 is not the only Hsp90 client it’s hard to imagine how an 
inhibitor of this chaperone could avoid the appearance of undesired side-effects. A 
large number of clinical trials of Hsp90 inhibitors in cancer have been conducted in 
last years (189) which ended with very different results (190–192). 
 
4.1.6 Modulating FGFR3 expression cleavage and/or nuclear function (6) 
 
In 2011 it was identified that FGFR3, as other transmembrane signalling 
receptors, was regulated by intramembrane proteolysis (RIP) in response to ligand 
stimulation, switching FGFR3 localisation from the membrane to the nucleus (193). 
The major responsible for this displacement is the enzyme γ-secretase that is able to 
cleave a cytoplasmic fragment of the receptor from its membrane anchorage. The 
consequence of RIP on the function of FGFR3 in the growth plate remains unknown. 
Altering the cleavage events of FGFR3 could allow to modify FGFR3 functions 
influencing endochondral ossification. A number of drugs have been developed to 
alter the activity of γ-secretase because of its role in other diseases the most cancer-
related. These drugs have potential to modulate FGFR3 RIP and its contribution to 
ACH. Since γ-secretase influences normal human physiology in many ways, it would 
be risky to administrate a drug that modifies its function in a pediatric population 
(194). In addition to influencing the cleavage of FGFR3, the nuclear function and/or 
potential genes regulated by nuclear FGFR3 might become new drug targets for 
ACH. 
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4.1.7 Inhibition of FGF ligands (7) 
 
Since the binding of FGFs leads to an increase in phosphorylation and 
consequent activation of FGFR3 the strategy of intercept these ligands before their 
interaction with the receptor is tempting. To achieve this result it has been 
synthetized a soluble form of the extracellular domain of FGFR3 (sFGFR3) that 
competes with the endogenous full-form FGFR3 by binding the natural ligands FGF9 
and FGF18 (195). Subcutaneous injections of recombinant sFGFR3 in the Fgfr3Ach 
mouse model for ACH (120) was found to decrease mortality and improve skeletal 
growth (195).This sFGFR3 was also characterized by a long half-life time that is a 
strong point in the study of a potential new drug as already discussed for the 
synthesis of BMN 111. An enlarged half-life time could allow to pass from a daily 
treatment to a once in a week treatment and maybe in an even less frequent 
treatment. However some issues still need to be addressed before reaching a phase 
1 clinical trial. First of all decoy receptors as sFGFR3 have the potential to cause 
immunogenicity reactions and the emerging antibodies against could also cause 
toxicity issues if there is any cross-reactivity for related human receptors (196). 
Another consideration is that BMN-111 is a 39 amino acids long peptide, whereas 
sFGFR3 is about 700 amino acids long. Since growth plate cartilage is an area 
difficult to attain even by smaller compounds it’s difficult to believe that the sFGFR3 
action could be directly play in this tissue. Finally, as already argued for FGFR3 
antibodies, recent studies show that the mutant FGFR3 is phosphorylated and 
activated even in absence of ligand (15). If these findings are correct, the strategy of 
the inhibition / interception of ligands would lose importance. 
 
4.1.8 SNAIL inhibition (8) 
 
As already detailed in “FGF signalling in growth plate” SNAIL 1 is a protein 
that regulates and activates STAT1 and MAPK (93, 126). In a transgenic mouse 
model expressing a chimeric construct in which Snail1 could be activated by 
tamoxifen gave rise to a short stature phenotype (124). From 2008 a patent was 
registered for Snail1 activity inhibiting compounds in a chondrodrodystrophia context 
(WO2008107508A1) however no treatment has been proposed in preclinical studies. 
Instead it has been proposed by the same group the use of morpholinos against 
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SNAIL1 to treat renal fibrosis in vivo in mice (197). Antisense morpholinos inhibit the 
interactions of macromolecules with mRNA by base pairing with the targeted mRNA. 
This prevents the initiation complex read-through or modifies the mRNA splicing 
(198). Since Snail1 is involved in growth plate homeostasis the use of these 
morpholinos could produce interesting results for the goal of curing ACH. 
 
4.1.9 MEK direct inhibition (9) 
 
There is no doubt that activation of FGFR3 results in activation of ERK 
pathway and that this stimulus is more important in pathologies related to gain-of-
function mutations (199). As already discussed in the RNAi section, a group of 
scientists performed experiments to reverse the Apert syndrome phenotype in a 
mouse model (185). They succeeded in their attempt and to validate their discovery 
they obtained the same positive results treating the affected mice with U0126, an 
inhibitor of mitogen-activated protein (MAP) kinase kinase 1 and 2 (MEK1/2) that 
blocks phosphorylation and activation of ERK1/2. Even if from this data we would be 
tempted of exploring furtherer the use of such inhibitors we have to remember that 
ERK1/2 are proteins which functions are not limited to chondrocytes. Also in this 
approach the lack of a specific drug delivery system is an important obstacle. 
 
4.2 FGFR3-unrelated preclinical studies with effects on bone growth 
 
In this section we will explore preclinical studies of compounds not strictly 
targeting the FGFR3 pathways previously described. These investigations have 
produced interesting results on ACH mouse models bone growth. 
The first of these researches consider the treatment of TD and ACH mice 
(Fgfr3K644E/+; Fgfr3369C/+ under Ella-Cre promoter). With intermittent PTH injections 
they partially rescued the lethality and skeletal growth phenotype (200). On the other 
hand the mechanism leading to these positive effects is difficult to elucidate. In 
cultured cells, PTH treatment down-regulated FGFR3 expression. This observation 
could make a pair with the fact that CSRh, transcriptional regulatory element of Fgfr3 
promoter, is repressed by PTH through a cAMP and protein kinase A (PKA)-
dependent mechanism (140). However it is also reported that PTH treatment 
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inhibited FGFR3 phosphorylation, suggesting that PTH may function in part through 
regulation of FGFR3 signalling (200). 
Another study highlights the role of statin in ameliorating the skeletal 
development. In induced pluripotent stem cells (iPSCs) differentiated into 
chondrodrocytes derived from fibroblasts of TD and ACH patients, the compound 
lovastatin, belonging to the statin family, was able to reduce FGFR3 expression and 
MAPK phosphorylation (201). In Fgfr3Ach mouse model intraperitoneal injections of 
another statin, rosuvastatin, were able to induce a growth increase. However it’s not 
clear how the cholesterol lowering drug could produce such effects that are 
somewhat at odds with prior studies on cholesterol signalling and FGFR3 function in 
chondrocytes, as well as statin use in patients with osteoarthritis (202). 
Finally an investigation showed promising results with the molecule meclozine. 
This antihistamine, routinely used to reduce motion sickness, was able to suppress 
as able to stimulate chondrocyte proliferation and differentiation, and inhibit ERK 
phosphorylation (203). The authors of this study showed that the drug was able to 
promote bone growth embryonic tibial explants of Fgfr3Ach mice. Moreover, oral 
administration of the drug to Fgfr3Ach mice, was able to increase the longitudinal 
skeletal growth, but failed in enlarging the foramen magnum and the spinal canal 
(204). 
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Objectives 
 
   
   
 
In the first part we will evaluate the effects of the TKI NVP-BGJ398 in vitro, ex vivo 
and in vivo. The in vitro investigations, conducted employing cell cultures, will 
highlight the effects on FGFR3 and its downstream signalling pathways. The ex vivo 
and in vivo studies will be performed to assess the potential effects on bone growth. 
For the ex vivo an in vivo analyses we will use the ACH mouse model Fgfr3Y367C/+. 
TKIs are considered a promising therapeutic strategy for ACH and they have never 
been tested before in a mouse model of Fgfr3-related disorders. These results have 
been published (2016 May 2;126(5):1871-84. doi: 10.1172/JCI83926. Epub 2016 Apr 
11) on The Journal of Clinical Investigation “Tyrosine kinase inhibitor NVP-BGJ398 
functionally improves FGFR3-related dwarfism in mouse model”. 
 In the second part we will explore the mandibular defects in ACH and in our 
Fgfr3Y367C/+ mouse model. This work features experiments with the TKI NVP-BGJ398 
useful to understand the mandibular growth and the origin of its pathological aspect. 
These results brought together in the article “Meckel’s and condylar cartilages 
anomalies in achondroplasia result in defective development and growth of the 
mandible” that has been recently e-published (Hum Mol Genet. 2016 Jun 3. pii: 
ddw153). 
 In the last part we will investigate the three FGFR3 mutations (K650N, K650M, 
K650E) localised at the same position leading to pathologies with increasing severity 
depending on the substituting aminoacid. In silico studies (from the collaboration with  
ITODYS lab) will detail the molecular changes of the FGFR3 protein, while biological 
studies will provide findings on the effects that such mutations produce on the 
molecular signalling pathways. These results are preliminary data that will be studied 
furtherer and organized in an article titled “Best understanding of structural and 
functional impact of FGFR3 mutations at the same position (K650N, K650M, K650E) 
leading to both mild and lethal dwarfism”.  
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Introduction
Achondroplasia (ACH) is the most common form of dwarfism, 
which occurs with an estimated prevalence of between 1/16,000 
and 1/25,000 live births (1, 2). ACH patients are characterized 
by disproportionate short stature, with a long trunk deformed 
by excessive lordosis. The head is large with frontal bossing and 
the midface is hypoplastic (2). ACH is an autosomal-dominant 
disorder, and patients with ACH have been found to have a gain-
of-function mutation (p.Gly380Arg) localized in the transmem-
brane domain of the fibroblast growth factor receptor 3 (FGFR3), 
a member of the receptor tyrosine kinase family (3, 4). The FGFR3 
mutation disturbs the balance of proliferation and differentia-
tion in the growth plate. Several papers reported both decreased 
and increased proliferation related to stage-specific development 
(5–8). Chondrocyte differentiation is also impaired (9, 10) and 
seems to be controlled by SRY-box 9 (Sox9) expression in the 
growth plate (11). The ACH mutation activates the tyrosine kinase 
activity of the receptor and facilitates the transautophosphoryla-
tion of key tyrosine residues in the intracellular domain and acti-
vates mainly the downstream canonical MAP pathway. Other 
signaling pathways have been implicated in addition in ACH, e.g., 
STAT, Wnt/β-catenin, PI3K/AKT, and PLCγ pathways (9, 12, 13).
Potential therapeutic strategies have emerged for ACH over 
the last 5 years; these have aimed at reducing excessive activa-
tion of FGFR3 and its signaling pathways to stimulate linear bone 
growth. Our group conducted preclinical studies on a C-natriuret-
ic peptide (CNP) analog (14), BMN111, and we showed that this 
treatment led to a substantial improvement of skeletal parameters 
in the Fgfr3Y367C/+ mouse, which is a preclinical model of ACH (15). 
BMN111 (vosoritide) is currently in a (phase 2) clinical trial in pedi-
atric patients with ACH (ClinicalTrials.gov NCT02055157). Other 
preclinical studies using different strategies and various com-
pounds, such as parathyroid hormone (PTH) (16), soluble FGFR3 
(17), statin (18), and meclozine (19), reported changes in the dwarf 
Fgfr3ach mouse phenotype (7). For most of these strategies, the 
mechanism of action in the growth plate needs to be elucidated. 
However, the most direct therapeutic strategy would be to coun-
teract the hyperactivity of FGFR3 using a tyrosine kinase inhibitor 
(TKI). NVP-BGJ398 was identified as a panspecific FGFR inhibi-
tor that was equally active against FGFR1, FGFR2, and FGFR3 and 
less active against FGFR4 (20). Recently, cell-free kinase assays 
showed that NVP-BGJ398 was more selective for FGFR3 than the 
other FGFRs (21). This TKI is effective in reducing FGFR3 acti-
vation and has been used in preclinical murine models for the 
treatment of several FGFR-related pathological conditions, such 
as hypophosphatemic rickets (22), malignant rhabdoid tumors 
(23), and hepatocellular carcinoma (24). We therefore decided 
to investigate whether NVP-BGJ398 could penetrate into the car-
Achondroplasia (ACH) is the most frequent form of dwarfism and is caused by gain-of-function mutations in the fibroblast 
growth factor receptor 3–encoding (FGFR3-encoding) gene. Although potential therapeutic strategies for ACH, which aim to 
reduce excessive FGFR3 activation, have emerged over many years, the use of tyrosine kinase inhibitor (TKI) to counteract 
FGFR3 hyperactivity has yet to be evaluated. Here, we have reported that the pan-FGFR TKI, NVP-BGJ398, reduces FGFR3 
phosphorylation and corrects the abnormal femoral growth plate and calvaria in organ cultures from embryos of the 
Fgfr3Y367C/+ mouse model of ACH. Moreover, we demonstrated that a low dose of NVP-BGJ398, injected subcutaneously, 
was able to penetrate into the growth plate of Fgfr3Y367C/+ mice and modify its organization. Improvements to the axial and 
appendicular skeletons were noticeable after 10 days of treatment and were more extensive after 15 days of treatment that 
started from postnatal day 1. Low-dose NVP-BGJ398 treatment reduced intervertebral disc defects of lumbar vertebrae, loss 
of synchondroses, and foramen-magnum shape anomalies. NVP-BGJ398 inhibited FGFR3 downstream signaling pathways, 
including MAPK, SOX9, STAT1, and PLCγ, in the growth plates of Fgfr3Y367C/+ mice and in cultured chondrocyte models of ACH. 
Together, our data demonstrate that NVP-BGJ398 corrects pathological hallmarks of ACH and support TKIs as a potential 
therapeutic approach for ACH.
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Figure 1. NVP-BGJ398 inhibits the activation of FGFR3 and rescues ex vivo bone growth of Fgfr3Y367C/+ mouse embryo femurs. (a) Phosphorylated 
FGFR3 expression in transfected human chondrocytes with FGFR3 (WT), FGFR3G380R (ACH), FGFR3Y373C (TDI), and FGFR3K650E (TDII) constructs. (B) 
Phosphorylated FGFR3 expression in transfected HEK293-Vnr cells with FGFR3 (WT), FGFR3Y373C (TDI), and FGFR3K650M (SADDAN) constructs. Lanes 
were run on the same gel, but were noncontiguous. (c) Gain of length of E16.5 femurs in culture for 6 days (Δ
D6-D0
) with or without treatment (Fgfr3+/+, 
n = 6; untreated Fgfr3Y367C/+, n = 6; 10 nM Fgfr3Y367C/+, n = 5; 100 nM Fgfr3Y367C/+, n = 6; Fgfr3Y367C/+, n = 8. *P < 0.05, 1-way ANOVA. Scale bar: 1 mm. (D) H&E 
staining and immunohistochemistry for Col X and Ki67 on embryonic distal femur following 6 days of culture with or without treatment. Arrows indicate 
hypertrophic area. Scale bars: 200 μm. (e) Number of Ki67-labeled cells in treated and untreated Fgfr3Y367C/+ compared with Fgfr3+/+ embryonic femur  
(n = 6 per group). *P < 0.05, 1-way ANOVA. (F) Col X–labeled growth plate area in Fgfr3+/+ and Fgfr3Y367C/+ treated and untreated embryonic femur (n = 5 
per group). *P < 0.05, 1-way ANOVA. Western blots are representative of 3 independent experiments. Data are expressed as mean ± SD.
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with WT femurs, +43.6% compared with untreated Fgfr3Y367C/+
femurs). These data show that the induced femoral elongation by 
NVP-BGJ398 was dose dependent, confirming the role of FGFR3 
as a negative regulator of bone growth (5).
In Fgfr3Y367C/+ mice, the coordinated proliferation and differen-
tiation of chondrocytes that ensure the continuous elongation of 
the growth plate are defective (29). We observed that in Fgfr3Y367C/+ 
explants cultured for 6 days, chondrocyte proliferation (i.e., Ki67
expression) was increased (7 times more than WT) as previously 
reported (ref. 26 and Figure 1, D and E). NVP-BGJ398 significantly 
reduced chondrocyte proliferation at 100 nM (–56.4% compared 
with untreated). Differentiated chondrocytes in the growth plate 
were assessed using an antibody against collagen X (Col X), and 
we observed that the growth-plate hypertrophic zone was reduced 
in Fgfr3Y367C/+ explants (–58.4% compared with WT) as previously 
reported (refs. 15, 30, and Figure 1, D and F). The area of the hyper-
trophic zone was increased (+167.6%) with NVP-BGJ398 treatment 
compared with vehicle alone, indicating that the defective differ-
entiation of the chondrocytes was ameliorated (Figure 1, D and F).
To analyze the membranous ossification defect in the 
Fgfr3Y367C/+ skull vault, we used ex vivo cultures of embryonic 
mouse calvaria. Previously, we reported a calvarial defect in ACH 
and Fgfr3Y367C/+ mice, indicating a role of FGFR3 in skull bone 
growth (28). This defect gradually disappears during skull growth, 
as it does in mouse calvaria cultures. We observed that the cal-
varial defect, corresponding to a bone ossification delay, resolved 
faster and more completely in NVP-BGJ398–treated cultures (100 
nM) compared with untreated Fgfr3Y367C/+ calvaria from culture day 
4 (+20.1%) to culture day 14 (+46.1%) (Figure 2, A and B). These 
data confirm that the calvaria-formation defect is directly related 
to the overactivation of FGFR3.
Together, these results indicate that in ex vivo bone models of 
ACH, NVP-BGJ398 can rescue chondrocyte proliferation and dif-
ferentiation defects and can reduce the bone-growth anomalies of 
the growth plate and the skull vault, thus modifying both chondro-
genesis and osteogenesis during embryonic bone development.
NVP-BGJ398 improves growth of the appendicular skeleton in 
Fgfr3Y367C/+ mice. On the basis of those encouraging in vitro and 
ex vivo data, we treated Fgfr3Y367C/+ newborn mice (P1) daily with 
subcutaneous injections of NVP-BGJ398 (2 mg per kg body weight 
per day) for 15 days (protocol 1). The Fgfr3Y367C/+ mouse phenotype 
mimics human ACH in several respects; short stature, macroceph-
aly, prognatism, fused synchondroses, and foramen magnum (FM) 
stenosis (28, 29). Our objective was to evaluate whether and how 
NVP-BGJ398 inhibition of the overactivity of FGFR3 would affect 
bone growth in vivo. The treatment was well tolerated by Fgfr3Y367C/+ 
and Fgfr3+/+ mice without noticeable modification of behavior.
X-ray analyses of the forelimbs (Figure 3A) and hind limbs 
(Figure 3B) showed in NVP-BGJ398–treated Fgfr3Y367C/+ mice a 
tilage and bone and improve the skeletal phenotype in ACH via 
its inhibitory action on FGFR3 and downstream signaling path-
ways. In our study, NVP-BGJ398 inhibited the hyperactivity of 
FGFR3 and the canonical MAPK in ACH human cartilage cells. 
NVP-BGJ398 rescued the anomalies of fetal calvaria and femur in 
organ cultures of tissue taken from the Fgfr3Y367C/+ mouse model of 
ACH. Moreover, NVP-BGJ398 treatment of Fgfr3Y367C/+ mice was 
able to correct the dwarf phenotype. The reduction in the activ-
ity of FGFR3 improved all pathological hallmarks of ACH in long 
bones, skull base, calvaria, intervertebral disc (IVD), and verte-
brae. The timing and type of the treatment were 2 important cri-
teria for the improvement of bone growth in Fgfr3Y367C/+ mice. At 
cellular and tissue levels, chondrocyte proliferation was restored, 
as demonstrated by STAT pathway downregulation, and chondro-
cyte differentiation was improved, as demonstrated by SOX9 and 
MAPK downregulation. Our data suggest that TKIs may represent 
a pharmacological approach for the treatment of FGFR3 hyperac-
tivation-related disorders.
Results
NVP-BGJ398 inhibits FGFR3 phosphorylation. We evaluated the 
ability of NVP-BGJ398 to inhibit FGFR3 phosphorylation in tran-
siently transfected human control chondrocyte lines (Figure 1A) 
and HEK293-Vnr cells (Figure 1B). Cells were transfected with 
constructs expressing FGFR3WT and FGFR3 gain-of-function 
mutations localized in different domains of FGFR3 responsible for 
chondrodysplasias (FGFR3G380R [transmembrane domain; ACH], 
FGFR3Y373C [extracellular domain; thanatophoric dysplasia type 
1 [TDI], FGFR3K650E intracellular domain; thanatophoric dyspla-
sia type 2 [TDII]) (25, 26). Twenty-four hours after transfection, 
phosphorylated FGFR3 was detected for each mutant (Figure 1, A 
and B). For all transfected cells expressing FGFR3 with activating 
mutations, NVP-BGJ398 reduced FGFR3 phosphorylation (Figure 
1, A and B). No phosphorylated FGFR3WT was detected in HEK293-
Vnr cells (Figure 1B).
NVP-BGJ398 restores bone growth in Fgfr3Y367C/+ embryonic 
femurs. In ACH, FGFR3-activating mutations disturb endochon-
dral and membranous ossifications (27, 28). Our in vitro findings 
therefore prompted us to test the impact of NVP-BGJ398 on long 
bone and skull growth. To investigate the effect on endochondral 
ossification, we used ex vivo cultures of embryonic femurs iso-
lated from Fgfr3Y367C/+ mice (E16.5) with various concentrations 
of NVP-BGJ398. At day 6, untreated Fgfr3Y367C/+ femurs exhibited 
a reduction of length (–16.7%) compared with WT femurs (Fig-
ure 1C and Table 1). Six days of ex vivo culture with 10 nM NVP-
BGJ398 did not affect bone growth of WT femurs, whereas 100 
nM NVP-BGJ398 rescued completely the bone growth defect of 
Fgfr3Y367C/+ femurs (Figure 1C and Table 1). At 1 μM, NVP-BGJ398 
induced bone overgrowth of Fgfr3Y367C/+ femurs (+19.6% compared 
table 1. improvement of femur lengths after NVP-BGJ398 treatment
Fgfr3+/+ Fgfr3Y367C/+ Fgfr3Y367C/++NVP-BGJ398, 10 nM Fgfr3Y367C/++NVP-BGJ398, 100 nM Fgfr3Y367C/++NVP-BGJ398, 1 μM
5,604 ± 144 μm 4,667 ± 104 μm 4,659 ± 61 μm 5,311 ± 127 μm 6,702 ± 151 μm
Size of femurs after 6 days of culture with NVP-BGJ398. Data are expressed as mean ± SD.
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taining (Figure 4C and Supplemental Figure 1B). In these treated 
mice, the expression of Col X was observed in the calcified carti-
lage, showing an active process of bone growth at the subtrabecu-
lar bone level (Figure 4C and Supplemental Figure 1B). Previously, 
we reported that angiogenesis was disturbed in Fgfr3Y367C/+ mice 
(29). We hypothesized that the action of NVP-BGJ398 on cartilage 
could affect angiogenesis in the growth plate and thus activate 
mineralization reflected by the altered size of the secondary ossi-
fication center (Figure 4A, and Supplemental Figure 1B). In sup-
port of this hypothesis, CD34, a marker of immature endothelial 
cells, was higher in the chondroosseous junctions of Fgfr3Y367C/+
mice with the NVP-BGJ398 treatment in comparison with the 
control treatment (Supplemental Figure 1C). These data suggest 
that NVP-BGJ398 treatment increased formation of endothelial 
sprouts and initiation of angiogenesis in Fgfr3Y367C/+ mice.
NVP-BGJ398 improves growth of the axial skeleton in Fgfr3Y367C/+
mice. Most ACH patients exhibit kyphosis, lordosis, platyspondyly, 
spinal stenosis, and short pedicles, indicating that the axial skel-
eton is also affected (1). For this reason, we investigated the spine 
of Fgfr3Y367C/+ mice. The rate of tail-length growth in Fgfr3Y367C/+
mice was increased with NVP-BGJ398 treatment from day 9 until 
the end of the treatment in comparison with the control treatment 
(+14.9% at day 9, +26.5%, at day 16) (Figure 5A).
Coronal and sagittal x-ray analyses of the axial skeleton did 
not reveal obvious scoliosis and kyphosis in Fgfr3Y367C/+ mice at 2 
weeks of age. In order to assess differences in the size of the axial 
skeleton, we decided to study lumbar vertebral bodies, which are 
usually affected in ACH. On x-rays and μCT, we observed that lum-
distinct increase in size of these limbs compared with those of 
control Fgfr3Y367C/+ littermates. At necropsy, long bones of treated 
Fgfr3Y367C/+ mice (NVP-BGJ398 and vehicle) and their Fgfr3+/+ con-
trol littermates were measured. In Fgfr3Y367C/+ mice, the lengths 
of proximal and distal long bones were significantly higher with 
NVP-BGJ398 treatment than control treatment (femur +20.9%, 
humerus +11.9%, tibia +32.6%, ulna 22.3%, and radius +24.1%) 
(Figure 3C and Supplemental Figure 1A; supplemental mate-
rial available online with this article; doi:10.1172/JCI83926DS1). 
μCT imaging confirmed these data and also showed that NVP-
BGJ398 treatment expanded the total cross-sectional tissue area 
of Fgfr3Y367C/+ mouse distal femur metaphysis (+30% vs vehicle) 
(Figure 3, D–F). The long-bone growth of Fgfr3+/+ mice treated with 
NVP-BGJ398 was not affected (data not shown), and no prema-
ture death was observed, confirming the mild or null effect of the 
inhibitor on Fgfr3+/+ mice.
Histological analyses of the epiphyseal growth plate of long 
bones showed that NVP-BGJ398 improved growth-plate cartilage 
homeostasis in both distal and proximal femurs (Figure 4A) and 
tibias (Supplemental Figure 1B).
Chondrocyte proliferation was lower in Fgfr3Y367C/+ untreated 
mice (–59.9%) compared with Fgfr3+/+ mice, as measured with 
BrdU incorporation into the growth plate. By contrast, chondrocyte 
proliferation was significantly higher with NVP-BGJ398 treatment 
than control treatment in Fgfr3Y367C/+ mice (+162.1%) (Figure 4B).
Likewise, the impaired differentiation of hypertrophic chon-
drocytes in femurs and tibias of Fgfr3Y367C/+ mice was rescued by 
NVP-BGJ398 treatment, as demonstrated by Col X immunos-
Figure 2. NVP-BGJ398 reduces the 
ossification gap of Fgfr3Y367C/+ mouse 
embryo calvariae ex vivo. (a) Fetal 
calvaria gaps of Fgfr3Y367C/+ mice with 
or without treatment are indicated 
by white lines. Magnified images 
show the effects on suture. (B) The 
modifications of calvaria gap size  
of the Fgfr3Y367C/+ treated mice  
(n = 11) compared with the untreated 
Fgfr3Y367C/+ mice (n = 5) are indicated 
in the graph. *P < 0.05, Mann-Whit-
ney U test. Scale bars: 1 mm. Data 
are expressed as mean ± SD.
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with NVP-BGJ398, the size was greater than with the control treat-
ment (+12.1%) (Figure 5D and Supplemental Figure 2A).
To complete these analyses, we focused on IVDs, where 
FGFR3 is expressed (Supplemental Figure 2B). The IVD con-
tains the cartilage endplate (CEP) and fibrocartilaginous tissues, 
including the annulus fibrosus (AF) and the nucleus pulposus 
bar pedicles were shorter (–62.4%) in Fgfr3Y367C/+ mice compared 
with Fgfr3+/+ mice. After treatment with NVP-BGJ398 in Fgfr3Y367C/+ 
mice, the lumbar pedicles were greater in size than with the con-
trol treatment (+21.8%) (Figure 5, B and C, and Supplemental Fig-
ure 2A). We noted a lower size of the L4–L6 segment in Fgfr3Y367C/+ 
compared with Fgfr3+/+ mice (–29%), and after 15 days of treatment 
Figure 3. NVP-BGJ398 improves growth of the appendicular skeleton in Fgfr3Y367C/+ mice. (a) Radiograph of Fgfr3+/+ and treated and untreated Fgfr3Y367C/+ 
forelimbs. Scale bar: 1 cm. (B) Radiograph of Fgfr3+/+ and treated and untreated Fgfr3Y367C/+ hind limbs. (c) Lengths of femur, tibia, humerus, ulna, and 
radius (Fgfr3+/+, n = 13–14; untreated Fgfr3Y367C/+, n = 9–10; treated Fgfr3Y367C/+, n = 12–13). *P < 0.05, 1-way ANOVA. (D) 2D μCT of the distal femur metaphysis 
cross-sectional area. Scale bar: 400 μm. (e) 3D μCT of the distal femur metaphysis cross-sectional area. Scale bar: 400 μm. (F) Total bone mineral area 
in the distal femur metaphysis (Fgfr3+/+, n = 8; untreated Fgfr3Y367C/+, n = 8; treated Fgfr3Y367C/+, n = 6). *P < 0.05, 1-way ANOVA. All data are from animals 
treated with protocol 1 (16 days old). Data are expressed as mean ± SD.
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Figure 4. NVP-BGJ398 improves 
chondrocyte differentiation and 
proliferation in growth plate. (a) 
Safranin O (SO) staining on femur 
from Fgfr3+/+ and untreated or 
treated Fgfr3Y367C/+ mice. Scale bars: 
100 μm. Asterisks show second-
ary ossification centers (Fgfr3+/+ 
and treated Fgfr3Y367C/+ have these 
centers more developed compared 
with Fgfr3Y367C/+ vehicle). Arrowhead 
highlights appearance of columnar 
hypertrophic chondrocytes, while 
arrow indicates flattening of prehy-
pertrophic cells in Fgfr3Y367C/+ treated 
mice. (B) BrdU immunohistology 
on distal femur growth plates from 
Fgfr3+/+ and untreated or treated 
Fgfr3Y367C/+. Quantification of cell 
proliferation (BrdU-labeled cells/
μm2) (n = 10 per group). *P < 0.05, 
1-way ANOVA. Scale bar: 100 μm. (c) 
Immunohistochemistry for Col X on 
femur from Fgfr3+/+ and untreated 
or treated Fgfr3Y367C/+. Scale bar: 100 
μm. Images shown are representa-
tive of n = 6 animals per group. All 
data are from animals treated with 
protocol 1 (16 days old). Data are 
expressed as mean ± SD.
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(NP) (31). The NP is a gelatinous tissue located in the center of 
the IVD surrounded by the lamellar structured AF. First of all, we 
observed a lower width (–52.6%) and a greater length (+54.2%) of 
the NP in Fgfr3Y367C/+ mice compared with Fgfr3+/+ mice at 16 days 
(Figure 6, A and B). These defects were significantly ameliorated 
by NVP-BGJ398 treatment compared with control treatment for 
both the width (+73.3%) and length (–17.1%) in Fgfr3Y367C/+ mice. 
In order to analyze the AF extracellular matrix (ECM), we stud-
ied Col I and II expression. The cartilaginous area (Col II) cor-
responds to the inner AF (IAF), and the fibrous area (Col I) forms 
the outer AF (OAF) (31). Interestingly, we observed for what we 
believe is the first time that the length of the IAF was higher in 
Fgfr3Y367C/+ mice (+72.4%) than in Fgfr3+/+ mice (Figure 6C and 
Supplemental Figure 2B). This IAF phenotype was significantly 
ameliorated by NVP-BGJ398 treatment compared with control
treatment (–60%). As a consequence, the IAF/OAF ratio was also 
modified with the treatment.
In addition, we observed that the size of the CEP was lower in 
Fgfr3Y367C/+ mice (–18%) compared with Fgfr3+/+ mice, probably due 
to defective hypertrophic-chondrocyte differentiation (Supple-
mental Figure 3, A and B). This CEP phenotype was significantly 
ameliorated by NVP-BGJ398 treatment compared with control 
treatment (+29.3%) (Supplemental Figure 3, A and B).
Taking these data together, we demonstrate here that 15 
days of NVP-BGJ398 treatment corrected the size of L4–L6 and 
pedicles and modified collagen expression in the IVD. These data 
suggest a possible improvement of the ACH spinal stenosis phe-
notype with treatment.
NVP-BGJ398 improves the growth of the craniofacial skeleton in 
Fgfr3Y367C/+ mice. The cranial base is severely affected in humans 
with ACH and in Fgfr3Y367C/+ mice and hence contributes greatly to 
the craniofacial phenotype (28).
Therefore, we assessed whether early treatment with NVP-
BGJ398 could correct the cartilage defects of the skull base and thus 
prevent the premature loss of synchondroses. Imaging of the skull 
using μCT revealed that after 2 weeks of NVP-BGJ398 treatment 
compared with control treatment, the brachycephalic appearance 
of Fgfr3Y367C/+ mice was less obvious because the anterior-posterior 
length of the skull was greater (+5.9%) (Figure 7A). In addition, we 
observed that the size of nasal-bone length was lower in Fgfr3Y367C/+ 
mice (–33.8%) than in Fgfr3+/+ mice. This nasal-bone phenotype was
significantly ameliorated by NVP-BGJ398 treatment compared 
with control treatment (+20.45%) (Figure 7A). NVP-BGJ398 treat-
ment partially prevented the loss of 4 synchondroses: the spheno-
occipital synchondrosis (SOS), the intersphenoidal synchondrosis 
(ISS), and the 2 interoccipital synchondroses (IOSs) in Fgfr3Y367C/+ 
mice (Figure 7, A and B). The efficacy of the NVP-BGJ398 treat-
ment was more prominent on the IOSs (all treated mice had at least 
one IOS active) than on the SOS and ISS (Table 2).
The size of the FM is much smaller in ACH patients and 
Fgfr3Y367C/+ mice, causing cervicomedullary compression (28). In 
Fgfr3Y367C/+ mice, the size of the FM was significantly higher after 
Figure 5. NVP-BGJ398 improves axial skeleton defect of Fgfr3Y367C/+ mice. (a) Tail length from P1 to P16 of Fgfr3Y367C/+ untreated or treated mice (untreated 
Fgfr3Y367C/+, n = 9; treated Fgfr3Y367C/+, n = 12). *P < 0.05, Mann-Whitney U test. (B) 3D μCT scan of Fgfr3+/+ and treated and untreated Fgfr3Y367C/+ mice. Red 
arrows show landmarks used to measure L5 pedicle lengths. Scale bar: 1 mm (frontal view). (c) L5 pedicle length of Fgfr3+/+ and treated and untreated 
Fgfr3Y367C/+ mice (Fgfr3+/+, n = 14; untreated Fgfr3Y367C/+, n = 10; treated Fgfr3Y367C/+, n = 13). *P < 0.05, 1-way ANOVA. (D) Spine length L4 to L6. Fgfr3+/+ and 
treated and untreated Fgfr3Y367C/+ mice (Fgfr3+/+, n = 14; untreated Fgfr3Y367C/+, n = 10; treated Fgfr3Y367C/+, n = 13). *P < 0.05, 1-way ANOVA. All data are from 
animals treated with protocol 1 (16 days old). Data are expressed as mean ± SD.
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which controls proliferation (32). The FGFR3 canonical down-
stream MAPK signaling pathway is more active in FGFR3-related 
disorders (33, 34). Consistent with decreased FGFR3 phosphoryla-
tion, the activation of MAPK and PLCγ pathways was reduced with 
NVP-BGJ398 dosing in HEK293-Vnr cells and human chondro-
cytes transiently transfected with constructs encoding activation 
mutants of FGFR3 (Supplemental Figure 5, A and B). These results 
were confirmed using human immortalized ACH (p.Gly380Arg/+) 
and TD (p.Ser249Cys/+) chondrocytes (ref. 25 and Supplemental 
Figure 5C) and using human (ACH, control) and mouse primary 
chondrocytes (Figure 9, A and B). With these cell cultures, we also 
observed a NVP-BGJ398 dose-dependent decrease in the level of 
phosphorylated ERK1/2 (Supplemental Figure 5C).
High levels of phosphorylated ERK1/2 were observed in 
Fgfr3Y367C/+ chondrocyte cultures and in the growth plate of 
Fgfr3Y367C/+ mice in vivo, thus confirming the constitutive activa-
tion of the MAPK pathway in those mice (Figure 9C). Interestingly, 
ERK1/2 phosphorylation was undetectable in NVP-BGJ398–treat-
ed chondrocyte cultures, and ERK1/2 phosphorylation was lower 
in growth-plate cartilage after NVP-BGJ398 treatment compared 
with control treatment in Fgfr3Y367C/+ mice (Figure 9, A–C, and 
Supplemental Figure 5, A–C). These data show that NVP-BGJ398 
inhibited FGFR3 activity in a RAS-ERK–dependent fashion.
NVP-BGJ398 treatment (area, +16.8%; transversal length, +15.8%; 
and sagittal length, +7.6% as assessed by μCT) (Figure 8, A and B). 
The rescue of the synchondroses phenotype presumably played a 
role in the amelioration of the FM phenotype.
These data indicate an impact of FGFR3 on both mesenchy-
mal (synchondroses) and neural crest–derived osteoblasts (nasal 
bone) and suggest an important role of FGFR3 on both intramem-
branous and endochondral ossification processes.
NVP-BGJ398 rescues defective FGFR3 signaling. FGFR3 is 
expressed in proliferative and prehypertrophic zones of the growth 
plate and modulates both proliferation and differentiation of the 
chondrocytes (32). The activating mutation stabilizes the receptor 
in cells, as demonstrated by the high expression of the receptor in 
the growth plate. The treatment of NVP-BGJ398 had a beneficial 
effect on the turnover of the receptor and lowered its expression in 
chondrocytes (Supplemental Figure 4A). In our Fgfr3Y367C/+ mice, 
as expected, another tyrosine kinase, FGFR1, was expressed in the 
hypertrophic zone of the growth plate, and its expression was not 
modified with NVP-BGJ398 treatment (Supplemental Figure 4B).
FGFR3 negatively regulates chondrocyte proliferation and dif-
ferentiation via several signaling pathways. The 2 principal signal-
ing pathways are the MAPK pathway, which regulates matrix pro-
duction and chondrocyte differentiation, and the STAT1 pathway, 
Figure 6. NVP-BGJ398 reduces iVD defects of Fgfr3Y367C/+ mice. (a) Safranin O staining on lumbar IVD. Dashed arrow shows NP width; arrow indicates 
NP height. Scale bar: 200 μm. (B) NP width (Fgfr3+/+, n = 11; untreated Fgfr3Y367C/+, n = 6; treated Fgfr3Y367C/+, n = 6). Height and ratio between height 
and width (Fgfr3+/+, n = 11; untreated Fgfr3Y367C/+, n = 6; treated Fgfr3Y367C/+, n = 6). *P < 0.05, 1-way ANOVA test. (c) IAF and OAF lengths (Fgfr3+/+, n = 9; 
untreated Fgfr3Y367C/+, n = 6; treated Fgfr3Y367C/+, n = 6). *P < 0.05, 1-way ANOVA. All data are from animals treated with protocol 1 (16 days old). Data are 
expressed as mean ± SD.
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this process comes to a halt at puberty and corresponds to the 
disappearance of the growth plate. Therefore, in ACH patients, 
treatment effectiveness may be better if the treatment commenc-
es before puberty. For this reason, we chose to treat Fgfr3Y367C/+
mice from day 1 for 15 days (protocol 1). However, in order to 
compare the efficacy of NVP-BGJ398 with that shown in previ-
ously published data, we also tested a second protocol (protocol 
2), similar to the one used for BMN111 (start at day 7 for 10 days) 
(15). The gain of growth of femurs and tibias was 50% higher in 
animals treated earlier and longer with NVP-BGJ398 (from day 1) 
than those treated from day 7 (Supplemental Figure 6 and Table 
3). When NVP-BGJ398 treatment was compared with BMN111 
treatment in Fgfr3Y367C/+ mice using protocol 2, we observed a 
greater amelioration of several aspects of the dwarfism pheno-
The role of the transcription factor SOX9 in chondrogenic dif-
ferentiation is well recognized (35, 36). Previously, it was reported 
that activated FGFR3 prevents the downregulation of transcrip-
tion factor SOX9 in differentiated chondrocytes (11). This mecha-
nism was also observed in Fgfr3Y367C/+ mice where the high expres-
sion of SOX9 in the prehypertrophic chondrocytes was lowered 
with NVP-BGJ398 treatment (Figure 9D). Also, the downregula-
tion of SOX9 correlated with the modification of the size and the 
shape of hypertrophic chondrocytes (Figure 4, A and C).
In FGFR3-related disorders, it has been demonstrated that 
the STAT1 pathway regulates chondrocyte proliferation (37, 38). In 
the Fgfr3Y367C/+ growth plate, the level of phosphorylated STAT1 is 
higher than in Fgfr3+/+ mice, and the level of phosphorylated STAT1 
is lowered by NVP-BGJ398 treatment (Supplemental Figure 5D). 
Hence, these data provide an underlying molecular 
explanation for the higher rate of chondrocyte prolifer-
ation with NVP-BGJ398 treatment in Fgfr3Y367C/+ mice, 
as shown with BrdU data (Figure 4B).
Overall, the data suggest that NVP-BGJ398 treat-
ment in Fgfr3Y367C/+ mice restores the activity of FGFR3 
downstream-signaling pathways to that of levels 
observed in Fgfr3+/+ mice.
Effect of timing and type of treatment on the improve-
ment of bone growth. Bone elongation relies on an active 
process controlled by proliferation and differentiation 
of chondrocytes within the growth plate. In humans, 
Figure 7. NVP-BGJ398 improves growth 
of the craniofacial skeleton in Fgfr3Y367C/+ 
mice. (a) Skull anteroposterior length and 
nasal bone length (Fgfr3+/+, n = 9; untreated 
Fgfr3Y367C/+, n = 8; treated Fgfr3Y367C/+, n = 10). 
*P < 0.05, 1-way ANOVA. Data are expressed 
as mean ± SD. (B) 2D μCT scan of Fgfr3+/+ 
and treated and untreated Fgfr3Y367C/+ 
mouse skulls shows the presence and loss 
of synchondroses. Scale bar: 1 mm. All data 
are from animals treated with protocol 1 (16 
days old).
table 2. active synchondroses
Fgfr3+/+ Fgfr3Y367C/+ Fgfr3Y367C/+ + NVP-BGJ398
ISS 100% (9/9) 0% (0/10) 37.5 % (3/8)
SOS 100% (9/9) 0% (0/10) 25% (2/8)
Both IOSs 100% (9/9) 0% (0/10) 75% (6/8)
1 IOS only – 0% (0/10) 25% (2/8)
Percentage of active synchondroses. All data are from animals treated with protocol 1  
(16 days old).
Downloaded from http://www.jci.org on June  8, 2016.   http://dx.doi.org/10.1172/JCI83926
61
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
1 8 8 0 jci.org   Volume 126   Number 5   May 2016
signaling through the control of SOX9 (32) and chondrocyte pro-
liferation is suppressed by STAT1 activation (12).
One therapeutic strategy to rescue the defective skeletal 
development caused by FGFR3 gain-of-function mutations is to 
reduce or counteract the hyperactivity of FGFR3. Among the puta-
tive therapeutic approaches for ACH, the use of TKIs seems the 
most suitable. Although TKIs have been successfully used in can-
cer (45–47), TKIs have so far not been applied in skeletal disorders. 
Here, we demonstrate that NVP-BGJ398, a pan-FGFR inhibitor 
(20), was able to reduce the increased phosphorylation of FGFR3 
and the activation of its downstream signaling pathways in vitro, 
in human and mouse (Fgfr3Y367C/+) chondrocyte models of ACH, 
and to rescue the growth-plate phenotype in vivo in Fgfr3Y367C/+
mice. We believe the result obtained with NVP-BGJ398 is novel, 
as previous in vivo experiments using TKIs failed to demonstrate 
any rescue of the dwarf phenotype (48). Previously, NVP-BGJ398 
was tested in animal models for cancers, including hepatocellu-
lar carcinoma (24) and malignant rhabdoid tumors (23) as well as 
FGF23-dependent hypophosphatemic rickets (22). The effective 
doses administrated in these preclinical studies for cancer were 
10 to 100 times higher than the doses used in this present study 
to correct the dwarfism phenotype. Other therapeutic strategies 
were explored for ACH, with protocols using soluble FGFR3 (17), 
statin (18), or meclozine (19) in another mouse model of ACH 
(Fgfr3Ach) in which the Fgfr3 transgene with the ACH mutation 
is expressed under the control of Col2a1 (7). The comparison of 
those results with the results from our study is made complicated 
by the differences among the mouse models (genotypes, skeletal 
type with NVP-BGJ398 than with BMN111 (femur, tibia, tail, 
L4–L6) (Supplemental Figure 6, Table 3, and ref. 15). In conclu-
sion, NVP-BGJ398 treatment of Fgfr3Y367C/+ mice appeared more 
effective when administered earlier postnatally and for a longer 
period. NVP-BGJ398 treatment also appeared more effective than 
BMN111 treatment, suggesting that directly targeting FGFR3 with 
a TKI represents a better approach than targeting FGFR3 down-
stream-signaling pathways.
Discussion
Elevated kinase activity of the FGFR3 receptor due to germinal or 
somatic mutations disrupts several biological functions, as dem-
onstrated in FGFR3-related disorders (ACH, TD, hypochondro-
plasia, Muenke syndrome) (1, 2, 39) and numerous cancers (blad-
der cancers and multiple myeloma) (40–42). Hyperactive FGFR3 
signaling causes dwarfism, including ACH, which is character-
ized by anomalies in bone development, and the gain-of-function 
Fgfr3Y367C/+ mutation can be used to model ACH in mice (6, 28, 29, 
43). Conversely, a total impairment of the FGFR3 signaling path-
way can cause bone overgrowth, confirming that FGFR3 is a nega-
tive regulator of bone growth (5). On a functional level, FGFR acti-
vation affects various cell behaviors via the downstream activation 
of the MAPK intracellular signaling cascade. The MAPK pathway 
plays an important role in bone development, as demonstrated in 
MEK1 gain-of-function mice (12) and ERK1 and ERK2 null mice 
(44), leading to a dwarf or skeletal overgrowth phenotype, respec-
tively. The underlying mechanisms in FGFR3-related disorders 
suggest that chondrocyte differentiation is regulated by MAPK 
Figure 8. NVP-BGJ398 reduces FM defects in 
Fgfr3Y367C/+ mice. (a) FM μCT images. Scale bar: 
1 mm. (B) FM area, transversal and sagittal 
length, ratio between FM sagittal and transver-
sal length (Fgfr3+/+, n = 9; untreated Fgfr3Y367C/+, 
n = 8; treated Fgfr3Y367C/+, n = 10). *P < 0.05, 
1-way ANOVA test. All data are from animals 
treated with protocol 1 (16 days old). Data are 
expressed as mean ± SD.
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tion (2). Here, we demonstrate that the axial skeleton was affected 
in Fgfr3Y367C/+ mice and the size of the lumbar vertebral bodies and 
pedicles was reduced. In addition, we showed that the 3 compo-
nents (NF, AF, CEP) of the IVD were affected. One of the findings 
of this study is that NVP-BGJ398 treatment remarkably corrected 
the lumbar vertebral body and pedicle size defects and modified 
the components of the ECM of the IVD. These data demonstrate 
that overactivation of FGFR3 disturbs cartilage, IVDs, and bone-
forming lumbar rachis, thus explaining the spinal stenosis, herniat-
ed disc, and kyphoscoliosis phenotypes of ACH patients. The posi-
tive impact of NVP-BGJ398 treatment is particularly noteworthy in 
this context: an improvement of axial skeletal development in ACH 
could reduce the need for decompressive laminectomy surgery, a 
procedure required for treating severe spinal stenosis (52).
The duration of the NVP-BGJ398 treatments were probably 
too short for the amelioration of the defective bone structure of 
the long bones in Fgfr3Y367C/+ mice (43). Longer treatments might 
be necessary to improve the bone architecture, as demonstrated 
previously with 2 months of PTH injection in an Fgfr3-related 
phenotypes, and FGFR3 expression pattern) (17–19). Interestingly, 
NVP-BGJ398 treatment for 10 days improved the bone growth 2 to 
3 times more than what had been reported for BMN111 (15). NVP-
BGJ398 (2 mg/kg) treatment of WT mice did not affect skeletal 
growth (data not shown), and treatment of Fgfr3Y367C/+ mice did not 
modify the expression of FGFR1 in the hypertrophic zone of the 
growth plate. Thus, in this preclinical study, NVP-BGJ398–medi-
ated effects were mainly due to FGFR3 inhibition, with no other 
gross side effects being observed.
The rescue of the growth-plate disorganization, the defective 
chondrocyte proliferation, and the delay of differentiation and 
secondary ossification were remarkable. The disrupted down-
stream FGFR3 signaling pathways were corrected with the NVP-
BGJ398 treatment, confirming the key role of ERK1/2, SOX9, and 
STAT1 signaling during skeletal development (32).
Of major importance, NVP-BGJ398, when applied from birth 
onwards, increased the size of the reduced FM and inhibited the 
premature fusion of synchondroses. In addition, the size of the 
neural crest–derived nasal bone was increased, reflecting that 
intramembranous ossification is also affected 
in ACH (28). These treatment-related effects 
on the skull suggested the potential of correct-
ing facial appearance in ACH patients and, 
most importantly, the potential of reducing 
the risks related to the cervicomedullary com-
pression and early death that can occur in ACH 
children (1, 49, 50).
The spine anomalies of children and adults 
with ACH are kyphosis at the thoracolumbar 
junction (51) and spinal stenosis (52), eventually 
leading to leg paralysis and neurogenic claudica-
table 3. effect of timing and type of treatment
Treatment Tail Femur Tibia L4–L6
NVP-BGJ398 2 mg/kg (protocol 1) 26.5%A 20.9%A 32.6%A 12.1%A
NVP-BGJ398 2 mg/kg (protocol 2) 25.8%A 12.1%A 25.5%A 11.6%A
Gain in length (percentage) for tail, femur, tibia, and L4–L6 of NVP-BGJ398–treated mice 
compared with vehicle 1. A best improvement is observed with animals treated at day 1 
(protocol 1). The dwarfism improvement is more important with NVP-BGJ398 than with BMN111 
(protocol 2 compared with data from ref. 15). AP < 0.05 by 1-way ANOVA test.
Figure 9. NVP-BGJ398 rescues defec-
tive FGFR3 signaling. (a) Phosphory-
lated ERK1/2 expression in mouse 
primary chondrocytes (Fgfr3+/+ and 
Fgfr3Y367C/+). (B) Phosphorylated ERK1/2 
expression in human primary chon-
drocytes expressing FGFR3WT or the 
heterozygous mutation G380R (ACH). 
(c) Immunohistology for phosphorylat-
ed ERK1/2 in femur distal growth plate 
of protocol 1 mice. Scale bar: 100 μm. 
Images shown are representative of  
n = 9 animals per group. (D) Immu-
nohistology for SOX9 in femur distal 
growth plate of protocol 1 mice. Scale 
bar: 100 μm. Images shown are repre-
sentative of n = 6 animals per group. 
All immunohistological data are from 
animals treated with protocol 1 (16 days 
old). Western blots are representative 
of 3 independent experiments.
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with ImageJ (https://imagej.nih.gov/ij/). Protocol 2 was as follows: 
Fgfr3Y367C/+ mice were 7 days old at treatment initiation and received 
daily subcutaneous administrations of NVP-BGJ398 (2 mg/kg body 
weight) or vehicle (HCl 3.5 mM, DMSO 5%) for 10 days; this protocol 
is similar to the BMN111 protocol previously described (15).
Genotyping. Genomic DNA was isolated from tail tips by protein-
ase K digestion and extracted with NucleoSpin Tissue (Macherey-
Nagel) according to the manufacturer’s instructions. PCR was per-
formed using primers as previously described (29).
Femoral culture system. Ex vivo femur cultures were conducted 
as described previously (30). Right femur was cultured with NVP-
BGJ398 at a concentration of 10–100 nM to 1 μM and compared with 
the untreated left femur. The bone length was measured at the begin-
ning (before treatment) and at the end of time course. Each experi-
ment was repeated at least 5 times. Images were captured with an 
Olympus SZX12 stereo microscope. The size of the femur was mea-
sured using cellSens software (Olympus).
Calvarial culture system. Ex vivo calvarial cultures were con-
ducted as described previously (28). Calvaria (E18.5) were placed in 
24-well plates on top of 250 μl of Matrigel (BD Biosciences) previous-
ly placed at the bottom of the well. Calvaria were cultured in α-MEM 
(Gibco, Life Technologies) supplemented with 10% FBS (Gibco, Life 
Technologies), 100 μg/ml ascorbic acid (Sigma-Aldrich), and 1% 
penicillin/streptomycin (Gibco, Life Technologies) and NVP-BGJ398 
at 100 nM over 14 days. Images were captured with an Olympus 
SZX12 stereo microscope. The size of the calvaria defect was mea-
sured using ImageJ software.
Histological and immunohistochemical analyses. Fetal femur 
explants, long bones (femurs, tibias), and L4–L6 vertebrae were fixed 
in 4% paraformaldehyde, decalcified with EDTA 0.4 M, and embed-
ded in paraffin. Serial sections of 5 μm were stained with H&E and 
safranin O. For immunohistochemistry, sections were labeled with 
antibodies against Ki67 (monoclonal antibody, Abcam ab92353; 
1:3,000 dilution), Col X (BIOCYC, N.2031501005; 1:50 dilution), 
CD34 (monoclonal antibody, Abcam ab8158; 1:100 dilution) Col I 
(polyclonal antibody, Novotec, catalog 20151; 1:1,000 dilution), Col II 
(polyclonal antibody, Novotec, catalog 20251; 1:1,000 dilution), 
SOX9 (polyclonal antibody, Santa Cruz Biotechnology Inc., catalog 
D0609; dilution 1:75), phospho-ERK1/2 (monoclonal antibody, Cell 
Signaling, catalog 4370; 1:100 dilution), phospho–Stat 1 (polyclonal 
antibody, Abcam, catalog ab119331; 1:200 dilution), FGFR1 (poly-
clonal antibody, Abcam, catalog ab63601; 1:75 dilution), and FGFR3 
(polyclonal antibody, Sigma-Aldrich, catalog F0425; 1:250 dilution) 
using the Dako Envision Kit. Proliferation was analyzed with the BrdU 
Staining Kit (Life Technologies). Images were captured with an Olym-
pus PD70-IX2-UCB microscope and cellSens software. Labeled cells 
were counted using ImageJ software.
X-rays and CT scanner. The whole skeletons of the mice were 
radiographed using Faxitron (MX-20). μCT analyses were performed 
using a μCT40 Scanco vivaCT42 (Scanco Medical) instrument and the 
following settings: integration time, 300 ms (skull) or 175 ms (femur); 
45 E(kVp); 177 μA. For determination of femoral structural param-
eters, a segmentation threshold of 270 was applied and a Gaussian 
filter (σ = 0.7, support of 1 voxel) was used to suppress the noise. The 
evaluated volume was proportional to the femoral length, as measured 
on plain radiographs using a specimen radiography system (Faxitron 
LX-60), and corresponded to an average of 142 μm (metaphysis) or 
dwarf mouse model (16). Because short-term NVP-BGJ398 treat-
ment improved the chondroosseous junction in the long bones of 
the growing Fgfr3Y367C/+ mice, there is potential that longer NVP-
BGJ398 treatments could lead to a secondary positive effect on the 
resulting bone structure.
The different skeletal phenotypes and molecular pathways 
evaluated in our study provide a wide range of markers that can 
be monitored for further optimization of dosing schedules of TKI 
in addition to prolongation, such as reductions in dose quantity or 
frequency (e.g., intermittent injections every 2 or 3 days).
In summary, we have shown that NVP-BGJ398 inhibits FGFR3 
and its downstream signaling pathways, which are overactive in 
cartilage in ACH. As a consequence, NVP-BGJ398 rescues the 
endochondral and membranous ossification processes in a mouse 
model of ACH. Our results provide a rationale for targeting FGFR3 
with a specific TKI for the treatment of children with ACH.
Methods
Transient transfections of cDNA FGFR3 constructs. Human control 
chondrocyte lines (25) and human embryonic kidney (HEK) cells (26) 
at 80%–90% confluence were transiently transfected with FGFR3 
human constructs (FGFR3WT, FGFR3G380R, FGFR3Y373C, FGFR3K650E, 
FGFR3K650M) obtained as previously reported (26) using JetPrime 
(Polyplus-transfection) following the manufacturer’s instructions. 
Transfected cells were incubated with NVP-BGJ398 (Novartis Basel, 
ref. 20) at concentrations of 100 nM, 1 nM, or 10 μM overnight. Trans-
fected cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.6, 150 
mM NaCl, 0.5% NP40, and 0.25% sodium deoxycholate, supplement-
ed with protease and phosphatase inhibitors; Roche). Immunoprecipi-
tations were performed by incubating 3 μl rabbit anti-FGFR3 (Sigma-
Aldrich F0425)/500 μg protein with protein A–agarose (Roche).
Primary and immortalized human chondrocytes and mouse chondro-
cytes cultures. Primary and immortalized mutant cells were obtained 
as previously described (25). The protocol used for mouse chondro-
cytes was previously reported (24). Human and mouse cells were incu-
bated with NVP-BGJ398 (1, 10, 50, 100, 250, and 500 nM) overnight.
Immunoblotting. Whole-cell lysates and immunoprecipitated 
proteins were subjected to NuPAGE 4%–12% bis-tris acrylamide gels 
(Life Technologies). Blots were probed with antibodies using standard 
protocols: anti-FGFR3 polyclonal antibody (Sigma-Aldrich F0425; 
1:1,000 dilution), anti–phospho-tyrosine P-Tyr-100 monoclonal anti-
body (Cell Signaling catalog 9411; 1:1,000 dilution), anti–phospho-
ERK1/2 monoclonal antibody (Cell Signaling catalog 4370; 1:1,000 
dilution), anti-ERK1/2 polyclonal antibody (Sigma-Aldrich M5670; 
1:1000 dilution), anti–phospho-PLCγ polyclonal antibody (Cell Sig-
naling catalog 2821; 1:1,000 dilution), and anti-PLCγ polyclonal anti-
body (Cell Signaling catalog 2822; 1:1,000 dilution).
Mouse model and drug treatment. Fgfr3Y367C/+ mice were described 
previously (29). All mice were on a C57BL/6 background. Cartilage 
and bone analyses were performed in 16-day-old mice. Protocol 1 
was as follows: Fgfr3Y367C/+ mice were 1 day old at treatment initiation 
and received daily subcutaneous administrations of NVP-BGJ398 for 
15 days (2 mg/kg body weight) or vehicle (HCl 3.5 mM, DMSO 5%). 
Treated and control mice received an intraperitoneal BrdU (Invitro-
gen) injection (1 ml per 100 g body) 2 hours before sacrifice. Long 
bones were measured by caliper (VWRi819-0013, VWR Interna-
tional), while vertebrae measures were determined from radiograph 
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Supplemental Figure 1. NVP-BGJ398 daily injections rescue long bone defect of 
Fgfr3Y367C/+mice. (A) Femur and tibia bone length measured with µCT images (Fgfr3+/+ n = 8, 
untreated Fgfr3Y367C/+ n = 9, treated Fgfr3Y367C/+ n = 6, *P < 0.05 by One-way ANOVA test). 
Data are expressed as mean ± s.d. (B) Safranin-O staining and immunohistochemistry for 
Col X on histological section of tibia (scale bar = 200 µm). Asterisks show secondary 
ossification centers. Images shown are representative of n = 5 animals per group. (C) 
Immunohistochemistry for CD34 on histological section of distal tibia (scale bar = 200 µm). 
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Images shown are representative of n = 5 animals per group. All data concern animals 
treated with protocol 1 (16 days old). 
Supplemental Figure 2. NVP-BGJ398 improves axial skeleton of Fgfr3Y367C/+ mice. (A) 
X-rays of lumbar vertebrae (L4-L6), the black arrows show the L4-L6 segment and red arrow 
show L5 pedicle landmarks (scale bar = 2 mm). (B) Immunohistochemistry for FGFR3, Col I 
and Col II on lumbar IVD outlying IAF (dashed arrows) and OAF (full arrows) (scale bar = 
100 µm). Images shown are representative of n = 6 animals per group. All data concern 
animals treated with protocol 1 (16 days old). 
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Supplemental Figure 3. NVP-BGJ398 improves cartilage end plate of Fgfr3Y367C/+ mice. 
(A) Vertebra Cartilage End Plate (CEP) length (Fgfr3+/+ n = 9, untreated Fgfr3Y367C/+ n = 6, 
treated Fgfr3Y367C/+ n = 6, *P < 0.05 by One-way ANOVA test). (B) Safranin-O staining and 
immunohistochemistry for Col X on histological section of CEP (scale bar = 200 µm). Images 
shown are representative of n = 6 animals per group. All data concern animals treated with 
protocol 1 (16 days old). Data are expressed as mean ± s.d. 
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Supplemental Figure 4. FGFR3 and FGFR1 expression in femoral growth plate. (A) 
Immunohistological analyses of FGFR3 show that the FGFR3 expression is increased in
Fgfr3Y367C/+ mice and decreased after NVP-BGJ398 treatment. (B) The expression of FGFR1 
revealed by immunohistochemistry is not modified in all conditions. All data concern animals 
treated with protocol 1 (16 days old) (scale bar = 50 µm). All images shown are 
representative of n = 6 animals per group. All data concern animals treated with protocol 1 
(16 days old). 
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Supplemental Figure 5. NVP-BGJ398 inhibits the FGFR3 downstream signaling 
pathways. (A) Phosphorylated ERK1/2 and PLCγ expression in transfected human 
chondrocytes with FGFR3WT, FGFR3G380R (ACH), FGFR3Y373C (TDI) constructs are reduced 
with NVP-BGJ398. (B) Phosphorylated ERK1/2 expression in transfected HEK293-Vnr cells 
with FGFR3WT, FGFR3Y373C (TDI), FGFR3K650M (SADDAN) constructs are reduced with NVP-
BGJ398. (C) Dose response effect of NVP-BGJ398 on phosphorylated ERK1/2 in 
immortalized ACH (G380R/+) and TDI (S249C/+) human chondrocytes. (IP = 
Immunoprecipitation, IB = Immunoblotting). (D) Immunohistological analyses of 
phosphorylated STAT1 show an increase expression in Fgfr3Y367C/+ mice and decreased 
expression after NVP-BGJ398 treatment. Images shown are representative of n = 4 animals 
per group (scale bar = 50 µm). All data concern animals treated with protocol 1 (16 days old).
Western blots are representative of 3 independent experiments. 
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Supplemental Figure 6. NVP-BGJ398 improves growth of the axial and appendicular 
skeleton in Fgfr3Y367C/+ mice (protocol 2) 
(A) Radiographs of Fgfr3+/+, treated and untreated Fgfr3Y367C/+ skeletons show the benefit 
effect of the treatment (scale bar = 1 cm). (B) NVP-BGJ398 improvement of the lengths of 
femur, tibia, humerus, ulna, tail, radius and L4-L6 (Fgfr3+/+ n = 6, untreated Fgfr3Y367C/+ n = 5, 
treated Fgfr3Y367C/+ n = 7, *P < 0.05 by One-way ANOVA test). Data are expressed as mean 
± s.d. 
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ABSTRACT 
 
 Activating FGFR3 mutations in human result in achondroplasia (ACH), the most 
frequent form of dwarfism, where cartilages are severely disturbed causing long bones,
cranial base and vertebrae defects. Since mandibular development and growth rely on 
cartilages that guide or directly participate to the ossification process, we investigated 
the impact of FGFR3 mutations on mandibular shape, size and position. By using CT-
scan imaging of ACH children and by analyzing Fgfr3Y367C/+ mice, a model of ACH, we 
show that FGFR3 gain-of–function mutations lead to structural anomalies of primary 
(Meckel’s) and secondary (condylar) cartilages of the mandible, resulting in mandibular 
hypoplasia and dysmorphogenesis. These defects are likely related to a defective 
chondrocyte proliferation and differentiation and pan-FGFR tyrosine kinase inhibitor 
NVP-BGJ398 corrects Meckel’s and condylar cartilages defects ex vivo. Moreover, we 
show that low dose of NVP-BGJ398 improves in vivo condyle growth and corrects 
dysmorphologies in Fgfr3Y367C/+ mice, suggesting that postnatal treatment with NVP-
BGJ398 mice might offer a new therapeutic strategy to improve mandible anomalies in 
ACH and others FGFR3-related disorders.  
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INTRODUCTION 
 
Achondroplasia (ACH) is the most common form of chondrodysplasia and is 
characterized by a rhizomelic dwarfism with short limbs, macrocephaly, frontal bossing
and midface hypoplasia(1)(2)(3). ACH is caused by an activating mutation of Fibroblast 
Growth Factor Receptor 3 (FGFR3) that affects both endochondral and membranous 
ossification (3–5). FGFR3 over-activation disturbs the proliferation and differentiation 
of chondrocytes in the growth plate of long bones (6–8) and synchondroses of the 
cranial base (3, 9). Other cartilaginous structures are affected in ACH, such as the inner 
ear (10), vertebral bodies and intervertebral disc (11), and joints (7).  
 Mandibular growth relies greatly on primary and secondary cartilages, even 
though their exact roles in the acquisition of the mandible final shape and size are not 
fully understood (12)(13). Meckel’s cartilage (MC) is a rod-shaped primary cartilage that 
runs through the mandibular process of the first pharyngeal arch and acts as a 
morphogenic template for the membranous ossification of the mandible body. It is 
transiently present in the developing mandible and disappears at birth. Secondary 
cartilages (symphyseal, angular and condylar cartilages) form prenatally and eventually 
ossify by endochondral ossification during post-natal growth, serving as growth centers 
(12). The central role of cartilages in mandibular development and growth is 
exemplified by the mandibular phenotype observed in several chondrodysplasias where 
mutations in genes involved in chondrocyte function, such as Collagen II (responsible for 
Achondrogenesis type II), Sox9 (Campomelic dysplasia) or PTHrP (Jansen type of 
metaphyseal chondrodysplasia) result in abnormal mandibular shape, size or position 
(14–16).  
 Mutations of FGFR1, FGFR2 and FGFR3 genes are associated with various aspects 
of abnormal craniofacial development such as craniosynostoses and maxillary 
hypoplasia (2, 17, 18). FGFR2 and FGFR3 are expressed in MC (19, 20) and throughout 
all phases of the chick mandibular development (21). FGFR3 signaling is required for the 
elongation of chick MC and FGFR2 and FGFR3 play a role during membranous 
ossification of mandible (22). Mandibular defects have also been observed in Fgfr1/2dcko 
mice, with a shorter and smaller mandible at birth (20). The deletion in mice of the 
FGFR3 signaling molecule Snail (23) is associated with a growth retardation of MC and a 
reduction in mandibular length (24) and mice deficient for the FGFR3 ligand FGF18 
display a reduced size of MC and a hypoplastic mandible (25). These data support the 
role of FGFR signaling in the elongation of MC and morphogenesis of the mandible. 
 However, it is unknown whether mandibular growth and development are 
affected in children with ACH and if mandibular cartilages are disturbed by FGFR3 
mutations. Analysis of lateral cephalogram from adult ACH patients has shown a 
prognathic mandible (i.e. anteriorly displaced) (26)(27). It has also been reported that 
in humans, other skeletal dysplasia caused by activating mutations of FGFR3 can result 
in mandibular dysmorphogenesis as seen in thanatophoric dysplasia (TD) (28), and 
Muenke syndrome (MS) (29).  
In this paper, we studied the mandible growth and development in children with 
ACH and observed an abnormal shape, size and position of the mandible. We compared 
the human data with those obtained with a mouse model of ACH (Fgfr3Y367C/+, (10)), for 
which we analyzed MC and secondary cartilages of the mandible. We observed 
proliferation and differentiation defects in chondrocytes of the mandibular cartilages 
and a delay in the replacement of MC by bone. By targeting the excessive activity of 
FGFR3 with a tyrosine kinase inhibitor NVP-BGJ398 (30), in organ cultures, we 
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corrected the modifications of size and shape of the mandibles.  Using NVP-BGJ398 in 
vivo, we observed a strong improvement of the mandibular phenotype. Taken together, 
these data bring out anomalies of the mandible in ACH and its mouse model and offer 
new perspective of treatment for ACH.
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RESULTS 
 
Achondroplasia results in mandibular hypoplasia and dysmorphogenesis 
Although the craniofacial phenotype of patients with ACH has been described (2,
3, 26), no specific analysis of the mandible has been conducted. We took advantage of CT 
images acquired for assessment of risks for cervicomedullary-junction compression in 
infants with ACH (n=8, mean age: 21.3 months) and compared these images with those 
of age-matched controls obtained after traumatic events (n=9, mean age: 24.9 months). 
The length of the mandible, measured as the distance between condylion (Co) and 
gnathion (Gn), was significantly and consistently decreased in ACH patients compared to 
controls (-14%; p<0.05; Fig. 1A & 1B). Mandibular body length (Gonion (Go) – Menton 
(Me)) and mandibular ramus length (Go – Co) were also significantly decreased in ACH 
children (-16%; p<0.01 and -17%; p<0.05 respectively).  
The analysis of tridimensional coordinates of anatomical landmarks with 
geometric morphometrics (31) showed differences in mandible shape between ACH 
patients and controls. Principal components analysis (PCA) of the human mandible 
shape resulted in the separation of ACH patients and controls along PC1 accounting for 
47% of total variance on the basis of shape features represented in Fig. 1C. When 
compared with controls, mandibles of ACH children were characterized by a defective 
orientation and size of the ramus with prominent coronoid processes and relatively 
shorter condyles. 
 
FGFR3 activation in mice results in mandibular hypoplasia and dysmorphogenesis 
The role of Fgfr1 and Fgfr2 during mandibular development was demonstrated in 
mice with a mesenchyme-specific disruption of Fgfr1 and Fgfr2 (20), while, the impact 
of an activating Fgfr3 mutation on the mandible has not been studied. Here, we 
compared the mandible size and shape of Fgfr3Y367C/+ mice that accurately mimic ACH (3, 
10, 32) with WT mice at different ages. We sacrificed pregnant mice to collect 
Fgfr3Y367C/+ and control littermate embryos at gestational day E16.5 and E18.5. Mice 
were also sacrificed at postnatal day 0 and 21. The mandibles were dissected and 
stained with alcian blue for cartilage and alizarin red for mineralized tissue. We 
observed a significant reduction in the length of the mandible body in the mutant mice 
at all time-points: -11% p<0.005, -9% p<0.005, -10% p<0.005, -16% 
p<0.0001 compared with WT littermates at E16.5, E18.5, P0 and P21 respectively (Fig.  
1D & 1E).  
 To identify potential dysmorphologies in Fgfr3Y367C/+ mandibles in addition to the 
hypoplasia, we measured anatomical landmarks on 3D reconstructed micro CT images 
of P21 mandibles and analyzed their coordinates with geometric morphometrics. The 
PCA of the mandible shape resulted in the separation of Fgfr3Y367C/+ mice and controls 
littermates along PC1 accounting for 78% of total variance on the basis of shape features 
(mainly located on the ramus) represented in Fig. 1F. Our results revealed that the 
shape changes observed in ACH patients and Fgfr3Y367C/+ mice were relatively similar. 
 
Chondrocytes homeostasis is disturbed in Meckel’s cartilage of Fgfr3Y367C/+ mice 
We hypothesized that Fgfr3 activation disturbs chondrocytes homeostasis in MC, 
as it was shown in other cartilages, such as the growth plate (10), the inner ear (10), the 
cranial base synchondroses (3) or vertebral bodies (11), and that these defects could be 
responsible for the mandibular hypoplasia and dysmorphogenesis observed in 
Fgfr3Y367C/+ mice. We therefore collected embryos at gestational day E16.5 and E18.5 and 
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analyzed markers of chondrocyte proliferation and differentiation on histological 
sections.  
At E16.5, MC was readily identifiable on sections stained with safranin’O (Fig. 2A). 
We focused on the cartilage within the developing mandible. In its central part,
chondrocytes are organized into layers (33, 34), as in a growth plate or a synchondrosis. 
We used several markers to compare the spatial organization of the chondrocytes into 
distinct zones in WT and mutant embryos and observed that the chondrocyte 
differentiation was disrupted in mutant embryos. First, immunostaining for Collagen X 
showed that the size of the hypertrophic chondrocytes zone relative to the total size of 
the cartilage was reduced (-43% compared to WT, p<0.05; Fig. 2A & 2B), as was the size 
of individual hypertrophic chondrocytes (-51% compared to WT, p<0.0001; Fig. 2A & 
2C) in Fgfr3Y367C/+ embryos. Immunostaining of the proliferation marker Ki67 indicated 
that more cells were proliferating in MC of mutant embryos (+81% compared to WT, 
p<0.01; Fig. 2A & 2D). In WT and Fgfr3Y367C/+ embryos, the zones of proliferating and 
hypertrophic cells were clearly delimited and were almost completely mutually 
exclusive (Fig 2A). We then observed that the number of Fgfr3 positive cells in this 
cartilage was increased in Fgfr3Y367C/+ embryos (+151%, p<0.0001; Fig. 2A & 2D) as 
reported in the growth plate of the same mouse model (11, 35) and ACH and TD fetuses 
(6). FGFR3 exhibits a specific pattern of expression during chondrocyte differentiation 
(5, 36) and in the growth plate its expression is mostly limited to the resting, 
proliferating and pre-hypertrophic chondrocytes (37). In WT embryos, Fgfr3 was 
expressed by proliferative and prehypertrophic chondrocytes (Fig. 2A) whereas in 
Fgfr3Y367C/+ embryos, the pattern of expression was less clearly delimited, with an 
overlapping of Collagen X and Fgfr3 positive cartilage areas.  
Differentiation into hypertrophic chondrocytes precedes and contributes to the 
disappearance of MC and replacement by bone (38)(39). At E18.5 large remnants of 
cartilage were detected in Fgfr3Y367C/+ embryos, in contrast with WT embryos where MC 
was mostly replaced by bone (Fig 2E and 2F) and the size of MC was significantly 
increased in Fgfr3Y367C/+ embryos mandible (+129%, p<0.05). Similar defects lead to an 
ossification delay in the growth plate (40).  
Overall, these results suggest that Fgfr3 constitutive activation disturbed the 
chondrocytes proliferation and differentiation and delayed the ossification process in 
MC.  
 
FGFR3 activation reduces condylar growth in humans and mice 
Deviations in the growth of the mandibular condyle can have major functional 
and aesthetic consequences (41). Although the majority of the mandible is formed by 
membranous ossification, the upper part of the ramus is formed by endochondral 
ossification of the condylar cartilage. This process allows the mandible to elongate and 
grow upward and backward (42). In both humans and mice, endochondral ossification is 
severely disturbed by FGFR3 activating mutations and defects in condylar cartilage 
could contribute to mandibular hypoplasia and dysmorphogenesis. For these reasons, 
we characterized the condylar process, first in children with ACH, then in Fgfr3Y367C/+ 
mice. We observed on sagittal sections from CT images that the length of the condylar 
neck in children with ACH was reduced compared to age-matched controls (-21%, 
p<0.005; ACH: n= 12, mean age= 32.4 months; controls: n= 14, mean age= 32.4 months) 
(Fig. 3A and 3B). This reduction was observed in children aged from 1 to 42 months. In 
Fgfr3Y367C/+ mice (P21), condylar hypoplasia was also present (Fig. 3C and 3D). In mutant 
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mice, condyles were significantly reduced in length (-14.2%, p<0.01) and width (-15.8%, 
p<0.001).  
To identify the mechanism that led to this shorter condylar neck, we examined 
the condylar cartilage on histological sections of E16.5 embryos and P21 mice. In
Fgfr3Y367C/+ mice, the size of the hypertrophic zone in the cartilage was reduced 
compared to WT littermates as was the average size of individual hypertrophic 
chondrocytes (E16.5: -48%, p<0.001; P21: -56,3%, p<0.05) (Fig. 3E, 3F, 3G & 3H).  
 
Tyrosine kinase inhibition corrects primary and secondary cartilages defects in 
Fgfr3Y367C/+ embryos  
To test the hypothesis that the mandibular hypoplasia and dysmorphogenesis 
observed in children with ACH and Fgfr3Y367C/+ mice are direct consequences of an 
overactive FGFR3, we analyzed the effect on mandibular development and growth of 
pharmacological inhibition of FGFRs using NVP-BGJ398, a pan-specific FGFR inhibitor 
(30). We first developed an ex vivo system of mandible explant cultures, similar to the 
femur explant cultures we used to test pharmacological approaches of FGFR inhibition 
(11, 32, 35). We isolated the mandible from WT and Fgfr3Y367C/+ embryos at E16.5, 
dissected the mandibles into two hemi-mandibles and cultured those separately for 6 
days. One hemi-mandible was treated with NVP-BGJ398, while the other served as 
control. As expected, the body and condyle of hemi-mandible from Fgfr3Y367C/+ embryos 
treated with DMSO were smaller compared to those of WT hemi-mandibles also treated 
with DMSO (-10,1%, p<0.05; -18%, p<0.05 respectively, Fig. 4A & 4B). Incubation with 
NVP-BGJ398 of Fgfr3Y367C/+ hemi-mandibles led to an increase in mandible body (+11%, 
p<0.05) and condylar neck (+26%, p<0.05) size, reach
ing the size of cultured WT hemi-
mandibles treated with DMSO (Fig. 4A & 4B).  
Increases in mandible length with NVP-BGJ398 treatment were associated with 
the correction of chondrocyte defects observed in primary and secondary mandibular 
cartilages of Fgfr3Y367C/+ embryos. While the size of MC hypertrophic zone relative to the 
size of the cartilage was clearly reduced in Fgfr3Y367C/+ hemi-mandible treated with 
DMSO compared to WT (-40.2%, p<0.05), this zone expanded following Fgfr3 inhibition 
in mutant mandible (+68.3%, p<0.05) (Fig. 4C & 4D). This expansion was associated 
with an increased size of individual hypertrophic chondrocytes in hemi-mandible from 
Fgfr3Y367C/+ embryos treated with NVP-BGJ398 (+165% compared to Fgfr3Y367C/+ treated 
with DMSO, p<0.0001) (Fig. 4C & 4E). We noted an increased replacement of MC by bone 
in the treated mandibles, compared to the untreated Fgfr3Y367C/+ mandible, rescuing the 
extinction delay of MC observed in Fgfr3Y367C/+ mice. The kinase inhibitor also corrected 
the overexpression of Fgfr3 and the increased proliferation of chondrocytes in MC of 
Fgfr3Y367C/+ hemi-mandible (Fig. 4F). 
In the condylar cartilage, similar changes were observed. Treatment with NVP-
BGJ398 increased the size of the cartilage hypertrophic zone and the size of individual 
hypertrophic chondrocytes in condyles of Fgfr3Y367C/+ embryos (+98.4%, p<0.0005 
compared to condyles from Fgfr3Y367C/+ hemi-mandibles treated with DMSO) (Fig 4G & 
4H).  
Altogether, we observed that the reduction of Fgfr3 activity with NVP-BGJ398 
corrected the defective growth and cellular defects observed in the presence of an 
overactive Fgfr3. As those improvements occurred in the absence of any systemic 
regulation (ex vivo explants), the effect of the inhibitor is likely direct. This reinforces the 
view that the cartilage defects are responsible for the mandibular hypoplasia.  
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Tyrosine kinase inhibition improves the mandibular dysmorphogenesis 
and the size of the condyle in Fgfr3Y367C/+ mice 
Finally, we tested the potential benefit of a pharmacological use of tyrosine 
kinase inhibitor to correct in vivo the mandibular hypoplasia and dysmorphogenesis of
Fgfr3Y367C/+ mice. We performed daily subcutaneous injection of either NVP-BGJ398 
(2mg/kg) or vehicle on one-day-old mice from P0 to P15 (11). The mandibles of P16 
mice were then imaged by microCT. As in the ex vivo experiments, we observed 
phenotypic changes of the condylar neck in Fgfr3Y367C/+ mice treated with NVP-BGJ398 
compared to Fgfr3Y367C/+ littermates treated with DMSO. The length (+20.9%, p<0.005) 
and width (+22%, p<0.005) of the condylar neck were increased by the reduction of the 
over-activation of FGFR3 (n=7, n=8 & n=7 for WT vehicle, Fgfr3Y367C/+ vehicle and
Fgfr3Y367C/+ NVP-BGJ398 respectively) (Fig. 5A and 5B). As expected, the length of 
mandible body was unchanged since MC had already been replaced by bone at the start 
of the injections. We confirmed the positive effect of NVP-BGJ398 on condylar cartilage 
with histological sections of the condyles (Fig. 6A & 6B). The PCA of the Procrustes 
shape coordinates of the landmarks measured on all mandibles was also run. As for P21 
mice, PC1 separated the WT vehicle and the Fgfr3Y367C/+ vehicle mice (Fig. 5C & 5D). The 
Fgfr3Y367C/+ NVP-BGJ398 mice occupied a somewhat intermediate position though they 
overlap with the Fgfr3Y367C/+ vehicle mice (Fig. 5C & 5D). P-values from permutation 
tests (10000 permutation rounds) for Mahalanobis distances among groups showed 
that the Fgfr3Y367C/+ NVP-BGJ398 mice were significantly different in the shape of the 
mandible from either the Fgfr3Y367C/+ vehicle mice or the WT vehicle. When comparing 
the centroid size (CS) used as a proxy for overall size of the mandible, WT mice 
displayed significantly larger mandible than Fgfr3Y367C/+ mice treated with the vehicle 
(t=-6.96; p<0.005) or NVP-BGJ398 (t=-7.35; p<0.005). Fgfr3Y367C/+ NVP-BGJ398 mice did 
not display significantly larger mandible than the Fgfr3Y367C/+ vehicle mice (t=-0.0887; 
p=0.931). These data confirm that the length of the mandible was not corrected by the 
treatment but that the overall shape of the mandible of Fgfr3Y367C/+ was improved with 
NVP-BGJ398. 
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DISCUSSION 
 
 Deviation from normal mandible growth can strongly affect the masticatory and 
respiratory functions, speech and aesthetic appearance of the face (41)(43) and
mandibular cartilages are recognized as critical growth centers for the mandible. 
Although many cartilages are affected in FGFR3-related chondrodysplasias, most 
strikingly the cartilaginous growth plate in the growing skeleton, mandibular cartilages 
and their impact on mandible growth had never been investigated in ACH. Our 
hypothesis was that mandibular cartilages would be affected by FGFR3 activating 
mutations, similar to other cartilages, and that these defects would cause modifications 
in the shape, size and/or position of the mandible.  
 We first observed differences in the size and shape of the mandible between ACH 
and control children. The mandible as a whole, or subunits such as the mandibular body 
and ramus were reduced in size at all ages in children with ACH and morphometric 
analysis revealed modifications in the shape of the ramus. Comparable changes were 
present in Fgfr3Y367C/+ mice, and in both children and mice, the mandibular hypoplasia 
worsened with age. Our findings illustrate again the similarity of this mouse model with 
ACH.  
 In addition to ACH, FGFR3 activating mutations cause four other types of 
chondrodysplasia (hypochondroplasia, severe achondroplasia with developmental delay 
and acanthosis nigricans (SADDAN), and TD type I and II) (1, 2) and two types of 
craniosynostoses (MS and Crouzon syndrome with acanthosis nigricans) (44). The 
presence of mandible abnormalities in these diseases has rarely been studied. A report 
showed mandibular clefting in a case of TD I (28), two cephalometric studies in adult 
ACH patients reported opposite results concerning the size of the mandible (normal for 
(26) or decreased for Cardoso et al (27)), while another study showed that MS patients 
had shorter mandibular body length than controls (29). Several mouse lines carrying 
Fgfr3 activating mutations have been generated but a very few comprehensive analysis 
of the mandible are available. The homozygous Fgfr3 G380R mouse, a model for ACH, 
has a reduced mandible length (79% of controls) (45) and the homozygous Fgfr3 P244R 
mouse, a model for MS, has a hypomorphic condyle (46).  
 The FGFR3 mutations responsible for chondrodysplasias and craniosynostoses 
were until recently known to primarily affect different ossification processes 
(endochondral vs membranous), but as observed in ACH (3), FGFR3 over activation can 
consistently disturbs both ossification processes. The ossification of the mandible relies 
on these two types, the body being formed by membranous ossification while the ramus 
is mainly formed by endochondral ossification. If the effect of FGFR3 mutations 
responsible for ACH on the ramus is expected, it is intriguing that the same mutations 
can affect the size of the mandibular body. In order to understand what led to these 
changes we studied a primary (Meckel’s) and a secondary (condylar) cartilage. The exact 
role of MC is not yet fully understood as it disappears before birth and only marginally 
participates in the ossification process of the mandible (47). It could play a role in the 
elongation of the mandible body as exemplified by the severe micrognathia present 
when MC is strongly perturbed as in the case of Sox9 haploinsufficiency (48) or deletion 
of Snai1 and Snai2 (24). Here, we found that Fgfr3 over activation disturbed the 
differentiation of chondrocytes in MC. The size of the hypertrophic zone was markedly 
shortened, as was the size of individual hypertrophic chondrocytes. The same defects 
were observed in the growth plate of ACH patients (6) and Fgfr3Y367C/+ mice (10, 40). As 
the chondrocytes differentiate in the growth plate, the volume enlargement to become 
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hypertrophic determines the size of the growth plate elongation (49, 50)(51). The same 
mechanism could occur in MC and the disruption of MC chondrocytes differentiation 
caused by FGFR3 over activation could lead to the shortening of the mandible body. 
Supporting this view, we observed that reduction of the tyrosine kinase activity of
FGFR3 with NVP-BGJ398 corrected not only the hypertrophic chondrocyte phenotype in 
mandible ex vivo cultures but also improved the shortening of the mandible of 
Fgfr3Y367C/+ embryos. In contrast, the same molecule had no effect on the mandible body 
once MC was replaced by bone. We assume this is due to the disappearance of MC before 
birth and, to us, reinforces the importance of MC in the elongation of the mandible. In 
mice of this age, ossification of the symphyseal is limited and therefore contributes 
marginally to the elongation of the mandible body (52). 
 The activity of FGFR3 must be precisely tuned for normal mandible elongation 
since the injection of dominant negative (DN) form of FGFR3 in the chick embryo leads 
to the truncation or shortening of MC (22). In the same study, the DN form reduced the 
proliferation of the cells in MC, while we observed in our study that it was markedly 
increased by the activating mutation. Increased chondrocyte proliferation was also 
observed in the growth plate of embryos carrying either the Fgfr3 Y367C or K644E 
mutations (40, 53). In MC, the expression of Fgfr3 was also increased by the Y367C Fgfr3 
mutation. It could be the result of a prolonged half time of the protein, since the 
mutation of the transmembrane domain could delay the turnover and degradation of the 
activated receptor (54, 55).  
 FGFR3 mutations responsible for ACH could also affect the ossification of the 
mandibular process that was delayed in Fgfr3Y367C/+ embryos. It could be a consequence 
of the defective MC homeostasis and subsequent initiation of ossification. Alternatively, 
mesenchymal cells lateral to MC that directly differentiate into osteoblasts (20) could be 
independently affected by FGFR3 activation. Further work is needed to determine if this 
delay affects mandible bone mass acquisition during growth, as reported in long bones 
(40, 56).  
 Secondary cartilages are sites of late prenatal and early postnatal growth and 
eventually ossify. Here we focused on the condylar cartilage. It develops adjacent to the 
intramembranous bone of the mandible, distinct from MC and in contrast with MC, 
directly contributes to the formation of the ramus by endochondral ossification and 
persists postnatally to function as a growth center (42). Genetic defects in 
chondrogenesis can cause abnormal condylar growth as in Pierre Robin sequence (41), 
an entity associated with genetic defects of SOX9 (57). We found that children with ACH 
had shorter condylar neck, a feature also found in Fgfr3Y367C/+ mice. Histological analysis 
of the condyle in Fgfr3Y367C/+ mice, revealed a disturbed cartilage where the hypertrophic 
chondrocytes were smaller and the hypertrophic zone shortened, as in MC or in the 
growth plate of the same mice (10). Altered differentiation of chondrocyte is also 
present in condyles of TD infants (58) and in the hypolpastic condyle of homozygous 
Fgfr3 P244R mice (46). Here, cultures of hemi-mandibles and in vivo experiments with 
partial inhibition of Fgfr3 activity showed that it is likely that the defective chondrocyte 
differentiation and proliferation directly contributes to the reduced elongation of the 
condyle. The persistence of the condylar cartilage postnatally allowed us to observe that 
in vivo tyrosine kinase inhibition rescue condylar growth in Fgfr3Y367C/+ mice, increasing 
its length by 21% after 15 days of treatment. The same treatment improved the growth 
of appendicular and axial skeletons with a similar magnitude of change of long bones 
(11).  
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 Current treatments of maxillofacial deformities and skeletal dysplasia are 
primarily surgical and can require multiple interventions during childhood (59, 60). 
Innovative pharmacological treatments of these diseases are needed and reducing the 
excessive activity of the FGFR3 receptor in FGFR3-related chondrodysplasias or
craniosynostoses with specific tyrosine kinase inhibitors, such as NVP-BGJ398, is an 
appealing approach. It potentially targets all downstream signaling pathways of the 
receptor and in this aspect, NVP-BGJ398 has been shown to normalize in vitro and in 
vivo ERK1/2 and PLCγ pathways (11). Our pre-clinical experiments showed here that 
this inhibitor enters mandibular cartilages and improves cranio-facial growth. 
 In summary, we showed in this paper that a FGFR3 gain-of–function mutation 
disturbs the development and growth of the mandible, via structural anomalies of 
Meckel’s and condylar cartilages. These anomalies are likely related to the defective 
chondrocyte proliferation and differentiation and the tyrosine kinase inhibitor NVP-
BGJ398 corrects these defects and improves condyle growth. This suggests that 
postnatal treatment with the molecule could be a therapeutic strategy to improve 
mandible growth in ACH and others FGFR3-related disorders.  
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MATERIALS AND METHODS 
 
Human subjects
All patients with ACH (n= 12, mean age= 32.4 months) or age-matched controls (n= 14, 
mean age= 32.4 months) were examined and followed at the Craniofacial Surgery Unit of 
Necker-Enfants Malades Hospital. Ethics approvals were obtained from the institutional 
review Board of Necker-Enfants Malades Hospital. 
 
Mouse models  
All the experiments were conducted in Fgfr3Y367C/+ mice, a mouse model that display 
parts of the clinical hallmarks of ACH (32), or WT littermates, used as controls. WT and 
Fgfr3Y367C/+ mice were generated by crossing Fgfr3neoY367C mice (10) and Cmv-Cre mice 
(61). The mutant mice express the c.1100A>G (p.Tyr367Cys) mutation corresponding to 
the c.1118A>G (p.Tyr373Cys) in thanatophoric dysplasia. All mice were on a C57BL/6 
background. Mice were genotyped by PCR of tail DNA as described previously (10). 
Experimental animal procedures and protocols were approved by the French Animal 
Care and Use Committee. 
 
Computed Tomography (CT) images of human patients and mice 
Human patients CT images were produced by a 64-slice CT system (LightSpeed VCT, 
General Electric Medical Systems, Milwaukee, WI, USA). The images were reconstructed 
in 3 dimensions (3D) using Carestream PACS v11.0 software (Carestream Health, 
Rochester, NY, USA). Cephalometric analysis of the mandible was carried on sagittal 
views of the 3D reconstructions.  
Following 15 days of NVP-BGJ398 treatment, Fgfr3Y367C/+ mice and their control 
littermates were sacrificed and the whole heads were imaged using a μCT40 Scanco 
vivaCT42 (Scanco Medical, Bassersdorf, Switzerland). The following settings were used: 
integration time: 300 ms; 45 E(kVp); 177 µA. The mandible images were reconstructed 
in 3D using OsiriX 64-bit version software (Pixmeo, Bernex, Switzerland).  
 
Morphometric analysis  
The samples consisted of computed tomography (CT) images of patients with ACH and 
unaffected age-matched individuals, and of high-resolution CT images of 7 P21 
Fgfr3Y367C/+ mice and 7 control littermates. 3D coordinates of 10 landmarks were 
recorded on the 3D reconstructed mandibles of humans and mice and analyzed with 
geometric morphometric methods. Standardization for position, scale, and orientation 
was obtained by Procrustes superimposition (62)(63) and shape information 
(Procrustes coordinates) and size (centroid size (63)) were extracted. Shape 
information was subsequently analyzed by principal components analysis (PCA) (for 
more information on geometric morphometrics applied to craniofacial birth defect see 
for example (31)). Wireframes are used to visualize the shape differences between 
positive and negative values of principal component (PC) 1 corresponding to control and 
ACH mandibles respectively. Geometric morphometric analyses were run with Morpho J 
(64). 
 
Whole-mount Alcian blue-alizarin red staining 
Mandibles of Fgfr3Y367C/+ mice and their wild type littermates at E16.5, E18.5, P0 and P21 
were fixed in 95% ethanol and then stained with Alizarin Red and Alcian Blue, cleared 
 at C
E
R
D
I o
n
 Ju
n
e 8
, 2
0
1
6
h
ttp
://h
m
g
.o
x
fo
rd
jo
u
rn
als.o
rg
/
D
o
w
n
lo
ad
ed
 fro
m
 
84
 13
by KOH treatment, and stored in glycerol according to standard protocols. Size of the 
mandibles and the condyles were measured on images captured with an Olympus PD70-
IX2-UCB using CellSens software (Olympus). Total length of the mandible was measured 
as well as the length of the condylar and symphyseal cartilages (identified with the
alcian blue staining). The length of the body was calculated as the total length minus the 
condylar and symphyseal cartilages. 
 
Immunohistochemistry 
Mandibles of Fgfr3Y367C/+ and their wild type littermates at E16.5, E18.5, P0 and P21 
were fixed in 4% paraformaldehyde at 5°C for 24 hours and decalcified in 0.5 M EDTA 
(pH 8.0) overnight or up to one week, depending on the age of the mice, and then 
dehydrated in graded series of ethanol, cleared in xylenes and embedded in paraffin. 5 μm sagittal sections were cut and stained with hematoxylin and eosin (H&E), safranin-O 
or subjected to immunohistochemical staining using standard protocols using an 
antibody against Collagen X (1:50 dilution; BIOCYC, Luckenwalde, Germany), FGFR3 
(1:250; Sigma-Aldrich Co, St. Louis, MO, USA) or Ki67 (1:3000; Abcam, Cambridge, MA, 
USA) using the Dako Envision kit (Dako North America, Inc, CA, USA). Images were 
captured with an Olympus PD70-IX2-UCB microscope (Olympus, Tokyo, Japan) and 
morphometry was performed with ImageJ software (National Institutes of Health, 
Bethesda, MD, USA). 
 
Ex vivo experiments 
Mandibles from WT and Fgfr3Y367C/+ E16.5 embryos were dissected and cut at the 
symphysis to separate the two hemi-mandibles. For each embryo, the two hemi-
mandibles were incubated for 5 days in DMEM medium with antibiotics and 0.2% BSA 
(Sigma), one supplemented with NVP-BGJ398 (100nM) while the other served as control 
and was supplemented with DMSO (0.1%). The length of the hemi-mandibles was 
measured at the end of time course, following whole-mount Alcian blue-alizarin red 
staining.  
 
In vivo experiments 
Fgfr3Y367C/+ mice were 1 day old at treatment initiation and received daily subcutaneous 
administrations of NVP-BGJ398 at 2mg/kg body weight or vehicle (HCl 3.15 mM, DMSO 
2%) for 15 days. Cartilage and bone analyses were thus performed in 16-d-old male and 
female mice. Experimental animal procedures and protocols were approved by the 
French Animal Care and Use Committee. 
 
  
Statistical analysis 
Differences between experimental groups were assessed using analysis of variance 
(ANOVA) or Mann-Whitney test. The significance threshold was set at p≤0.05. Statistical 
analyses were performed using GraphPad PRISM (v5) (GraphPad Software Inc., La Jolla, 
CA, USA). All values are shown as mean ± SD.   
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LEGENDS 
 
Figure 1. FGFR3 over activation in humans and mice results in mandibular 
hypoplasia and dysmorphogenesis. (A) 3D reconstructed CT images with volume
rendering of a control and ACH patient (scale bar = 1cm). (B) Mandible length, measured 
as the distance between condylion (Co) and gnathion (Gn) on sagittal sections of 3D 
reconstructed CT images of controls (n= 9, mean age: 24.9 months) or ACH patients (n=8,
mean age: 21.3 months) and plotted against the age of the children. (C) Landmarks and 
associated wireframes measured on the 3D reconstructed human mandibles and 
corresponding superimposition of the control and ACH wireframes computed on the 
basis of PC scores along PC1, the PC best separating the two groups and accounting for 
47% of total shape variance. (D) & (E) Mandible length of embryos (E16.5 and E18.5), 
new born and 3 weeks-old WT and Fgfr3Y367C/+ mice (n≥6 individuals for each age and 
genotype), measured following alcian blue and alizarin red staining between the 
condylar and symphyseal ends (marked with *) (scale bar = 1mm). (F) Landmarks and 
associated wireframes measured on the 3D reconstructed mouse mandibles and 
corresponding superimposition of the control and Fgfr3Y367C/+ wireframes computed on 
the basis of PC scores along PC1, the PC best separating the two groups and accounting 
for 78% of total shape variance. Data shown as mean with SD; * p<0.05, ***p<0.005. 
 
Figure 2. Chondrocytes homeostasis is disturbed in Meckel’s cartilage of 
Fgfr3Y367C/+ mice. (A) Histological staining (Safranin’O) and immunostaining for 
Collagen X, Ki67 (proliferation marker) and Fgfr3 of MC of WT and Fgfr3Y367C/+ E16.5 
embryos. An enlargement of the ColX immunostaining (red box) highlights the 
modification in the size of hypertrophic chondrocytes in Fgfr3Y367C/+ embryos (scale bar 
= 200μm). Area delimited with doted lines on the ColX panel corresponds to the 
hyperthrophic zone. Areas delimited with doted lines on the Ki67 and Fgfr3 panels 
correspond to immunonegative zones (respectively non-proliferative and Fgfr3-
negative). Enlargements of the Ki67 and Fgfr3 immunostainings  (red box) highlight the 
limits of the positive and negative zones. (B) Measurement of the ColX positive zone 
inside MC of WT and Fgfr3Y367C/+ E16.5 embryos (n≥7 individuals for each genotype). (C) 
Mean percentage of hypertrophic chondrocytes for different size categories (expressed 
in μm2) inside MC of WT and Fgfr3Y367C/+ E16.5 embryos (n≥50 cells from n≥6 
individuals for each genotype). (D) Mean number of immuno-positive cells for Fgfr3 or 
Ki67 inside MC of WT and Fgfr3Y367C/+ E16.5 embryos (n≥7 individuals for each 
genotype). (E) Histological staining (Safranin’O) of WT and Fgfr3Y367C/+ E18.5 embryos 
(scale bar = 200μm). (F) Mean cartilage area, measured on sagittal sections of MC in WT 
and Fgfr3Y367C/+ E16.5 and E18.5 embryos (n≥7 individuals for each age and genotype). 
Data shown as mean with SD; *p<0.05, **p<0.01, ***p<0.005. 
 
Figure 3. FGFR3 over activation in humans and mice results in condyle hypoplasia. 
(A) Representative sagittal sections of a control and ACH child, both 17 months of age, 
generated from the CT scans (scale bar = 1cm). (B) Condylar neck length, measured on 
CT scans sagittal sections of controls (n= 14, mean age= 32.4 months) or ACH patients 
(n= 12, mean age= 32.4 months) and plotted against the age of the children. (C) 
Representative macroscopic views of condyles of 3 weeks old WT and Fgfr3Y367C/+ mice, 
following alcian blue and alizarin red staining (scale bars = 2mm and 1mm). (D) 
Condylar neck length of 3 weeks-old WT and Fgfr3Y367C/+ mice, measured following 
alcian blue and alizarin red staining (n≥6 individuals for each genotype) (E) & (F) 
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Histological staining (Safranin’O) and immunostaining for Collagen X of the condylar 
cartilage of WT and Fgfr3Y367C/+ E16.5 embryos (E) and 3 weeks old mice (F) (scale bar = 
100μm). An enlargement of the ColX immunostaining (black box) highlights the 
modification in the size of hypertrophic chondrocytes in Fgfr3Y367C/+ embryos and P21
mice. (G) & (H) Mean percentage of hypertrophic chondrocytes for different size 
categories (expressed in μm2) inside the condylar cartilage of WT and Fgfr3Y367C/+ E16.5 
embryos (G) and 3 weeks old mice (H) (n≥ 50 cells from n≥6 individuals for each age 
and genotype). Data shown as mean with SD; **p<0.01, ***p<0.005. 
 
Figure 4. NVP-BGJ398 corrects primary and secondary cartilages defects in ex vivo 
cultures of mandibles from Fgfr3Y367C/+ embryos. (A) Representative macroscopic 
views of hemi mandibles from E16.5 WT or Fgfr3Y367C/+ embryos, treated with DMSO or 
NVP-BGJ398 and cultured for 6 days, following alcian blue and alizarin red staining. 
Symphyseal (s), condylar (c) and Meckel’s (m) cartilages are indicated. (B) Mandibular 
body and condylar neck length of cultured hemi mandibles (n≥5 individuals for each 
genotype and treatment). Total length of the hemi-mandible was measured as well as 
the length of the condylar and symphyseal cartilages (identified with the alcian blue 
staining). The length of the body was calculated as the total length minus the condylar 
and symphyseal cartilages. (C) Histological staining (Safranin’O) and immunostaining 
for ColX of cultured hemi mandibles. An enlargement of the ColX immunostaining 
highlights the modification in the size of hypertrophic chondrocytes in MC of Fgfr3Y367C/+ 
embryos and the correction of the defect with NVP-BGJ398 (scale bar = 200μm). (D) 
Measurement of the ColX positive zone inside MC of cultured hemi mandibles (n≥6 
individuals for each genotype and treatment). (E) Mean percentage of hypertrophic 
chondrocytes for different size categories (expressed in μm2) inside MC of cultured hemi 
mandibles (n≥50 cells from n≥5 individuals for each genotype and treatment). (F) Mean 
number of immune positive cells for Fgfr3 or Ki67 inside MC of WT, Fgfr3Y367C/+ DMSO 
and Fgfr3Y367C/+ NVP-BGJ398 E16.5 embryos (n≥5 individuals for each genotype). (G) 
Histological staining (Safranin’O) and immunostaining for Collagen X of cultured hemi 
mandibles condylar cartilage (scale bar = 100μm). Meckel’s cartilage (m) is indicated. 
(H) Mean percentage of hypertrophic chondrocytes for different size categories 
(expressed in μm2) inside condylar cartilage of cultured hemi mandibles (n≥50 cells 
from n≥5 individuals for each genotype and treatment). Data shown as mean with SD; 
*p<0.05, **p<0.01. 
 
Figure 5. NVP-BGJ398 improves in vivo condyle growth of Fgfr3Y367C/+ mice. (A) 
Representative 3D reconstructions of 16 days old WT and Fgfr3Y367C/+ mice treated with 
DMSO or NVP-BGJ398 for 15 days since P01 (scale bar = 1mm). (B) Measurement of the 
mandible body and the condyle length and width of WT and Fgfr3Y367C/+ mice treated 
with DMSO or NVP-BGJ398 (n≥6 individuals for each genotype and treatment). Total 
length of the mandible was measured as well as the length of the condyle. The length of 
the body was calculated as the total length minus the condyle. (C) & (D) PCA of the 
Procrustes shape coordinates of the landmarks measured on mandibles of WT and 
Fgfr3Y367C/+ mice treated with DMSO or NVP-BGJ398 and corresponding superimposition 
(n≥6 individuals for each genotype and treatment). Data shown as mean with SD; 
***p<0.005. 
 
Figure 6. NVP-BGJ398 improves in vivo the chondrocyte differentiation in condyle 
of Fgfr3Y367C/+ mice. Histological staining (Safranin’O) (A) and immunostaining for 
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collagen X (B) of condylar cartilage of 16 days old WT and Fgfr3Y367C/+ mice treated with 
DMSO or NVP-BGJ398 for 15 days since P01 (scale bar = 100μm).  
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FGFR3 over activation in humans and mice results in mandibular hypoplasia and dysmorphogenesis. (A) 3D 
reconstructed CT images with volume rendering of a control and ACH patient (scale bar = 1cm). (B) 
Mandible length, measured as the distance between condylion (Co) and gnathion (Gn) on sagittal sections of 
3D reconstructed CT images of controls (n= 9, mean age: 24.9 months) or ACH patients (n=8, mean age: 
21.3 months) and plotted against the age of the children. (C) Landmarks and associated wireframes 
measured on the 3D reconstructed human mandibles and corresponding superimposition of the control and 
ACH wireframes computed on the basis of PC scores along PC1, the PC best separating the two groups and 
accounting for 47% of total shape variance. (D) & (E) Mandible length of embryos (E16.5 and E18.5), new 
born and 3 weeks-old WT and Fgfr3Y367C/+ mice (n≥6 individuals for each age and genotype), measured 
following alcian blue and alizarin red staining between the condylar and symphyseal ends (marked with *) 
(scale bar = 1mm). (F) Landmarks and associated wireframes measured on the 3D reconstructed mouse 
mandibles and corresponding superimposition of the control and Fgfr3Y367C/+ wireframes computed on the 
basis of PC scores along PC1, the PC best separating the two groups and accounting for 78% of total shape 
variance. Data shown as mean with SD; * p<0.05, ***p<0.005.  
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Chondrocytes homeostasis is disturbed in Meckel’s cartilage of Fgfr3Y367C/+ mice. (A) Histological staining 
(Safranin’O) and immunostaining for Collagen X, Ki67 (proliferation marker) and Fgfr3 of MC of WT and 
Fgfr3Y367C/+ E16.5 embryos. An enlargement of the ColX immunostaining (red box) highlights the 
modification in the size of hypertrophic chondrocytes in Fgfr3Y367C/+ embryos (scale bar = 200µm). Area 
delimited with doted lines on the ColX panel corresponds to the hyperthrophic zone. Areas delimited with 
doted lines on the Ki67 and Fgfr3 panels correspond to immunonegative zones (respectively non-
proliferative and Fgfr3-negative). Enlargements of the Ki67 and Fgfr3 immunostainings  (red box) highlight 
the limits of the positive and negative zones. (B) Measurement of the ColX positive zone inside MC of WT 
and Fgfr3Y367C/+ E16.5 embryos (n≥7 individuals for each genotype). (C) Mean percentage of hypertrophic
chondrocytes for different size categories (expressed in µm2) inside MC of WT and Fgfr3Y367C/+ E16.5 
embryos (n≥50 cells from n≥6 individuals for each genotype). (D) Mean number of immuno-positive cells 
for Fgfr3 or Ki67 inside MC of WT and Fgfr3Y367C/+ E16.5 embryos (n≥7 individuals for each genotype). 
(E) Histological staining (Safranin’O) of WT and Fgfr3Y367C/+ E18.5 embryos (scale bar = 200µm). (F) 
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Mean cartilage area, measured on sagittal sections of MC in WT and Fgfr3Y367C/+ E16.5 and E18.5 
embryos (n≥7 individuals for each age and genotype). Data shown as mean with SD; *p<0.05, **p<0.01, 
***p<0.005.  
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FGFR3 over activation in humans and mice results in condyle hypoplasia. (A) Representative sagittal 
sections of a control and ACH child, both 17 months of age, generated from the CT scans (scale bar = 1cm). 
(B) Condylar neck length, measured on CT scans sagittal sections of controls (n= 14, mean age= 32.4 
months) or ACH patients (n= 12, mean age= 32.4 months) and plotted against the age of the children. (C) 
Representative macroscopic views of condyles of 3 weeks old WT and Fgfr3Y367C/+ mice, following alcian 
blue and alizarin red staining (scale bars = 2mm and 1mm). (D) Condylar neck length of 3 weeks-old WT 
and Fgfr3Y367C/+ mice, measured following alcian blue and alizarin red staining (n≥6 individuals for each 
genotype) (E) & (F) Histological staining (Safranin’O) and immunostaining for Collagen X of the condylar 
cartilage of WT and Fgfr3Y367C/+ E16.5 embryos (E) and 3 weeks old mice (F) (scale bar = 100µm). An
enlargement of the ColX immunostaining (black box) highlights the modification in the size of hypertrophic 
chondrocytes in Fgfr3Y367C/+ embryos and P21 mice. (G) & (H) Mean percentage of hypertrophic 
chondrocytes for different size categories (expressed in µm2) inside the condylar cartilage of WT and 
Fgfr3Y367C/+ E16.5 embryos (G) and 3 weeks old mice (H) (n≥ 50 cells from n≥6 individuals for each age 
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and genotype). Data shown as mean with SD; **p<0.01, ***p<0.005.  
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NVP-BGJ398 corrects primary and secondary cartilages defects in ex vivo cultures of mandibles from 
Fgfr3Y367C/+ embryos. (A) Representative macroscopic views of hemi mandibles from E16.5 WT or 
Fgfr3Y367C/+ embryos, treated with DMSO or NVP-BGJ398 and cultured for 6 days, following alcian blue 
and alizarin red staining. Symphyseal (s), condylar (c) and Meckel’s (m) cartilages are indicated. (B) 
Mandibular body and condylar neck length of cultured hemi mandibles (n≥5 individuals for each genotype 
and treatment). Total length of the hemi-mandible was measured as well as the length of the condylar and 
symphyseal cartilages (identified with the alcian blue staining). The length of the body was calculated as the 
total length minus the condylar and symphyseal cartilages. (C) Histological staining (Safranin’O) and 
immunostaining for ColX of cultured hemi mandibles. An enlargement of the ColX immunostaining highlights
the modification in the size of hypertrophic chondrocytes in MC of Fgfr3Y367C/+ embryos and the correction 
of the defect with NVP-BGJ398 (scale bar = 200µm). (D) Measurement of the ColX positive zone inside MC 
of cultured hemi mandibles (n≥6 individuals for each genotype and treatment). (E) Mean percentage of 
hypertrophic chondrocytes for different size categories (expressed in µm2) inside MC of cultured hemi 
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mandibles (n≥50 cells from n≥5 individuals for each genotype and treatment). (F) Mean number of immune 
positive cells for Fgfr3 or Ki67 inside MC of WT, Fgfr3Y367C/+ DMSO and Fgfr3Y367C/+ NVP-BGJ398 E16.5 
embryos (n≥5 individuals for each genotype). (G) Histological staining (Safranin’O) and immunostaining for 
Collagen X of cultured hemi mandibles condylar cartilage (scale bar = 100µm). Meckel’s cartilage (m) is 
indicated. (H) Mean percentage of hypertrophic chondrocytes for different size categories (expressed in 
µm2) inside condylar cartilage of cultured hemi mandibles (n≥50 cells from n≥5 individuals for each 
genotype and treatment). Data shown as mean with SD; *p<0.05, **p<0.01.  
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NVP-BGJ398 improves in vivo condyle growth of Fgfr3Y367C/+ mice. (A) Representative 3D reconstructions 
of 16 days old WT and Fgfr3Y367C/+ mice treated with DMSO or NVP-BGJ398 for 15 days since P01 (scale 
bar = 1mm). (B) Measurement of the mandible body and the condyle length and width of WT and 
Fgfr3Y367C/+ mice treated with DMSO or NVP-BGJ398 (n≥6 individuals for each genotype and treatment). 
Total length of the mandible was measured as well as the length of the condyle. The length of the body was 
calculated as the total length minus the condyle. (C) & (D) PCA of the Procrustes shape coordinates of the 
landmarks measured on mandibles of WT and Fgfr3Y367C/+ mice treated with DMSO or NVP-BGJ398 and 
corresponding superimposition (n≥6 individuals for each genotype and treatment). Data shown as mean 
with SD; ***p<0.005.
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ABSTRACT 
 
 Three different missense mutations in the tyrosine kinase domain of Fibroblast 
Growth Factor Receptor 3 (FGFR3) affecting a lysine residue at position 650 lead to 
dwarfism with a spectrum of severity, hypochondroplasia (p.Lys650Asn), severe 
achondroplasia with developmental delay and acanthosis nigricans (p.Lys650Met), 
and thanatophoric dysplasia (p.Lys650Glu). Fgfr3 mutations induce a constitutive 
activation of the receptor characterized by a different sustained phosphorylation. To 
understand the severity of the clinical phenotype, we developed computational and 
biological studies. Computational studies were conducted to get an atomic 
description of the various phenotypes. The FGFR3K650M, FGFR3K650E and 
FGFRK650N were built using a validated structural model of the FGFR3 kinase 
domain. Structural analyses indicate that the salt bridge between R655 and E686 
represents the FGFR3 kinase autoinhibitory molecular brake. This salt bridge is, 
significantly, disturbed with Lys650Glu mutation and is destroyed with Lys650Met 
and Lys650Asn mutants. There is a qualitative correlation with the severity of the 
clinical phenotype. We evaluated also the impact of the FGFR3 mutants on signaling 
pathways. Transient transfections of DNA mutants at position 650 in control human 
growth plate chondrocyte line show higher FGFR3 phosphorylation levels compared 
to FGFR3WT. The level of FGFR3 phosphorylation is correlated with the severity of 
the disease. Studying FGFR3 downstream signaling pathway, we observed the 
overactivation of the Mapkinase and PLCγ pathways in all mutants. Moreover 
different expressions of β-catenin and Adamts5 were observed in K650 mutants 
compared to WT. In conclusion, Lys650 mutation alters differently the conformation 
of the kinase domain thus leading to activate different signalling pathways. Various 
biological mechanisms seem to be responsible for moderate, severe and lethal 
dwarfism.  
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INTRODUCTION 
 
In this study, we evaluated the changes in the FGFR3 molecular structure for 
Lys650N, Lys650Met and Lys650Glu mutants in silico. We observed protein 
conformational modifications that rationalize the mutant over-phosphorylation level. 
We then performed in vitro analyses using a human growth plate chondrocyte line 
transfected with the FGFR3 mutants to outline the outcome of the three activating 
mutations on signaling pathways. We confirmed the over-activation of FGFR3 
canonical signaling pathways and we found interesting differences in β-catenin and 
“A disintegrin and metalloproteinase with thrombospondin motifs 5” (Adamts5) protein 
expression levels between the three mutants. The association of these data may 
provide clues on the molecular system behind the escalating severity of the 
pathological hallmarks. Activating mutations of Fibroblast Growth Factor Receptor 3 
(FGFR3) are responsible for a family of chondrodysplasias marked by both 
endochondral and membranous bone defects (Vajo et al., 2000). Gain-of-function 
mutations in FGFR3 lead to the receptor over-activation determining alterations in the 
balance of chondrocyte proliferation and differentiation at the growth plate cartilage 
level (Legeai-Mallet et al., 2004). Different FGFR3 mutations lead to distinct 
pathologies such as chondrodysplasias and craniosynostoses affecting appendicular 
and axial skeleton or skull respectively (Ornitz and Marie, 2015). Nonetheless the 
effects due to the different mutations on the cartilage and bone signaling pathways 
are not well understood. In an effort to deepen our knowledge of the molecular 
pattern underlying the FGFR3 pathological activation we decided to study the 
molecular aspects of three FGFR3-related diseases: Hypochondroplasia (HCH), 
Severe Achondroplasia with Development Delay and Acanthosis Nigricans 
(SADDAN) and Thanatophoric Dysplasia type 2 (TDII). 
HCH is the milder form of FGFR3-related chondrodysplasia, characterized by 
a rhizomelic dwarfism with short limbs, macrocephaly and lumbar lordosis (Bober et 
al., 1993). These pathological features are very similar to those observed in 
achondroplasia (ACH), but tend to be more moderate. SADDAN is a viable severe 
form of dwarfism due to the gain-of-function mutation in FGFR3. SADDAN patients 
develop a characteristic skin lesion named acanthosis nigricans (Bellus et al., 1999). 
TD is a dwarfism, that occurs with an estimated incidence closer to 1/20000 live 
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births, defined by its severity and perinatal lethality. Two types of TD are clinically 
diagnosed: TD type 1 (TDI) show prominently curved femurs, while TDII patients 
display typically straight femurs (Karczeski and Cutting, 1993; Maroteaux et al., 
1967).  
HCH, SADDAN and TDII present different phenotypic aspects. However, they 
share a particular common trait: the three chondrodysplasias are due to a missense 
mutation localized on the same Lys650 amino acid residue of FGFR3. In fact the 
substitution p.Lys650Asn has been detected in HCH patients, p.Lys650M mutation 
has been reported to be at the origin of SADDAN while all TDII individuals present 
the amino acid change p.Lys650Glu (Bellus et al., 1999, 2000; Leonard, 2016; 
Tavormina et al., 1999). Thus we decide to explore the substitution of Lys650 as a 
model to better understand the molecular pathways inducing such different disorders. 
In this study, we evaluated the changes in the FGFR3 molecular structure for 
Lys650N, Lys650Met and Lys650Glu mutants in silico. We observed protein 
conformational modifications that rationalize the mutant over-phosphorylation level. 
We then performed in vitro analyses using a control human growth plate chondrocyte 
line transfected with the three FGFR3 mutants in order to study the FGFR3 
downstream signaling pathways. We confirmed the over-activation of FGFR3 
canonical Mpakinase and PLCγ signaling pathways and we found interesting 
differences in β-catenin and “A disintegrin and metalloproteinase with 
thrombospondin motifs 5” (Adamts5) protein expression levels between the three 
mutants. An inhibition of β-catenin has been detected in cell transfected with 
FGFR3K650E mutant whereas we observe a down-regulation of Adamts5 in cells 
tranfected with FGFR3K650M or FGFR3K650E. The association of these data may 
provide clues on the molecular system behind the various severities of the 
pathological hallmarks. 
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RESULTS 
 
Lys650 substitution modifies FGFR3 structure and alters 
transautophosporylation interactions 
Computational studies were conducted to get an atomic description of the 
p.Lys650Met (SADDAN), p.Lys650Glu (TD) and p.Lys650Asn (HCH) built using a 
validated structural model of the FGFR3 kinase domain derived from the FGFR1 
crystal structure (Jonquoy et al., 2012; Li et al., 2015; Tak-Tak et al., 2011). 
Monitoring of kinetic, potential, and overall energies along the 50 ns trajectories, as 
well as the density, pressure, and temperature, demonstrates the stability of the WT, 
K650E, K650M and K650N systems. For all systems, RMSD curves of the backbone 
atoms residues were produced, along the first 50 ns trajectories, to observe 
molecular movements and fluctuations. All curves reached a plateau after 5 ns. 
Comparison of the average protein structures in all complexes showed that the 
secondary structures and globular form of FGFR3 were retained during the 
simulations. AMD simulations were engaged for all systems in order to enhance their 
conformational sampling so that the ergodicity of systems may be considered. We 
performed AMD simulations of 100 ns which, broadly speaking, correspond to 1 µs of 
classical MD simulations. From these trajectories, we verify that the secondary 
structures of the 4 systems remain identical. 
In non-mutant FGFRs the first step in the receptor activation process is the activation 
loop (A-loop) tyrosine phosphorylation ruled by the conformational modifications 
induced by the interaction of the extracellular domain with FGF ligands (Goetz and 
Mohammadi, 2013). Hence, in our FGFR3 model the two tyrosine residues involved 
in the receptor activation are Tyr647 and Tyr648 residing in the A-loop. 
As for any chemical reaction, phosphorylation requires an access to the reactants. 
Therefore, the ability to phosphorylate Tyr647 or Tyr648 residues is proportional to 
their solvent accessibility. Structural analyses extracted from molecular dynamics 
trajectory indicate that a salt bridge between R655 and E686 is the cornerstone of 
the Tyr647/Tyr648 solvent exposition (Figure 1A). Thus this salt bridge constitutes 
the kinase autoinhibitory molecular brake (Chen et al., 2007). R655/E686 salt bridge 
is, significantly, disturbed with Lys650Asn (HCH) mutation and is totally absent in 
Lys650Met (SADDAN) and Lys650Glu (TDII) mutants. Moreover the effect on the salt 
108
bridge leads to FGFR3 A-loop folding modifications. We observe a major change for 
FGFR3K650M (SADDAN) and FGFR3K650E (TDII) that take a hairpin conformation and 
a milder modification for FGFR3K650N (HCH) that slightly moves away the A-loop from 
the C-terminal domain (Fig. 1A). 
A structural study was performed to evaluate the effect of these modifications during 
the transautophopshorylation process in a FGFR3 dimer (Figure 1B). Firstly we 
notice that in wild-type conformation a steric problem between the enzyme substrate 
helix harboring the tyrosine phosphorylatable residue Y648 and the enzyme kinase 
A-loop prevents the transautophosphorylation in FGFR3 dimers. This information 
suggests that the FGFR3WT needs a change in its structure to slightly move the A-
loop and allow the interaction. This adjustment may be provided through the binding 
of a FGF ligand (Goetz and Mohammadi, 2013). Secondly, if we consider the FGFR3 
mutants, we can observe the lack of steric hindrance previously detected in 
FGFR3WT. This feature in mutant FGFR3 indicates the likely independence of the 
mutant proteins from the A-loop activation. Furthermore the A-loop hairpin structure 
displayed by both FGFR3K650M (SADDAN) and FGFR3K650E (TDII) allows an improved 
transautophosphorylation interaction compared to FGFR3K650N (HCH) structure. This 
exceptional interaction coincides with an increase of phosphorylation; thus 
FGFR3K650M (SADDAN) and FGFR3K650E (TDII) are over-phosphorylated compared to 
FGFR3K650N (HCH). 
Quantification of the FGFR3s conformational modifications 
To quantify the structural differences examined in our FGFR3 molecular 
models we determined two reference points representing the A-loop (backbone 
gravity center of 650-656 aa) and the C-terminal domain (backbone gravity center of 
562-565 aa ; 620-623 aa) (Figure 2). The C-terminal domain is almost fixed in all 
FGFR3 reconstructions, the A-loop instead moves away. Thus we can measure the 
gap between these two points. We observe that the wider is the distance between 
the c-terminal domain and the A-loop and the more severe is the mutation (Table 1). 
Mutant FGFR3s over-phosphorylation is transduced to downstream signaling 
pathways  
We investigated the phosphorylation level of the three mutant FGFR3s in a 
human chondrocyte line derived from chondrocytes belonging to the growth plate. 
These cells have been transfected with suitable constructs to express the human 
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FGFR3 wild-type and mutant. Firstly we notice a different phosphorylation level of the 
mutant FGFR3 proteins. FGFR3K650M (SADDAN) appears the most phosphorylated, 
followed by FGFR3K650E (TDII) and ending with FGFR3K650N (HCH) (Figure 3A). 
Secondly we analyzed the FGFR3 canonical pathways ERK and PLC-γ (Figure 3B). 
The FGFR3 mutations have triggered the activation of both ERK and PLC-γ. 
However it is not possible to determine with evidence if one mutation leads to a 
higher phosphorylation than the other ones. 
Mutant FGFR3s modify β-catenin and Adamts5 expression 
We decided to explore proteins belonging to non-canonical pathways to find 
the molecular reasons for the various phenotype of the three K650-FGFR3-related 
disorders. Wnt/β-catenin pathway is known to be involved in chondrocyte maturation 
at the growth plate level (Staines et al., 2012), thus we chose to investigate the 
presence of imbalances in this pathway. Interestingly, the analysis of β-catenin 
showed a decrease of the expression in FGFR3K650E (TDII) compared to the wild-type 
form (Figure 4A). 
In our quest for molecular differences among the Lys650 mutants we 
considered the putative impact of the activating mutations on the cartilage matrix. It is 
known that a large set of degrading enzymes play a major role in endochondral 
ossification and that the ADAMTS family is part of the group (Cawston and Wilson, 
2006). For this reason we examined Adamts5 expression. Adamts5 provided different 
results among the FGFR3 variants (Figure 4B). While FGFR3K650N (HCH) produces 
an Adamst5 expression equivalent to FGFR3WT, FGFR3K650M (SADDAN) and 
FGFR3K650E (TDII) are characterized by a lower expression of the protein 
FGFR3K650M (SADDAN) (~1/2 FGFR3WT expression), with the lowest level attained by 
FGFR3K650E (~1/3 FGFR3WT expression).We decided to explore proteins belonging to 
non-canonical pathways to find the molecular reasons for the clinical appearance of 
the three mutations. The analysis of β-catenin showed an increase of its level in 
FGFR3K650N (HCH) compared to FGFR3WT and a decrease of the expression in 
FGFR3K650E (TD) always compared to the wild-type form (Figure 4A). The study of 
another protein, Adamts5, provided different results among the FGFR3 variants 
(Figure 4B). While FGFR3K650N (HCH) produces an Adamst5 expression equivalent 
to FGFR3WT, FGFR3K650M (SADDAN) (~1/2 FGFR3WT expression) and FGFR3K650E 
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(TD) are characterized by a lower expression of the protein, with the lowest level 
attained by FGFR3K650E (~1/3 FGFR3WT expression). 
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DISCUSSION 
Gain-of-function mutations are responsible for the biological dysfunctions that 
characterize FGFR3-related chondrodysplasias and cranyosinostoses (Baujat et al., 
2008; Karczeski and Cutting, 1993; Muenke et al., 1997; Tavormina et al., 1999). 
These mutations in FGFR3 determine an increase in the receptor phosphorylation as 
already been described in several studies (d’Avis et al., 1998; Bellus et al., 2000; 
Bonaventure et al., 2007; Gibbs and Legeai-Mallet, 2007; Naski et al., 1996). An 
absence of correlation between bone pathologies from which the FGFR3 mutations 
arise and the phosphorylation level of the receptor has also been described (Gibbs 
and Legeai-Mallet, 2007; Iwata et al., 2001). However, the biological processes 
between the various FGFR3 mutations and their effects on the receptor 
phosphorylation are still poorly understood. In an effort to shed light on these 
mechanisms we performed computational and biological studies of three FGFR3 
mutations inducing three different chondrodysplasias: p.Lys650N (HCH), Lys650Met 
(SADDAN) and Lys650Glu (TDII). 
The in silico analyses performed show that the phosphorylation of the receptor 
is linked with the conformational changes that the protein undergoes when mutated. 
In fact the salt bridge R655/E688, observed in FGFR3WT and FGFR3K650N (HCH), 
falls into a group of “molecular brake” mechanisms that regulate the activity of 
receptor tyrosine kinases already described (Chen et al., 2007). When the molecular 
brake is lost, as in the FGFR3K650M (SADDAN) and FGFR3K650E (TDII) salt bridge 
disruption, the kinase activity becomes independent from the phosphorylation of the 
A-loop residues. An almost identical event has been reported in the crystal structure 
of FGFR3KK650E validating our results (Huang et al., 2013). This peculiar A-loop 
insensitivity explains the elevated phosphorylation levels that we find in FGFR3K650M 
(SADDAN) and FGFR3K650E (TDII) (Figure 3A). Moreover, the absence of the 
molecular hindrance observed in all FGFR3 mutants in the transautophosphorylation 
interaction (Figure 2B) indicates that the three proteins will show a higher receptor 
activation compared to FGFR3WT. These findings corroborate the thesis of the link 
between FGFR3 mutations and increased activity of the receptor. This abnormal 
receptor activation system, due to tyrosine kinase domain mutations, appears to be 
different from the molecular pattern regulating the mutations located in the 
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transmembrane domain that is based on greater stabilization of the FGFR3 dimer (Li 
et al., 2006; Placone and Hristova, 2012; Sarabipour and Hristova, 2016).  
The steric hindrance observed in the FGFR3WT transautophosphorylation 
study, showing the necessity to move the A-loop to allow this interaction between two 
FGFR3 proteins, may indicate two potential non-mutant FGFR3 molecular behaviors. 
The first is that the interaction is still possible, but at a lower rate compared to the 
mutant FGFR3s. The second is that the binding with a FGF ligand could increase the 
transautophosphorylation rate in the FGFR3WT dimer inducing the A-loop movement 
necessary to allow the interaction between the enzyme kinase and the enzyme 
substrate (Goetz and Mohammadi, 2013; Hubbard, 2004). Furthermore, different 
FGF ligands may cause different FGFR3 conformations (Chen and Hristova, 2011) 
leading to the activation of different downstream proteins. 
The FGFR3 deep structural modifications, illustrated through our 
computational investigations, could allow a change in the protein-protein interactions 
selectivity. This affinity alteration would lead to the activation / inhibition of molecular 
pathways that could result in the dramatically various clinical phenotypes of FGFR3-
related disorders. The analyses of ERK and PLCγ pathways in human chondrocytes 
transiently expressing the FGFR3 mutants did not reveal any difference in the 
activation or expression of these proteins (Figure 3B). The equivalent ERK activation 
observed in FGFR3K650M (SADDAN) and FGFR3K650E (TDII) has already been 
reported in studies performed using RCS chondrocytes or HEK293 cells expressing 
the same mutants (Krejci et al., 2008; Lievens et al., 2006). However, we observed 
there that the ERK phosphorylation induced by FGFR3K650N (HCH), is comparable 
with the effects of the other two mutated proteins. Activation of MAPK pathway leads 
to chondrocyte differentiation defects (Ornitz and Marie, 2015), feature that we can 
observe among the three diseases (Krejci, 2014). By cons, PLCγ in chondrocytes is a 
signal transducer and activator of transcription of STAT1 (Harada et al., 2007; Ornitz 
and Itoh, 2015) whose activation inhibits cell proliferation (Sahni et al., 1999, 2001). 
The similar activation of PLCγ in the three conditions, seems to point to the presence 
of proliferation defects in the three mutants. However, there should be one or more 
molecular pathways responsible for the differences in HCH, SADDAN and TDII 
disorders. 
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Searching for alternative pathways we identified differences in the expression 
of β-catenin, protein belonging to the Wnt/β-catenin pathway. This pathway is 
strongly implicated in bone formation through osteoblasts regulation and growth plate 
chondrocytes differentiation as described in several studies (Akiyama et al., 2004; 
Day et al., 2005; Hu et al., 2005; Yuasa et al., 2009). We showed a downregulation 
of the expression of the protein in the presence of FGFR3K650E (TDII) (Figure 4A). A 
similar result have been obtained observing a decreased β-catenin expression level 
in the growth plate of mice expressing Fgfr3K644E under the promoter Prx1 (Shung et 
al., 2012). In addition the conditional knock-out of β-catenin under Prx1 promoter 
determined chondrocyte maturation defects (Hill et al., 2005) and its conditional 
inactivation under Col II promoter in mice caused endochondral ossification 
anomalies at the skull base level (Nagayama et al., 2008), thus confirming the 
importance of its correct expression. On the other hand recent studies on FGF2-
stimulated RCS chondrocytes demonstrate an upregulation of β-catenin expression 
mediated by LRP6 phosphorylation (Buchtova et al., 2015). In our in vitro 
experiments we observed a strong inhibition of Adamts5 expression in FGFR3K650M 
(SADDAN) and FGFR3K650E (TDII). A decreased expression of Adamts5, one of the 
main proteinases responsible for aggrecan degradation in vivo (Malfait et al., 2002), 
may determine an accumulation of aggrecan in cartilage matrix. This larger quantity 
of aggrecan could lead to inhibition of mineralization (Marcus et al., 2013). It has 
been recently established that a conditional deletion of Fgfr3 leads to an increase of 
Adamts5 detected by RT-PCR in articular cartilage (Zhou et al., 2016). If the lower 
level of Adamts5 observed in our cells is due to the presence of activating mutations 
it is reasonable to think that a Fgfr3 knockout could induce an increase of the protein 
expression and vice versa. Adamts5 expression in growth plate cartilage seems to be 
negatively regulated by PI3K/Akt pathway since Adamts5 expression level analyzed 
by RT-PCR increases with the PI3K inhibition (Ulici et al., 2010). Nonetheless it has 
been reported that the response of RCS chondrocyte to FGF2 produced an increase 
in Adamts5 expression determined by RT-PCR (Buchtova et al., 2015). The different 
β-catenin and Adamts5 expressions reported in (Buchtova et al., 2015) may be due 
to differences between the response of FGFR3WT stimulated in RCS cells and 
FGFR3-mutants expressed in human chondrocytes from the growth plate. 
Interestingly, it has been reported that β-catenin overexpression is correlated with an 
increase of Adamts5 expression in cultured mouse mature chondrocytes (Tamamura 
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et al., 2005). All together our biological data seem to point out a pathogenic role for 
Wnt/β-catenin and PI3K/Akt pathways in growth cartilage. 
In summary, we have decipher some of the molecular mechanisms by which 
the Lys650 mutations confer gain-of-function on FGFR3 kinase and we determined 
interesting imbalances in downstream signaling pathways due to these activating 
mutations.  
These results may provide the rational to design new therapeutic strategies to 
counteract the effects of the hyperactivity of the pathogenic FGFR3 mutants. 
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MATERIAL AND METHODS 
 
Molecular dynamics 
The FGFR3 kinase domain and its three mutants, K650E, K650M and K650N 
were considered for computational studies. All simulations were performed by using 
the Amber software package (Case et al., 2010) with ff99SBildn force-field 
(Wickstrom et al., 2009). The FGFR3 kinase coordinates were taken from a 
previously validated model (Jonquoy et al., 2012; Tak-Tak et al., 2011), from which 
the K650X mutations were created with the Leap module of Amber. The four systems 
(wild-type and the three mutants) were then immersed in periodic boxes of water 
solvent. The simulations started with an energy optimization of the water solvent 
followed by a global minimization of the whole systems. The systems were firstly 
heated from 0 to 300 K and a molecular dynamics production were then performed in 
the NTP ensemble, leading to a trajectory of 50 ns. Other details about the 
computational procedure may be found elsewhere (Barbault and Maurel, 2012). 
 
Accelerated molecular dynamics 
Accelerated molecular dynamics (AMD) is a recent technique (Hamelberg et 
al., 2007), which aims to enhance the conformational sampling of a classical MD 
through the adjunction of a supplemental potential. The goal of this bias energy, 
called a boost, is to fill the minima of a protein potential energy hyper-surface in order 
to reduce the energy walls barriers. This modification intervenes only if the potential 
energy is lower than the average potential energy. The implication of this method on 
the Hamiltonian describing the protein appears in the following equations: 
 
{ℋ(�⃗, �⃗) = �(�⃗) + �(�⃗)                      �� �(�⃗) ≤ ��������ℋ(�⃗, �⃗) = �(�⃗) + �(�⃗) + Δ�(�⃗)    �� �(�⃗) > ��������   
 
The p and r vectors represent, respectively, the momenta and coordinates of all 
atoms. K is the kinetic energy of the system whereas U is the potential energy 
calculated through the amber force-field equations. When this last energy is greater 
than the average potential energy (Eaverage) a boost is applied  (V)  through the 
following equation: 
116
Δ�(�⃗,�) = (���� − �(�⃗))2���� + ���� −�(�⃗) + (����� − �����(�))2����� + ����� − �����(�) 
 
In this last equation the boost of AMD is implemented for the torsional and the 
whole potential energy. The threshold (T) term and   factor are easily determined 
using basic system information: 
 ����� = 0.7 × ������−�����    ����� = 〈�����(�)〉 + ����� ���� = ������5         ���� = 〈�(�⃗)〉 + ���� 
 
 and T values were determined by averaging the energies of the last 10ns 
extracted from the whole 50ns simulations of classical molecular dynamics. For all 
molecular systems, the accelerated molecular dynamics were launched for 100ns. 
  
Computational analyses 
 To check the equilibration, root mean square deviations (RMSD) were 
recorded for all systems. The FGFR3 backbones atomic fluctuations were also 
recorded and mass-weighted for each residue. For each system, comparison of 
atomic fluctuations and RMSD between classical MD and AMD were performed to 
evaluate the impact of this last technique on the conformational sampling.  
A distance between the centers of gravity of the activation loop (backbone 
atoms of residues 650 to 655) and the C-terminal domain (backbone atoms of 
residues 562 to 565 and 620 to 623) was recorded along the trajectory. This specific 
distance was chosen to decipher and quantify the opening process of the kinase 
activation loop. In all simulations a hydrogen bond was considered when the donor-
acceptor distance was smaller than 3.5 Å and the donor-acceptor-H angle smaller 
than 60°. These weak criteria were chosen deliberately to count as much as possible 
hydrogen bonds. 
 Visualization and other analyses were performed with the help of VMD (Visual 
Molecular Dynamics) software (Humphrey et al., 1996). 
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 Transient transfections of cDNA FGFR3 constructs 
Human control chondrocyte lines (Benoist-Lasselin et al., 2007) at 80%–90% 
confluence were transiently transfected with FGFR3 human constructs (FGFR3WT, 
FGFR3K650N, FGFR3K650M, FGFR3K650E) obtained as previously reported (Gibbs and 
Legeai-Mallet, 2007) using JetPrime (Polyplus-transfection) following the 
manufacturer’s instructions. Transfected cells were lysed in RIPA buffer (50 mM Tris-
HCl pH 7.6, 150 mM NaCl, 0.5% NP40, and 0.25% sodium deoxycholate, 
supplemented with protease and phosphatase inhibitors; Roche). 
Immunoprecipitations were performed by incubating 3 μl rabbit anti-FGFR3 
(SigmaAldrich F0425)/500 μg protein with protein A–agarose (Roche). 
 
Immunoblotting 
Whole-cell lysates and immunoprecipitated proteins were subjected to NuPAGE 4%–
12% bis-tris acrylamide gels (Life Technologies). Blots were probed with antibodies 
using standard protocols: anti-FGFR3 polyclonal antibody (Sigma-Aldrich F0425; 
1:1,000 dilution), anti–phospho-tyrosine P-Tyr-100 monoclonal antibody (Cell 
Signaling catalog 9411; 1:1,000 dilution), anti–phosphoERK1/2 monoclonal antibody 
(Cell Signaling catalog 4370; 1:1,000 dilution), anti-ERK1/2 polyclonal antibody 
(Sigma-Aldrich M5670; 1:1000 dilution), anti–phospho-PLCγ polyclonal antibody (Cell 
Signaling catalog 2821; 1:1,000 dilution), anti-PLCγ polyclonal antibody (Cell 
Signaling catalog 2822; 1:1,000 dilution), anti-β-catenin polyclonal antibody (Cell 
Signaling catalog 9562; 1:1,000 dilution), anti-ADAMTS5 polyclonal antibody (abcam 
ab41037, 1:1,000 dilution). 
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FIGURES 
 
 
 
Figure 1. Wild-type and mutant FGFR3s modeling. (A) Predicted structures of FGFR3WT FGFR3K650N (HCH), 
FGFR3K650M (SADDAN), and FGFR3K650E (TDII). (B) Transphosphorylation model between a FGFR3 enzyme 
kinase (in different colors) and a FGFR3 enzyme substrate (transparent purple). FGFR3WT presents a molecular 
hindrance between the helix (opaque purple) carrying the phosphorylatable tyrosine (stick model) and the A-loop 
(green). ATP molecule is shown in stick model close to the phosphorylatable tyrosine.   
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Figure 2. Representation of the points indicating the position of the activation loop and the C-terminal 
domain. The two points are indicated by the orange spheres. The activation loop (green) is defined by the 
backbone gravity center of 650-656 aa while the C-terminal domain is exemplified by the backbone gravity center 
of 562-565 aa ; 620-623 aa. This last point is almost fixed in all mutants and WT. 
 
Table 1. Quantification of the distance between the activation loop and the C-terminal domain 
 
System Distance (Å) 
FGFR3WT 8.9 
FGFR3K650N 12.2 
FGFR3K650E 16.4 
FGFR3K650M 16.8 
 
We measured the distance between the points illustrating the activation loop and the C-terminal domain (Figure 
2). The more or less wide gap between the activation loop and the C-terminal domain correlates with the FGFR3 
phosphorylation level. 
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 Figure 3. FGFR3 mutants display different FGFR3 phosphorylation levels and activation of the canonical 
FGFR3 downstream pathways. (A) Phosphorylated FGFR3 expression in transfected human chondrocytes with 
FGFR3K650N (HCH), FGFR3K650M (SADDAN), and FGFR3K650E (TDII) constructs. (B) Phosphorylated ERK and 
PLC γ expression in transfected human chondrocytes with FGFR3K650N (HCH), FGFR3K650M (SADDAN), and 
FGFR3K650E (TDII) constructs. 
 
 
Figure 4. FGFR3 mutants have different β-catenin & Adamts5 protein expressions. (A) β-catenin expression 
level in transfected human chondrocytes with FGFR3K650N (HCH), FGFR3K650M (SADDAN), and FGFR3K650E (TDII) 
constructs revealed by western blot and quantified with actin ratio. (B)  Adamts5 expression level in transfected 
human chondrocytes with FGFR3K650N (HCH), FGFR3K650M (SADDAN), and FGFR3K650E (TDII) constructs 
revealed by western blot and quantified with actin ratio. 
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Conclusions and 
Perspectives 
 
1. TKIs as a potential therapeutic strategy for ACH 
 
The FGFR3 abnormal activation triggers its downstream molecular cascade 
leading to several disorders as already thoroughly discussed (93). Numerous 
strategies have been developed to counteract the consequences of the mutant 
FGFR3 activity (159). Among them the one that seems the most effective consists in 
modulating the FGFR3 kinase, a strategy that can be performed by TKIs. FGFR3-
TKIs have already demonstrated their therapeutic potential in the cancer field (160, 
161, 205) however they have never been employed in skeletal disorders. In pre-
clinical studies two FGFR3 selective inhibitors, one synthesized by Aviezer et al. and 
the other named A31, have been evaluated to restore bone growth (165, 167). 
Although these studies have revealed positive effects no assessment of those 
compounds in a living animal model has been reported. 
To establish the TKIs efficacy for ACH we decided to evaluate one of these small 
molecules: NVP-BGJ398 (Article 1 – (206)). For the first time, using the ACH mouse 
model Fgfr3Y367C/+, we demonstrated an in vivo beneficial effect on several 
pathological features. This work demonstrates the validity of the FGFR3-TKIs 
approach although it does not exclude the potential ineffectiveness of some of these 
small molecules or even toxicity if these compound are not highly selective for 
FGFR3 due to the inhibition of other tyrosine kinases as it has been recently 
described (169).  
The improvements produced by the NVP-BGJ398 are evident, however one of the 
most frequently asked questions concerns the comparison with the effects induced 
by other approaches validated in fgfr3 mouse models. To address this issue I have 
limited the comparative analysis to the femur growth that has been reported in all 
these pre-clinical studies (176, 195, 200, 201, 204, 206). If we consider these data, 
the compound that determined the most important growth is the TKI NVP-BGJ398 
(Table 5). However we have to note the presence of relevant discrepancies among 
these studies that could alter the comparative analysis here displayed. 
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Table 5. Comparison of ACH therapeutic approaches validated in vivo 
 
Several parameters concerning the in vivo study design differ among the data 
reported in these 6 papers. Firstly, the experiments have been performed on 3 
different mouse models: Ella-Cre Fgfr3G369C/+ mice, transgenic human Fgfr3G380R 
under Col2a1 promoter mice named “Fgfr3ach” and Cre-CMV Fgfr3Y367C/+ mice (120, 
166, 168). These mice share most of the dwarf features (short limbs, macrocephaly, 
growth plate anomalies) with the particularity that our Fgfr3Y367C/+ mouse model 
presents a more severe phenotype than Fgfr3G369C/+ and Fgfr3ach. 
Secondly, various routes of administration have been proposed. In most of the 
cases the pharmacological administration involves subcutaneous injections, but 
intraperitoneal injections and the oral route have also been proposed (Table 4). Our 
suggestion is that a change in the drug administration could improve or diminish the 
effect of the therapy. 
Thirdly, mice have been treated at different ages, for disparate periods and with 
different frequencies. Drug administration frequency could have an impact in the 
prospect of patient care. In fact  reducing dose frequency shows an effect on health 
outcomes and health care costs (207) thus meaning that a low frequency treatment 
would be more convenient. However the most crucial point consists in the beginning 
of the treatment. Since ACH is a disease detected prenatally (30) and considering 
that growth cartilage is replaced by bone in adulthood, we should administrate the 
treatment the earliest possible to reach the best phenotypic reversal. Overall, bone 
growth occurs progressively from the beginning of the ossification in embryo (E14.5 
in mice, second month of development in humans) to 15-18 years old in humans 
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(208) equivalent to approximately 3 months in mice, nonetheless treatments for 
achondroplasia should be administrated in this period. 
Table 6. Comparison BMN 111 / NVP-BGJ398 (Protocol 1 & 2) 
Thus, considering all the various differences observed among the design of the 
different studies, it is difficult to argue with certainty the effectiveness of NVP - 
BGJ398 over the other compounds proposed for ACH. We can just confirm that we 
have obtained a greater improvement with NVP-BGJ398 than BMN 111 as already 
reported (Article 1 – (206)). The comparison has been made possible modifying the 
period of treatment (Table 6). We observed a best improvement of the size of the 
femur with NVP-BGJ398 rather than BMN111 using the same protocol. The 
explanation behind this result probably reside in tyrosine kinase inhibitors direct 
action against the FGFR3 activation whereas BMN 111, CNP-analog, is more indirect 
antagonizing the FGFR3 downstream pathway through NPR-B stimulation. We 
observe that Protocol 1 is more effective than Protocol 2. However it is difficult to 
determine if the increased efficiency is due to the earlier therapy initiation, the longer 
time of treatment or a combination of both. 
In future studies the treatment times should be carefully analysed to choose the 
perfect timing and correct duration to deliver the most impressive results. Evaluation 
of the potential effects of the drug in utero could revolutionize ACH treatment and for 
this reason we have some on going in utero experiments. Finally, it should not be 
excluded the simultaneous test of multiple drugs to assess possible additive effects. 
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In fact compounds stimulating growth through different pathways could determine a 
greater effect if used combined.  
 
2. NVP-BGJ398 as an investigational tool for Fgfr3-related defects 
 
We have determined the ability of NVP-BGJ398 in inhibiting the FGFR3 
overactivity. Now this potential can be applied as a tool to analyze particular ACH 
features revealed in Fgfr3Y367C/+ mouse model.  
The experiments with NVP-BGJ398 allow us to understand IVD (Article 1 – 
(206)), Meckel’s cartilage (MC) and condylar cartilage (Article 2) and foramen 
magnum (FM) (Article 1 –(206)) defects in achondroplasia.  
We reported for the first time vertebrae and invertebral disc anomalies related to 
a FGFR3 activating mutation (Article 1 – (206)). In Fgfr3Y367C/+ mice we observed a 
reduced size of vertebral bodies presenting short pedicles and an abnormal shape of 
Nuclei Pulposi (NP) in IVDs. These defects were all corrected with NVP-BGJ398 
injections. These data revealed that vertebral body and IVD are severely affected in 
the mutant mice and confirm the impact of the activating FGFR3 mutation on the 
axial skeleton. These results are in agreement with clinical observations in ACH 
patients showing kyphosis, lordosis, platyspondyly, spinal stenosis and short 
pedicles. 
We focused also our study on the craniofacial anomalies and the prognatism in 
ACH and mutant mice. Here, we reported a reduced size of the mandible in both 
ACH patients and mice (Article 2). In mandible development a major role is played by 
MC, as a consequence of FGFR3 overactivation, the MC is affected in ACH. While in 
vivo NVP-BGJ398 had no effect on the body length mandible, ex vivo cultures of 
Fgfr3Y367C/+ embryos showed an improvement of the mandible length. If we consider 
that MC disappears before birth and in vivo experiments started from post-natal day 1 
we obtain a threefold information: firstly MC is fundamental for the elongation of the 
mandible; secondly the FGFR3 inhibition in MC restore the mandible growth; thirdly 
mutant FGFR3 affects the MC. Likewise we observed defects on the hypertrophy of 
condylar cartilage and these anomalies were corrected both ex vivo and in vivo by 
the TKI NVP-BGJ398.  
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Some ACH patients suffer of cervicomedullary compression related to FM 
defects that are due to synchondroses loss (25). We observed the presence of the 
same skull base defects in Fgfr3Y367C/+ mice (Appendix – (209)) and with the NVP-
BGJ398 treatment we corrected them pointing out the importance of synchondroses 
in skull base (Article 1 – (206); Figure 21). 
 
Figure 21. Interoccipital synchondroses. In Fgfr3Y367C/+ mice we observe the presence of bone 
(asterisk). The treatment with NVP-BGJ398 prevent this abnormal ossification. Safranin-O staining, 
scale bar = 50 µm  
 
In Di Rocco et al. we showed the appearance of membranous ossification defects 
in Fgfr3Y367C/+ mice. In Article 1 (206) the treatment with NVP-BGJ398 ameliorated 
the membranous skull defect in organotypic cultures of calvaria. Thus similarly to the 
study of the previously discussed defects the use of NVP-BGJ398 was a valuable aid 
validating the role of FGFR3 in membranous ossification (Appendix – (209)). 
 
3. Understanding of the pathological molecular patterns to determine 
new therapeutic approaches 
 
Three different mutations localized in the same position of FGFR3 are responsible 
for 3 different pathologies: Lys650Asn leads to HCH, Lys650Met induces SADDAN 
and Lys650Glu causes TD (35). Lys650 is positioned on the FGFR3 kinase domain 
and its mutation determines an abnormal activation of the receptor. We conducted an 
investigation of the activation of FGFR3 downstream signaling pathways that 
involved experiments in silico and in vitro (Preliminary data) 
The in silico works elucidated the FGFR3 kinase conformational modifications 
induced by the three mutants. The analysis of the mutant FGFR3 molecular behavior 
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has shedding light on the pathological molecular mechanisms, but it could also 
provide a basis for the development of new inhibitors based on these observations. 
Biological studies have outlined some of the changes in the downstream 
pathways involved in the three diseases (Figure 22). The reduction in β-catenin and 
Adamts5 expression led by the mutations responsible for the severe form of dwarfism 
(FGFR3K650M (SADDAN), FGFR3K650E (TDII), confirmed the defects on chondrocyte 
maturation present in their clinical pathological features (210). These investigations 
have to be improved to understand the modifications involved in the signalling 
pathways concerned (Wnt/β-cat and PI3K/Akt). Understanding the differences in 
these downstream signalling pathways triggered by the three mutants could lead to 
the identification of a potential target for the development of a new therapeutic 
strategy as for the discovery of the role of CNP that led to the development of BMN 
111.  
 
Figure 22. Scheme illustrating the signalling pathways involved in Lys650 mutation 
(Preliminary data). Dashed lines represent possible links, while full lines are used for data reported 
as Preliminary data.  
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FGFR3 gain-of-function mutations lead to both chondrodysplasias and craniosynostoses. Achondroplasia
(ACH), themost frequent dwarﬁsm, isdue toanFGFR3-activatingmutationwhich results in impaired endochon-
dral ossiﬁcation. The effects of themutation onmembranous ossiﬁcation are unknown. Fgfr3Y367C/1micemim-
icking ACH and craniofacial analysis of patients with ACH and FGFR3-related craniosynostoses provide an
opportunity toaddress this issue.Studying thecalvaria andskull base,weobservedabnormal cartilageandpre-
mature fusionof thesynchondroses leading tomodiﬁcationsof foramenmagnumshapeandsize inFgfr3Y367C/1
mice, ACH and FGFR3-related craniosynostoses patients. Partial premature fusion of the coronal sutures and
non-ossiﬁed gaps in frontal bones were also present in Fgfr3Y367C/1mice and ACH patients. Our data provide
strong support that not only endochondral ossiﬁcation but also membranous ossiﬁcation is severely affected
in ACH. Demonstration of the impact of FGFR3 mutations on craniofacial development should initiate novel
pharmacological and surgical therapeutic approaches.
INTRODUCTION
Fibroblast growth factor receptors (FGFRs) are known to be im-
portant receptor tyrosine kinase (RTK) involved in skeletal de-
velopment. FGFR3 gain-of-function mutations lead to both
chondrodysplasias and craniosynostoses. Among chondrodys-
plasias, achondroplasia (ACH), themost frequent genetic dwarf-
ism is due to one recurrent transmembrane (TM) activating
FGFR3mutation (p.Gly380Arg) that causes a structural change
which affects both the stability and activity of FGFR3 dimers
in the absence of ligand (1–4). Thanatophoric dysplasia (TD)
type I and II are a lethal form inwhich a point mutation localized
either in the extracellular (EC) or intracellular domain ofFGFR3
induces a dimerization of FGFR3 in the absence of ligand (5).
Muenke syndrome (MS), the most common craniosynostosis
syndrome, is also due to a single FGFR3 gain-of-function muta-
tion (p.Pro250Arg) in EC domain leading to varying effects on
ligand-binding speciﬁcity (6–8). Finally, a rare formof craniosy-
nostosis with skin disorder, a Crouzon syndromewith acanthosis
nigricans (CAN), results from another TM FGFR3 point
mutation (p. Ala391Glu) localized in the same functional
domain asACH(9).TheCANTMmutationenhances theactivity
of the receptor in the absence of ligand and facilitates the activa-
tion of the tyrosine located in the activating loop (9,10). FGFR3
mutations disturb several signaling pathways in chondrocytes
andosteoblasts suchasMAPK,P38,PLCg, STATandPKCpath-
ways thus inducing anomalies of cellular proliferation, differen-
tiation and/or apoptosis (11).
In order to understand the FGFR3-skeletal diseases, several
mousemodels have been generated, but they donot always faith-
fully and comprehensively mimic the human diseases. Mouse
models of MS syndrome (Fgfr3P244R) inconstantly share some
phenotypic traits with the human disorder such as hearing loss
and facial dysmorphology (12–14). Interestingly, the murine
Fgfr3P244R mutation does not only affect the skull but can also
disturb the long bones (13). Numerous Fgfr3-related chondro-
dysplasia mouse models have been generated as well (15–17).
Among them, we generated and studied the Fgfr3Y367C/+ mice
(18). These mutant mice present a severe dwarﬁsm phenotype
with a reduction of the length of the appendicular and axial
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skeleton, consequence of a disturbed endochondral ossiﬁcation
(18–21). In these mice, we also noted that the overall shape of
the skullwas affected,with a domedcranial vault and an inverted
bite (18,21). ACH patients present a similar craniofacial pheno-
type that is considered an endochondral ossiﬁcation defect
leading to shorter cranial base (22). The following issue there-
fore remains to be elucidated: is membranous ossiﬁcation pri-
marily affected in ACH? The availability of Fgfr3Y367C/+ mice
mimicking ACH provides an opportunity to address this issue
by studying speciﬁcally the calvaria and skull base. In addition,
the analysis of cranial anomalies in ACH and craniosynostosis
syndromes (MS, CAN) offers the opportunity to compare the
skull phenotype of three FGFR3-related diseases.
Here, we ﬁrst provide evidence obtained through analysis of
bothFgfr3Y367C/+mice and childrenwithACHshowing that dis-
ruption of endochondral ossiﬁcation result in skull base anomal-
ies with premature fusion of the basal synchondroses and
reduction of the size of the foramenmagnum (FM). Then, study-
ing the skull vault, we highlight a defective membranous ossiﬁ-
cation in Fgfr3Y367C/+ mice and children with ACH. We
observed non-ossiﬁed gap in frontal bones and a partial and pre-
mature fusion of sutures in both mice and children with ACH.
Together, these data expand the general concept of dwarﬁsm
by showing that FGFR3 mutations affect not only the skull
base and facial skeleton but also induce anomalies of the skull
vault. This study sheds new light on the impact ofFGFR3muta-
tionsonmembranousossiﬁcation andcould explain clinical hall-
marks of ACH such as the macrocephaly and frontal bossing.
RESULTS
Fgfr3Y367C/1mice exhibit skull dysmorphy that
mimics the human pathology
To evaluate the impact of the activating Fgfr3 mutation
(p.Tyr367Cys) on the craniofacial phenotype, we analyzed the
growth of the skull of Fgfr3Y367C/+ mice (21) and their control
littermates at three different time-points: embryonic period
(E16.5), birth (P0) and 3 weeks of age (P21). We focused on
bones of the skull formed either by endochondral (nasal, occipi-
tal) or membranous (frontal, parietal, interparietal) ossiﬁcation,
whose developmental anomalies can contribute to overall skull
dysmorphy. The macroscopic analysis of the cranium showed
that a rounder shape of the head and shorter snout were present
inFgfr3Y367C/+mice at E16.5 compared with control littermates
(Fig. 1A).
The severity of the dysmorphyworsened as themicedeveloped
and increased frombirth (Fig.1B) to3weeksofage (Fig. 1C).This
is similar to alterations of the longbones inFgfr3Y367C/+mice that
worsen in the ﬁrst week of life (18). At 3 weeks of age, we
observed a signiﬁcant reduction in the length of the skull (66%
of the control size, P, 0.007) (Fig. 1D).
Themeasurementsof thesizeofeachcalvarialboneshowed that
the different bones are not equally affected by theFgfr3mutation.
We found a severe decrease in size in nasal (54% P, 0.001) and
occipital bones (47%, P, 0.001), which are in accordance with
anomalies in endochondral ossiﬁcation (18). Focusing on bones
formed by membranous ossiﬁcation, the size of the interparietal
bone was increased (125%, P, 0.001) (Fig. 1E), which could
be a compensation of the reduced size of the occipital bone. No
anomaly was observed in parietal bones, whereas the frontal
bones were signiﬁcantly reduced in size (82%, P, 0.01). We
also observed the presence of a non-ossiﬁed gap in the frontal
bones in all Fgfr3Y367C/+ mice. The cellular origin of these bones
formed by membranous ossiﬁcation is different; the frontal
bones are derived from cranial neural crest cells, whereas the par-
ietal bones are derived from mesodermal cells (23). Interestingly,
the mice expressing the Fgfr3 mutation constitutively in
mesoderm-derived tissues (Prx1,Fgfr3Y367C/+) did not display
frontal bone anomalies (data not shown). Our results show that
the expression of Fgfr3Y367C/+ mutation in neural crest-derived
tissues causes an abnormal membranous ossiﬁcation. Overall,
the anomalies of the cranial bones in Fgfr3Y367C/+ mice indicate
that activatedFgfr3disruptedbothendochondral andmembranous
ossiﬁcation and allow to conclude that FGFR3 also contribute to
the cranial vault development.
Next we compared the consequences on the craniofacial
phenotype of Fgfr3-activating mutations in mice and humans.
Viscerocranium and neurocranium were analyzed using
m-computed tomography (mCT) and CT scans. As observed on
macroscopic preparations of the skulls, Fgfr3Y367C/+ mice
exhibited a domed macrocephalic cranium with an alteration
of the frontal bones, a shorter snout and malocclusion at P21
(Fig. 2A). In humans, FGFR3-activating mutations induced
various skeletal anomalies of the skull. Comparative analysis
of CT scans of ACH, CAN (one child), MS patients and controls
showed that the various FGFR3 mutations do not alter the
morphology of the skull in the same way, but all of them
altered the growth of the skull vault (Fig. 2B). Interestingly,
we observed consistently a large non-ossiﬁed gap in the skull
vault of ACH and CAN patients (Fig. 2B). Though macroceph-
aly was present in the three conditions, the coronal sutures were
usually fused in MS and CAN patients inducing a typical turri-
brachycephaly. In both conditions, the craniosynostosis might
be severe and result in a cloverleaf shaped skull. Conversely,
the alterations of the midface are absent in MS (24), whereas
prognathism with reduced size of maxilla and mandible were
found in ACH patients and in the CAN patient with cloverleaf
skull studied here and others CAN patients reported previously
(9,25,26). Many of these features are observed in mice carrying
the mutation responsible for MS syndrome (Fgfr3P244R) such as
abnormal skull shape, reduced snout and malocclusion (12,27).
To further characterize these defects, we performed morpho-
metric analyses inFgfr3Y367C/+mice and childrenwithACHand
their respective controls.We analyzedmCT andCT scan images
of the skull using anatomical landmarks and geometric morpho-
metrics (28). The principal components analysis (PCA) of the
mouse skull shape separates the Fgfr3Y367C/+ mice and their
control littermates. When compared with their control litter-
mates, the Fgfr3Y367C/+ mice were characterized by a domed
cranial vault, more vertical interparietal and occipital bones,
an anteriorly and inferiorly projected FM, a shorter basioccipital
bone, a shorter palate mainly because of an anteriorly reduced
premaxilla, and a shorter snout (Fig. 2C). The modiﬁcation of
the posterior vault and position of the posterior sutures found
in the Fgfr3Y367C/+ mice could be explained by differences in
growth of the occipital and interparietal bones (Figs 1E and
2C). Importantly, total or partial premature fusion of coronal,
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frontonasal, squamous frontal and squamous parietal sutures
were observed in all Fgfr3Y367C/+mice thus indicating that acti-
vated Fgfr3 accelerated the closure of the sutures and disturbed
osteogenesis in dwarf mice (Supplementary Material, Fig. S1).
In humans, the PCA of the human skull shape separated the
ACH patients and the unaffected individuals. When compared
with unaffected individuals, ACH patients were characterized
by a domed cranial vault, an occipital bone more horizontally
positioned but without a shorter posterior cranial fossa, a
smaller FM, a shorter basioccipital bone, a shorter and ﬂatter
facial skeleton and a wider aspect of the most posterior facial
skeleton (Fig. 2C). Focusing our analyses on sutures of the
skull,weobservedpremature fusionof the sagittal and squamous
sphenoidal sutures inACHcases (3/6) (SupplementaryMaterial,
Fig. S1).This observation is consistentwith recent papers report-
ing synostosis of multiple sutures in patients with ACH (29).
Our results revealed that the shape changes were highly
similar in Fgfr3Y367C/+ mice and ACH and that activated
FGFR3 disrupt membranous ossiﬁcation in chondrodysplasia.
Fgfr3
Y367C/1
and human skull base anomalies
appear during development
To evaluate the impact of activatedFGFR3 on the skull base, we
focused our analyses on the spheno-occipital (SOS) and
intra-occipital (IOS) synchondroses. At E16.5, macroscopic
studies revealed no obvious abnormality (Fig. 3A). However,
histological studies showed that in control mice, the cartilage
Figure 1.Macroscopic analysis of the skull ofFgfr3Y367C/+mice fromantenatal to postnatal period. (A) Alizarin red andAlcian blue staining of the skull inFgfr3Y367C/+
(n ¼ 18)comparedwithWTembryos (n ¼ 20)atE16.5of age showing thepreliminaryongoingossiﬁcation. (B)Macroscopic analysisof the skull inFgfr3Y367C/+ (n ¼
10) compared withWTmice (n ¼ 11) at birth (P0) showing a skull dysmorphy in mutant mice. (C) In P21Fgfr3Y367C/+mice (n ¼ 41) andWTmice (n ¼ 40), a dra-
matic modiﬁcation of the skull is present: the mutant mice display a turribrachycephaly with persistent defect of the medial skull vault at the level of frontal bone
(non-ossiﬁed gap) with midface hypoplasia and inverted bite. (D) Measurements of the length and width of the skull of WT and Fgfr3Y367C/+ mice at P21
showing a signiﬁcant reduction of the length in mutant. (E) Measurements of the length of nasal, frontal, parietal, interparietal and occipital bones of Fgfr3Y367C/+
mice versus WT, expressed as percentage of control. i.p. (interparietal), p (parietal), f (frontal) and o (occipital). ∗∗∗P , 0.001.
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wasorganizedmuch like thegrowthplate cartilageof longbones,
whereas in the Fgfr3Y367C/+ mice, we observed a disorganized
cartilage characterized by a smaller hypertrophic zone
(Fig. 3B).AtP0, theSOSanomalywasobviouswith the sphenoid
and occipital bones partially fused in most pups (6/7) (Fig. 3A).
Both proliferative and hypertrophic zones were reduced, as was
the size of the hypertrophic chondrocytes, revealed by Col X
immunostaining (Fig. 3B). At P21, there was a total fusion of
theSOS inall themutants (Fig. 3A)andnohypertrophicchondro-
cytes were present (Fig. 3B).mCT scan analysis of the skull base
conﬁrmed this loss of SOS (Fig. 3C).Macroscopic andmCT ana-
lysis also showed that the IOSwere fused inFgfr3Y367C/+mice at
P21 (Fig. 3C).The synchondroses defects are constant and severe
compared with those reported in Fgfr3P244R mice, where mild
synchondroses anomalies are also present and lead to less prema-
ture closure of the IOS and SOS during development (12).
We next investigated the human cranial base in CT scans and
observed a loss of SOS and IOS in ACH patients (Fig. 3D; Sup-
plementary Material, Fig. S1) that was not found in MS or CAN
(data not shown). The premature loss of the principal growth car-
tilage at the cranial base impaired postnatal growth of craniofa-
cial bones and could explain some clinical hallmarks of ACH
including hypoplasia of the midface and facial dysmorphy.
Fgfr3
Y367C/1
mice present an abnormal craniovertebral
junction as in human pathology
Tomoreﬁrmly establish the extent of the anomalies at the cranio-
vertebral junction in FGFR3-related disorders, we analyzed this
region in both mouse model and human. mCT data of
Fgfr3Y367C/+ mice provided the opportunity to explore this area,
in particular to look at the shape and size of the FM and atlas
(C1). We observed a modiﬁcation of FM in shape and size in
Fgfr3Y367C/+mice at 3weeks of age (Fig. 4A andB). The stenosis
of the FM in Fgfr3Y367C/+ mice affected the inner surface of the
foramenwith reduced sagittal (220%;P, 0.001) and transverse
(240%; P, 0.001) diameters, modifying its shape. The inner
transverse and sagittal diameters of the spinal canal at the level
of C1were also smaller inFgfr3Y367C/+mice comparedwith con-
trols (225%; P, 0.01 and 210%; P, 0.01, respectively)
(Fig. 4A and C). These alterations of craniovertebral junction
are the consequence of both abnormal bone growth andpremature
fusion of cranial base synchondrosis.
In order to address the relevance to humans of these data, we
measured in patients with FGFR3-related syndromes the size of
the FM. It is established that the size of the FMinACHpatients is
reduced (30). Here, we observed that the FM is not only reduced
Figure2.mCTof the head ofFgfr3Y367C/+mice andCTofACH,MS,CANpatientswith FGFR3-activatingmutations. (A)mCTofFgfr3Y367C/+ (n ¼ 7) andWT (n ¼
7)mice at P21 showing domedmacrocephalic craniumwith an impressive alteration of the vault andmalocclusion inFgfr3Y367C/+mice. (B) RepresentativeCTof the
skull at 3 months of age of control, ACH, MS and CAN patients. All FGFR3-related syndromes display macrocephaly and an altered shape of the skull.
(C) Morphometric analyses of the Fgfr3Y367C/+ mice (n ¼ 7) versus their control littermates (n ¼ 7), and ACH patients (n ¼ 6) versus control patients of the
same age (n ¼ 6) showing the same modiﬁcation of the skull vault and the midface. Superposition (Procrustes) of the consensus shape of the controls (red lines)
and that of the mutants (black lines) showing similar anomalies.
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Figure 3.Analysis of the skull base of Fgfr3Y367C/+mice and ACH patients. (A) Macroscopic analysis of the skull base stained with Alizarin red and Alcian blue in
control andmutant mice fromE16.5 to 3 weeks of age (P21). Early fusion of the SOS and IOS during development inFgfr3Y367C/+mice. (B) Histological analysis of
SOS inE16.5 embryos, newborn pups (P0) and 3-week-oldmice (P21). The proliferative and hypertrophic zones of the cartilage are reduced inFgfr3Y367C/+mice.An
absence of SOS is observed at P21 inFgfr3Y367C/+mice. (C) RepresentativemCTofWT(n ¼ 6) andFgfr3Y367C/+ (n ¼ 6)mice at P21 showing an absence of SOSand
IOS inmutant. (D) Representative CT of ACH children (2 years old) and age-matched control showing the absence of SOS inACHpatient (n ¼ 6) and its presence in
controls (n ¼ 20). SOS (spheno-occipital synchondrosis), IOS (intra-occipital synchondrosis).
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in ACH (32% of the size of controls; P, 0.001) but also in MS
(81%; P , 0.01) and CAN patients (53%) (Fig. 4D and E). The
degree of alteration of the FM is thus variable in FGFR3-related
skeletal diseases and correlated to the severity of abnormal
endochondral bone growth and the degree of fusion of the
synchondroses.
Fgfr3Y367C/1mice exhibit cerebral alterations
as in human pathology
To visualize the cervicomedullary junction at the level of the
FM stenosis, we performed magnetic resonance imaging
(MRI) of Fgfr3Y367C/+ mice at 3 weeks of age. We observed
severe brain alterations (Supplementary Material, Fig. S2A).
The brain length was reduced by 20% (P, 0.001), and its
height increased by 15% (P, 0.01) reﬂecting the skull modiﬁ-
cations (Supplementary Material, Fig. S2B and C). When ana-
lyzing the posterior fossa, the neural structures in mutant mice
appeared compressed and distorted when compared with
controls. The cerebrospinal ﬂuid (CSF) signal was reduced
(Supplementary Material, Fig. S2D), especially at the level of
the IV ventricle. No signs of hydrocephalus, ventricular dila-
tion, nor increase of CSF subarachnoid spaces were found in
mutant mice.
To address the relevance of these observations to human path-
ology,weusedvolumetricMRIanalysis inhumans identical to the
methods used in Fgfr3Y367C/+ mouse model. We found brain
alterations in FGFR3-related diseases. In ACH, an enlargement
of the subarachnoid spaceswas commonly found (Supplementary
Material, Fig. S2E) associated to a compression of the craniover-
tebral junction. These alterations were also present in another
FGFR3-related chondrodysplasia, TD (data not shown) and in
the CAN patient studied in this paper (Supplementary Material,
Fig. S2E). In the great majority of MS patients, no compression
of the craniovertebral junction and no hydrocephalus were
found onMRI. Taken together, these results point toward the cor-
relation between the size of FM and the signiﬁcance of the cervi-
comedullary compression in FGFR3-related chondrodysplasia
and craniosynostoses.
Fgfr3Y367C/1mice and human chondrodysplasia patients
exhibit calvaria and coronal sutures defects
The skull vault consistsmainly of ﬂat bones formed bymembran-
ous ossiﬁcation and separated by sutures. MS is characterized by
uniorbilateral coronal suture synostosis (6,31).We testedhere the
hypothesis that activating Fgfr3 mutations disturb the suture de-
velopment in dwarf mice and FGFR3-related chondrodysplasia.
For that purpose, we analyzed coronal sutures of Fgfr3Y367C/+
and control mice at E16.5, P0 and P21. We ﬁrst conﬁrmed that
FGFR3 was present in the undifferentiated mesenchyme that
separates the two fronts in Fgfr3Y367C/+ coronal sutures at
E16.5, P0 and P21 (data not shown) as in WT sutures (32). At
P21, sagittal sections through the coronal sutures revealed that
either (i) the two ossiﬁcations fronts, identiﬁed following Col I
immunostaining, were fused or (ii) the overlap between the two
Figure 4.Reduction of the size of the FM inFgfr3Y367C/+mice andACH,MS, CAN patients with FGFR3-activatingmutations. (A) RepresentativemCT of FM (C0)
and atlas vertebra (C1) of Fgfr3Y367C/+mice and control littermate at 3 weeks of age. Modiﬁcation of shape and size in mutant mice (n ¼ 7). (B) Measurement of the
transverse and sagittal length of C0 showing reduction of the size of C0 inFgfr3Y367C/+mice (n ¼ 17) comparedwith control (n ¼ 14). (C)Measurement of the trans-
verse and sagittal length of C1 showing reduction of the size ofC1 inFgfr3Y367C/+mice. (D) RepresentativeCT of the FMat 3months of age of control, ACH,MS and
CANpatients. CT showing obvious reduction of the size of the FM inACHand smaller reduction inMS andCAN.Measurement of the area of FM in control (n ¼ 20,
mean age 5.4 months), compared with ACH (n ¼ 6, mean age 9.3 months), MS (n ¼ 8, mean age 5.8 months) and CAN (n ¼ 1, 3 months old) showing signiﬁcant
reduction of the size of ACH FM (P , 0.001) and MS (P , 0.01), ∗∗∗P , 0.001, ∗∗P, 0.01.
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fronts was increased (Fig. 5A). This is an important ﬁnding
because in Muenke mouse model coronal suture fusion was a
rare event (13).
Macroscopic examinations of P21 skull vaults conﬁrmed the
fusion or increased overlap of the ossiﬁcations fronts at the
coronal suture, as well as an important medial non-ossiﬁed gap
in Fgfr3Y367C/+ affecting the two frontal bones anteriorly to the
coronal suture (Fig. 5B). This defect was observed in .90% of
the Fgfr3Y367C/+ mice and was conﬁrmed with mCT scans
(Fig. 2A; Supplementary Material, Fig. S1).
Figure5.Partial fusionof the coronal suture inFgfr3Y367C/+miceandTDpatients. (A)HematoxilinEosinSafran (HES)stainingofcoronal suturesofE16.5,birth (P0),
3-week-old (P21)mutant and controlmice. At P21, sutures are occasionally completely fused (∗). Collagen type I (Col I) immunostaining of the coronal sutures, con-
ﬁrming the limits of theossiﬁcation fronts. (B)Macroscopic representation of the skull vault ofFgfr3Y367C/+mice andcontrol littermates at 3weeksof age stainedwith
Alizarin red and Alcian blue. Impressive defect of the frontal bone (∗) in mutant (n ¼ 13) absent in control mice (n ¼ 14). Sutures are occasionally completely fused
and theoverlapof theossiﬁcation fronts is increased. (C)Histological analysisofhumancoronal sutureofTD(n ¼ 6, aged13–24gestationalweeks,meanage ¼ 19.8)
(TD) and age-matched control (n ¼ 6, aged 16–26 gestational weeks, mean age ¼ 21.5) fetuses. HES staining of coronal sutures and Col I immunostaining of the
coronal sutures showing the premature fusion of TD suture compared with control at 17 and 24 gestational weeks. p (parietal), f (frontal).
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To parallel these analyses, we took opportunity of human
coronal sutures isolated from TD, a severe and lethal form of
chondrodysplasia associated with an FGFR3-activating muta-
tion and age-matched control fetuses. At 17 weeks of gestational
age, we observed an increased ossiﬁcation of the coronal suture
revealed by Col I immunostaining in TD when compared with
age-matched controls (Fig. 5C). This premature fusion of the
coronal suture in TD was even more pronounced at 24 weeks
of age (Fig. 5C). These data, obtained in human coronal
sutures, conﬁrm the crucial role of FGFR3 in suture homeostasis
during formation of the skull vault.
Fgfr3
Y367C/1
calvarial defects only partially resolve ex vivo
To add further support to the notion that FGFR3 mutation dis-
turbs skull vault, we next performed mouse calvarial ex vivo
studies. Indeed, in ACH, it has been suggested that premature
fusions of synchondrosis are responsible for the altered overall
shape of the skull. It is therefore plausible that the observed
defects of the cranial base may inﬂuence the fusion and growth
of calvarial ﬂat bones and contribute to the calvarial defect (for-
amina). In order to suppress any potential contribution of the
cranial base to this defect, calvaria from Fgfr3Y367C/+ and
control embryos (E16.5) were dissected from the rest of the
skull, separated from the inﬂuence of the brain and the cranial
base and cultured ex vivo during 14 days (33). This strategy
revealed that the cranial base and brain likely prevent the reso-
lution of the defect since the size of the defect rapidly decreased
when the calvaria was separated from the base (Fig. 6A and B).
The defect regressed by .50% in 4 days (Fig. 6C and D). The
defect however did not completely resolve andwas still detected
after 2weeksof culture (Fig. 6B–D).Studying thecoronal suture
after 14days of culture usingCol I immunostaining,weobserved
anomalies characterized by an increase of the overlap between
the two front of ossiﬁcation (frontal and parietal bones). These
data suggest that alterations of the underlying brain and skull
base alone do not explain all the modiﬁcations we observed at
the cranial vault and that activatedFgfr3 induces an autonomous
Figure6.Cultureof fetal calvaria isolated fromFgfr3Y367C/+miceandcontrol littermate. (A)Representative imagesof theexvivocultureof calvaria fromcontrolmice
(Fgfr3+/+) during 14 days (n ¼ 8). HES staining and Col I immunostaining of the sutures revealed the absence of calvarial defect and limited overlap of ossiﬁcations
fronts. Yellow line boxed images are representative images from sections of the coronal suture away from the sagittal midline, whereas red line boxed images are
representative of sections closer to the midline. (B) Representative images of the ex vivo culture of calvaria from Fgfr3Y367C/+ mice during 14 days (n ¼ 8). HES
staining and Col I immunostaining of the sutures revealed the presence of a large calvarial defect (red boxed) and increased overlap of ossiﬁcations fronts (yellow
boxed). Yellow line boxed images are representative images from sections of the coronal suture away from the sagittal midline, whereas red line boxed images
are representative of sections closer to the midline. (C) Higher magniﬁcation of the calvaria at Day 0 (d0) and Day 14 (d14) in Fgfr3Y367C/+ mice. The calvarial
defect is highlighted with a white line. (D) Evaluation of the reduction of the size of the calvaria defect during 14 days ex vivo culture in Fgfr3Y367C/+ fetal mice
(n ¼ 8).
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membranous ossiﬁcation delay of frontal bones. These results
further conﬁrm the role of FGFR3 in the vault formation and
suture growth and fusion. Thus membranous ossiﬁcation is dis-
turbed by FGFR3 mutations responsible for both chondrodys-
plasias and craniosynostoses.
DISCUSSION
This study arose from the observation that in humans,
FGFR3-activating mutations result in ACH and MS where the
bones predominantly affected are different: long bones formed
by endochondral ossiﬁcation in ACH and the parietal and
frontal bones formed by membranous ossiﬁcation in MS. It is
usually considered that in ACH, endochondral ossiﬁcation
defects lead to reducedgrowthplate and fusionof synchondroses
(22), while in MSmembranous defects cause unilateral or bilat-
eral premature fusion of coronal sutures (31). However, recent
studies on patients and mouse models of FGFR3-related dis-
eases, including this paper, draw a more complex picture.
Here, we showed that in ACH patients and Fgfr3Y367C/+ mice,
the defective cranial phenotype is not the sole consequence of
disturbed endochondral ossiﬁcation but thatmembranous ossiﬁ-
cation is also affected.
In the developing skull base,we observed a severe defect of the
endochondral ossiﬁcation characterized by reduced size of the
chondrocyteswith a lack of organization, inducing synchondrosis
premature fusion. This defect is similar to growth plate cartilage
anomalies observed in Fgfr3Y367C/+ mice, ACH and TD long
bones (34) and conﬁrms that activated FGFR3 disturbs all carti-
lages in the skeleton. Other reports on craniosynostosis and chon-
drodysplasiamurinemodels support the evidence thatFGFR3and
the Mapkinase pathway regulate synchondrosis closure
(12,35,36). We also provided evidence that the synchondroses
premature closure accounts for the FM stenosis and the cerebral
alteration at posterior fossae in Fgfr3Y367C/+ mice and ACH
patients. These data correlate with clinical features of ACH
(22,30). Interestingly, our study also demonstrated that in MS
patients a signiﬁcant reduction in the size of the FM was present
suggesting that cranial base anomalies occur in craniosynostoses.
The degree of reduction of FMarea varied among FGFR3-related
conditionswithdiverse clinical consequences; patientswithACH
and CAN might need a surgical decompression of the craniover-
tebral junction, whereas in typical MS such surgical decompres-
sion is not needed. This spectrum of anomalies varying in
FGFR3-related conditions may be due to the distinct impact of
speciﬁc FGFR3 mutations on chondrogenesis and osteogenesis
during bone growth and highlight the complexity of RTK signal-
ing in skeleton development. It was previously demonstrated that
FGF signaling activates multiple downstream targets such as the
mitogen-activated protein kinase pathway (21) and P38 (37) and
synergizes with partners like transforming growth factor-b (38)
andWnt (39). The variable impact of FGFR3mutations on endo-
chondral ossiﬁcation, limb and vertebral anomalies are reported
not only in ACH but also in MS (40) and CAN syndromes (25).
Interestingly, activating or loss-of-function mutations of FGFR1
and FGFR2, responsible for craniosynostosis, also induce defect-
ive long bone development (41).
The biological consequence of FGFR3mutations in craniosy-
nostoses is a disruption of skeletal growth characterized by
dysregulation of the intramembranous bone formation at the
suture. The impairment of proliferation or accelerated differenti-
ation of cranial osteoblasts leads to premature fusion of
cranial sutures thus disturbing the expansion of the skull vault
(42). Here, by investigating the skull vault of dwarf mice
(Fgfr3Y367C/+), we showed an alteration of membranous ossiﬁca-
tionwith partial andpremature fusionof the coronal sutures, and a
reduced formation of the frontal bones, contrasting with the
normal size of the parietal bones. To add further support to the
notion that membranous ossiﬁcation is affected in human path-
ology, we analyzed CT images of children with ACH and noted
a delayed development of the frontal bones. Furthermore, we
demonstrated that this ossiﬁcation delay of the frontal bones
was only partially rescued in calvaria cultured without skull
base thus providing evidence that activatedFGFR3 affects specif-
ically andautonomouslymembranous ossiﬁcation.Thehigh level
of expression of FGFR3 in the frontal bones compared with par-
ietal bones (43) and this can also explain the difference in size
(shorter frontals and normal parietals) due to the activating
FGFR3mutation. We also analyzed ACH scans and TD coronal
sutures by histology and we noted some degree of synostosis in
coronal and sagittal sutures. Similar to our results, several cases
of suture synostosis were reported in ACH patients (29,44,45),
hypochondroplasia (MIM 146000) (46), mild dwarﬁsm (47) and
TD (48,49). Growth in the calvarial sutures is perpendicular to
the orientation of the suture and is normally maintained through-
out the period of growth of the brain. Synostosis of one or more
sutures is accompanied by compensatory growth in other
sutures and remodeling of other parts of the skull. Our data
suggest thus that both synostosis and membranous ossiﬁcation
delay participate to the development of the prominent forehead
observed in ACH. Here, we provide convincing data that abnor-
mal FGF signaling leads to both synostoses and delay of mem-
branous ossiﬁcation.
This study highlights the impact of FGFR3mutations during
cranial development in ACH and shows that both endochondral
and intramembranous ossiﬁcations are primarily affected. The
relevant hallmarks of ACH such as frontal bossing and macro-
cephaly might be the consequence of the disruptedmembranous
ossiﬁcation. Demonstration of the impact of FGFR3 mutations
on craniofacial development should initiate novel pharmaco-
logical and surgical therapeutical approaches. Fgfr3Y367C/+
mice will constitute a unique model to test these new strategies.
MATERIALS ANDMETHODS
Human subjects
All patients with craniosysnostoses and ACH were examined
and followed at theCraniofacial SurgeryUnit ofNecker-Enfants
Malades Hospital.
Children with MS (n ¼ 8, mean age 5.8 months) and CAN
(n ¼ 1, 3 months old) presented with a brachycephaly due to a
bicoronal synostosis and were operated on.
Coronal sutures were isolated from fetal skull derived from
medically aborted control (n ¼ 6) and TD (n¼ 6). Parents of all
the subjects providedwritten, informedconsentbefore recruitment
into the study.Ethics approvalswere obtained from the institution-
al review Board of Necker-Enfants Malades Hospital.
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Mutational analysis of human FGFR3 gene
For the FGFR3 TMdomain (ACH, CAN) and EC domain (MS),
the primers usedwere described previously (2,6). Blood samples
wereobtainedwith the consents of theparents andwere collected
and processed in agreement with the French ethical committee
guidelines.
Mouse models
WT and Fgfr3Y367C/+ mice were generated by crossing
Fgfr3neoY367C mice (18) and Cmv-Cre mice (50). The mutant
mice express the c.1100A. G (p.Tyr367Cys) mutation corre-
sponding to the c.1118A . G (p.Tyr373Cys) in TD. All the
micewere genotyped byPCRof tailDNAas described previous-
ly (18). All the experiments were conducted in Fgfr3Y367C/+
mice, a mouse model that display parts of the clinical hallmarks
of ACH (21). Experimental animal procedures and protocols
were approved by the French Animal Care and Use Committee.
Whole-mount Alcian blue-Alizarin red staining
Calvariae of Fgfr3Y367C/+ and their wild-type mice at E16.5, P0
andP21wereﬁxed in 95%ethanol and then stainedwithAlizarin
red andAlcian blue, cleared byKOH treatment and stored in gly-
cerol according to standard protocols (18). Size of the calvarial
bones was measured on images captured with an Olympus
PD70-IX2-UCB using cell sens software (Olympus).
Immunohistochemistry
Calvariae of Fgfr3Y367C/+ and their wild-type littermates were
ﬁxed in 4% paraformaldehyde at 58C, and decalciﬁed in 0.5 M
EDTA (pH 8.0) overnight or up to 1 week, depending on the
age of the mice, and then dehydrated in graded series of ethanol,
cleared in xylenes and embedded in parafﬁn. Five microns of sa-
gittal sections were cut and stained with hematoxylin and eosin
(H&E)andsafrin-Oandsubjected to immunohistochemical stain-
ing using standard protocols using an antibody against FGFR3
(1:250 dilution; Sigma-Aldrich Co, St. Louis, MO, USA),
anti-Col X (1:50 dilution; BIOCYC, Luckenwalde, Germany)
and anti-Col I (1:500 for murine tissue, 1:1000 for human
tissue, Novotec, Lyon, France) using the Dako Envision Kit
(Dako North America, Inc, CA, USA). Same protocol was used
for human coronal sutures. TD fetuses were obtained from
legally terminated pregnancies according to the French ethical
committee recommendations. The control group included spon-
taneously aborted fetuses showing no evidence of skeletal abnor-
malities. ImageswerecapturedwithanOlympusPD70-IX2-UCB
microscope (Olympus, Tokyo, Japan).
CT scanner of mouse and human
The head of the Fgfr3Y367C/+ mice and their control littermates
were imaged by mCT using a VivaCT40 microscanner
(SCANCO Medical, Bru¨ttisellen, Switzerland). All specimens
from Fgfr3+/+ and Fgfr3Y367C/+ mice were scanned at the
LBTO facility (INSERM U1059-IFR 143-IFRESIS St Etienne,
France) using the following protocols (0.020 mm voxel reso-
lution, 55 kV, Sigma 1.5/Support 2/Threshold 148, 150 mA).
Human scans were performed with a 64-slice CT system
(LightSpeed VCT, General Electric Medical Systems, Milwau-
kee, WI, USA). The bone images were reconstructed in three
dimensionsusingCarestreamPACSv11.0 software (Carestream
Health, Rochester, NY, USA).
Morphometric analysis
The samples consist of CT images of six patients diagnosedwith
ACH and six unaffected individuals matching on age the ACH
patients (0.5–5 years), and of high-resolution CT images of
seven P21 Fgfr3Y367C/+ mice and seven control littermates. 3D
coordinates of 31 landmarks were recorded on the reconstructed
skulls of humans and mice and analyzed by geometric morpho-
metric methods. Standardization for position, scale and orienta-
tion was obtained by Procrustes superimposition (51,52), and
shape information (Procrustes coordinates) and size (centroid
size; (52)) were extracted. Shape information was subsequently
analyzed by PCA (for more information on geometric morpho-
metrics applied to craniofacial birth defect, see, for example
(28)).Wireframes areused tovisualize the shapedifferences cor-
responding to the skull associated with speciﬁc scores on princi-
pal component 1 and 2.
Magnetic resonance imaging
All MRI were conducted on anesthetized (isoﬂurane) Fgfr3+/+
and Fgfr3Y367C/+ mice using a 4.7 T Bruker Biospec MR imager
(Bruker BioSpin GmbH, Rheinstetten, Germany) at the Small
Animal Imaging Facility of Paris Descartes University,
INSERM, U970, Paris, France. The resolution was 0.0078×
0.0078 cm/px × 625 mm/px for a matrix size of 256× 256×
32 with three averages and a repetition time of 1200 ms (echo
time 80 ms) and two dummies scans. The total scan time was
30 min.Osirix softwarewasused for postprocessing.For thequan-
tiﬁcation of CSF, after a midsagittal plane selection, a region of
interest was drawn manually, delineating the posterior brain. The
midsagittal slice (S) was normalized by subtracting S by Sm
which was S ﬁltered by a large median ﬁlter (5 × 5), resulting in
a contrast image C ¼ S2 Sm. The distribution of gray levels of
C in brain tissue approximated a Gaussian behavior. Hence,
bright CSF pixels corresponded to outliers for this Gaussian distri-
bution. ForCSFdetection,we used one of themore current thresh-
old (Th) used in ‘box-and-whisker plots’. Th ¼ Q75 + 1.5IQ,
where Q75 and IQ are the 75 percentile and the interquartile
range of C in the posterior brain, respectively. Then the fraction
of pixels detected in the posterior brain (FCSF) was evaluated
for each exam and FCSF values were compared between groups
by a non-parametric Wilcoxon two-sample test. Difference
between groups were considered signiﬁcant for P, 5%.
In human, MRI was performed with a 1.5T (Signa General
Electric Medical Systems, Milwaukee, WI, USA) scanner
using Carestream PACS v11.0 software (Carestream Health,
Rochester, NY, USA). The MRI was performed without intra-
venous contrast enhancement.
Calvarial culture system
Ex vivo cultures were conducted as described previously (33)
with slight modiﬁcations. E18.5 embryos were aseptically
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dissected from the uterus of pregnant females and calvaria were
separated from the rest of the skull after removal of the skin. The
brain was detached form the calvaria and attention was paid not
to remove the dura mater. Calvaria were then placed in 24-well
plates, on top of 250 ml ofMatrigel (BDBiosciences) previously
placed at the bottom of the well. Calvaria were cultured in
a-MEM (Gibco) supplemented with 10% fetal bovine serum
(Gibco), 100 mg/ml ascorbic acid (Sigma) and 1% penicillin/
streptomycin (Gibco). After 2 weeks, calvaria were separated
from the gel, ﬁxed in 4% paraformaldehyde at 48C and embed-
ded in parafﬁn. Serial sections of 5 mm were stained with
H&E using standard protocols for histological analysis and sub-
mitted to immunohistological protocol. Images were captured
with an Olympus PD70-IX2-UCB microscope. The size of the
calvaria defect was measured using ImageJ software (NIH).
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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Supplementary Figure S1 
 
 
Computed Tomography of the head of Fgfr3Y367C/+ mice (μCT) and ACH patients 
(CT). (A) μCT images of vault and skull base of Fgfr3Y367C/+ (n=7) and WT (n=7) mice 
at P21 showing in mutant mice partially fused suture (green arrow) and absence of 
SOS (spheno occipital synchondrosis (SOS) and intra occipital synchondrosis 
(IOS)(red arrows). The patent sutures are indicated with a black arrow. (B) CT of 
patients with ACH (n=6) and age matched control (n=6). CT images of vault and skull 
base (endocranial view) of ACH (2 years old) and control (1.5 years old) showing in 
ACH patient fused sagittal sutures (red arrow) and partially fused squamous 
sphenoidal suture (green arrow) and absence of SOS (spheno occipital 
synchondrosis (SOS) and intra occipital synchondrosis (IOS)(red arrows). Each 
suture is numbered, coronal suture (1), sagittal suture (2), lambdoid suture (3), 
squamous parietal suture (4), squamous sphenoidal suture (5), interparietal 
supraoccipital suture (6), fronto-nasal suture (7). 
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 Supplementary Figure S2 
 
 
Magnetic Resonance Imaging (MRI) of the head of Fgfr3Y367C/+ mice and ACH, MS, 
CAN patients. (A) Representative image of MRI of Fgfr3Y367C/+ mice and control 
littermates. Severe brain alteration in shape and size in mutant (n=5) compared with 
control (n=6) at 3 weeks of age. (B) Measurement of length and height of the brain 
showing a decrease of the length and an increase of the height. (C) Measurement of 
sagittal diameter of the neural canal at the level of the foramen magnum showing a 
decrease of the size in Fgfr3Y367C/+ mice. (D) Evaluation of the quantity of 
cerebrospinal fluid in Fgfr3Y367C/+ mice (n=5) and control (n=6) showing strong 
reduction in mutant mice similar to FGFR3-related disorders (E) Representative MRI 
images at 2 months of age of control showing the severe alterations of the posterior 
fossa and foramen magnum. ***P<0,001, **P<0,01. 
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Abstract	
 
Missense mutations in the tyrosine kinase receptor FGFR3 (Fibroblast Growth Factor 
Receptor 3) lead to its overactivation causing biological dysfunctions in several 
diseases. Achondroplasia, the most common Fgfr3-related chondrodysplasia, is a 
rare genetic disorder, affecting 1 in 20000 live births, characterized by particular 
clinical features: rhizomelic dwarfism, short limbs, macrocephaly, midface hypoplasia, 
cervicomedullary compression. The abnormal activity of the receptor induces 
endochondral ossification defects that are responsible for the pathological 
phenotype. For a long time the only treatment for this disease was the limb 
lengthening surgery, however in recent years several researchers have developed 
potential therapeutic strategies based on molecular studies. The objective of my 
thesis was to evaluate a novel therapeutic approach for achondroplasia. 
A promising therapeutic strategy involved the use of small chemical inhibitors, 
known as tyrosine kinase inhibitors, that are able to arrest the FGFR3 activity. I have 
assessed the effects of one of these compounds, NVP-BGJ398, in a mouse model 
mimicking the acondroplastic dwarfism (Fgfr3Y367C/+). The experiments performed 
showed an improvement of all pathological hallmarks in NVP-BGJ398 treated mice.  
We have also inspected the impact of the activating FGFR3 mutation on the 
mandibular development. The study established a defect in mandibular growth in 
both affected patients and mice. Furthermore we could investigate the mandibular 
bone growth and correct the pathological defect with NVP-BGJ398. 
Finally I have participated in molecular analyses to describe how three FGFR3 
mutations at the same position could lead to three different dwarfisms with increasing 
severity. The results provided a better understanding of FGFR3 pathological 
molecular mechanisms and could lead to new targets for therapeutic approaches. 
  
Résumé 
 
Des mutations faux-sens au niveau du récepteur à activité tyrosine kinase FGFR3 
(Fibroblast Growth Factor Receptor 3) entrainent sa suractivation qui apporte des 
dysfonctions biologiques dans plusieurs maladies. L’achondroplasie, la forme la plus 
commune de chondrodysplasie liée à Fgfr3, est une maladie génétique rare, 
touchant 1 nouveau-né sur 20 000, caractérisée par des signes cliniques 
spécifiques : nanisme rhizomélique, membres courts, macrocéphalie, hypoplasie de 
l’étage moyen de la face, compression cervico-médullaire. L’activité anormale du 
récepteur induit des défauts de l’ossification endochondrale responsables du 
phénotype pathologique. Pendant longtemps le seul traitement pour cette maladie a 
été l’allongement chirurgical des membres, cependant au cours des dernières 
années de nombreux chercheurs ont développé des potentielles stratégies 
thérapeutiques basées sur des études moléculaires. L’objectif de ma thèse était 
d’évaluer une nouvelle approche thérapeutique pour l’achondroplasie. 
 Une stratégie thérapeutique prometteuse prévoit l’utilisation de petits 
inhibiteurs chimiques, connus sous le nom d’inhibiteurs de tyrosine kinases, qui sont 
capables d’arrêter l’activité de FGFR3. J’ai estimé les effets d’un de ces composés, 
NVP-BGJ398, dans un modèle murin mimant le nanisme achondroplase 
(Fgfr3Y367C/+). Des expérimentations effectuées ont montré une amélioration des 
caractéristiques pathologiques dans les souris traitées avec NVP-BGJ398. 
Nous avons également examiné l’impact de la mutation activatrice de FGFR3 sur le 
développement mandibulaire. L’étude a reconnu un défaut dans la croissance 
mandibulaire chez l’homme et la souris atteints. En outre nous avons pu investiguer 
la croissance osseuse de la mandibule et corriger le défaut pathologique avec NVP-
BGJ398. 
Enfin j’ai participé à des analyses moléculaires pour décrire comment trois mutations 
de FGFR3 localisées à la même position (Lys650) peuvent induire trois différents 
nanismes avec sévérité croissante. Les résultats ont fourni une meilleure 
compréhension des mécanismes moléculaires pathologiques et pourront mener à 
des nouvelles cibles pour des approches thérapeutiques. 
 
